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Biopolymer-based hydrogels have emerged as promising platforms for drug 
delivery systems (DDSs) due to their inherent biocompatibility, tunable physical 
properties and controllable degradability. Yet, drug release in majority of these 
systems is solely contingent on diffusion of drug molecules through the hydrogel, 
which often leads to burst release of drugs from these systems. As a result, the main 
aim of this thesis was to develop suitable hydrogel platforms that allow sustained 
release of anti-cancer drugs, to be ultimately used as implants for local delivery of 
drugs to tumors. To this end, inspired by the chemistry of mussel adhesive proteins, 
a new generation of coaxial hydrogel structures were developed that could 
simultaneously exert both affinity and diffusion control over the release of 
chemotherapeutic drugs. Specifically, dopamine-modified hydrogel along with 
chemotherapeutic drugs was used as the main core component to confer affinity-
controlled release, while a methacrylated hydrogel was used as the shell 
composition to provide the controlled diffusion barrier. Initially a well-recognized 
wet-spinning technique was employed to fabricate coaxial fibers with the given 
composition, mainly because this fabrication method allows high throughput and 
continuous production of coaxial structures. Accordingly, it was shown that the 
fabricated coaxial fibers were robust in both dry and wet conditions, and most 
importantly they were capable of exerting a controlled release of Doxorubicin (a 
chemotherapeutic drug) over a span of 3 weeks. Also, in vitro and in vivo 
evaluations showed that drug loaded coaxial fibers had optimal anticancer activity 
against pancreatic cancer cells.  
Given the obtained results from the coaxial fibers in delivering chemotherapeutics, 
they were next used for a combinational chemo-photothermal therapy. This 
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treatment requires that not only the system allowed sustained release of the drug, 
but also it could generate heat instigated by an external stimuli. Consequently, 
nanoparticles with photo-thermal properties (copper selenide nanoparticles; 
Cu2−xSe) were added into shell compartment of the coaxial fibers, while the core 
compartment contained a chemotherapeutic drug (Doxorubicin). The obtained 
results showed that addition of nanoparticles to the coaxial fibers further enhanced 
their mechanical properties in both dry and wet conditions, and it also endowed 
photo-thermal capabilities to the fibers instigated by near infra-red (NIR) laser 
irradiation. Remarkably, combination of chemo-photothermal modalities in these 
fibers allowed optimal anticancer activity both in vitro and in vivo when tested 
against breast cancer cells.  
 
Lastly, with the aim of fabricating drug-loaded implantable patches, a 3D printing 
technique was employed to produce novel coaxial hydrogel patches. Similar to 
previously fabricated coaxial fibers, the core-section of these patches contained a 
dopamine-modified methacrylated hydrogel loaded with a chemotherapeutic drug 
(Gemcitabine), while their shell section was solely comprised of a methacrylated 
hydrogel. Subsequently, these patches were further modified with CaCO3 cross 
linker and a polylactic acid (PLA) coating to facilitate prolonged release of the 
drug. Consequently, the results showed that addition of CaCO3 to the formula 
enhanced the mechanical properties of the patches and significantly reduced their 
swelling ratio as compared to that for patches without CaCO3. Furthermore, 
addition of PLA coating to CaCO3-containing patches has further reduced their 
swelling ratio, which then significantly slowed down the release of Gemcitabine, 
to a point where 4 layers patches were capable of releasing the drug over a period 
xii 
 
of 7 days in vitro. Remarkably, it was shown that 3 layers- and 4 layers Gemcitabine 
loaded patches were successful in inhibiting pancreatic cancer cell growth for a 
period of 14 days when tested in vitro. 
In conclusion, a range of coaxial hydrogel structures were developed either through 
wet-spinning or 3D-printing techniques, with the purpose of building suitable 
therapeutic platforms for sustained and local release of anti-cancer drugs to tumors.  
Based on the obtained results in this thesis, these drug-loaded coaxial hydrogel 
structures were successful in releasing Gemcitabine and Doxorubicin in a sustained 
manner, which in turn prevented cancer cell growth as indicated from both in vitro 
and in vivo experiments. The drug-loaded coaxial hydrogel structures produced in 
this work may find application as neoadjuvant or adjuvant therapies for controlled 
delivery of therapeutics locally to the tumor site with the aim of suppressing cancer 
growth, with reduced side effects.           
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In spite of remarkable improvements in cancer treatments and survivorship, cancer still 
remains as one of the major causes of death worldwide. Although current standards of 
care provide encouraging results, they still cause severe systemic toxicity and also fail in 
preventing recurrence of the disease. In order to address these issues, biomaterial‐based 
implantable drug delivery systems (DDSs) have emerged as promising therapeutic 
platforms, which allow local administration of drugs directly to the tumor site. Owing to 
the unique properties of biopolymers, they have been used in a variety of ways to institute 
biodegradable implantable DDSs that exert precise spatiotemporal control over the 
release of therapeutic drug. Of the many biopolymers currently utilized for drug delivery 
applications, hydrogels are among the most promising ones. Hydrogels are comprised of 
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polymeric networks that are capable of absorbing and retaining high amounts of water. 
Hydrogels are also tunable (both physically and chemically), are injectable, and have been 
used over the years for various drug delivery applications. Controlled drug release profiles 
attainable with these systems are dictated by factors such as porosity, network 
swelling/degradation, the size of the molecule to be released, and drug-polymer 
interactions. So far, various fabrication technologies have been utilized to institute 
hydrogel implants for drug delivery purposes, this included methods such as casting, 
electrospinning, 3D printing, and injectable gels. Among different structures that have 
been fabricated from hydrogels, coaxial structures offer specific advantages that are 
befitting for drug delivery applications. These advantages include: (i) the bioactive drug 
can be incorporated into the core while being safely protected by a shell, which protects 
the drug from loss of bioactivity, (ii) by choosing suitable components sustained release 
of a drug can be realized.  
This thesis presents a novel composition of coaxial hydrogel structures that were 
fabricated either through wet-spinning or 3D printing, and were aimed for sustained 
release of anti-cancer drugs to be ultimately used as implants for local delivery of 
chemotherapeutics to tumors.  
 
1.2. Thesis outline  
 
Methods for incorporation of drugs into hydrogels generally fall into three categories: (i) 
physical encapsulation, where drugs are simply entrapped within the cross-linked 
polymer network; (ii) covalent conjugation, where drugs are covalently bound to the 
polymer network; and (iii) affinity binding, where hydrophobic, ionic, or hydrogen 
bonding are utilized to retain drugs within the hydrogel network. Though, physical 
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encapsulation renders a simplistic approach for designing drug loaded hydrogels, these 
systems often face uncontrolled drug diffusion out of the bulk hydrogel immediately after 
formation (burst release). On the other hand, covalent conjugation of drugs to the 
hydrogel network yields a much slower drug release profile, where release is facilitated 
by cleavage of the covalent linkage or by complete hydrogel degradation. However, this 
strategy often involves chemical modification of drugs which not only can impact their 
FDA approval but could also alter their biological activity. Along those lines, affinity-
based drug delivery has emerged as an alternative to achieve controlled release of small-
molecule drugs, without compromising their activity. Affinity-controlled release is 
usually achieved by immobilizing a drug-binding ligand within a hydrogel matrix. Based 
on the type of drug molecule, a variety of ligands have been explored for affinity-
controlled release, this includes heparin-like moieties, binding peptides, cyclodextrins, 
and thiols. Recently, inspired by marine mussels, researchers have utilized 3, 4-
dihydroxyphenylalanine (DOPA) to confer affinity-controlled release to hydrogels. The 
catechol group of dopamine is shown to be capable of adhering to drug molecules by 
using a variety of mechanisms including hydrogen bonds, π-π interactions, cation-π 
interactions and dynamic covalent bonds.   Nevertheless, controlled release of drugs from 
hydrogels is also affected by tortuosity of the release path, which is determined by factors 
such as porosity and network swelling/degradation. In line with this, modification of 
biopolymers with methacrylate groups and their subsequent photo-crosslinking has been 
proven as an effective way to control physical properties of the hydrogels including their 
mechanical properties, porosity, swelling behaviours, and  degradation rate.  
 
This thesis describes the development of novel coaxial hydrogel structures using either 
wet-spinning or 3D-printing approach to be utilized for cancer drug delivery. More 
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specifically, the core section of these structures was comprised of dopamine-modified 
alginate along with chemotherapeutic drugs to confer affinity-controlled release, while a 
methacrylated-alginate was used as the shell composition to provide the controlled 
diffusion barrier. For one, coaxial hydrogel fibers were made via wet-spinning technique 
and they were subsequently used for delivery of two chemotherapeutic drugs 
(Gemcitabine and Doxorubicin). Then, incporation of nanoparticles with photothermal 
properties into these drug-loaded coaxial hydrogel fibers were assessed to allow chemo-
photothermal combinational cancer therapy. Lastly, a 3D-printing technique was utilized 
to develop coaxial hydrogel patches for prolonged release of chemotherapeutic drugs. 
This work is summarized in the chapters as follows:  
 
In Chapter 1, the significance of local delivery of chemotherapeutic drugs for cancer 
therapy is highlighted. Secondly, a brief description of the novel aspects of this work is 
highlighted, which is followed by a blueprint into contents of every chapters. 
Subsequently, this is followed by a comprehensive review of the current state and future 
outlook of biopolymers for Antitumor Implantable Drug Delivery Systems, including the 
various implemented biopolymers as well as their corresponding fabrication techniques. 
Lastly, based on the conducted literature review the thesis objectives were stated.  
 
In Chapter 2, a new generation of coaxial hydrogel fibers was developed using wet-
spinning technique, that could simultaneously exert both affinity and diffusion control 
over the release of chemotherapeutic drugs. Specifically, dopamine-modified alginate 
hydrogel along with chemotherapeutic drugs (Doxorubicin or Gemcitabine) was used as 
the main core component to confer affinity-controlled release, while a methacrylated-
alginate hydrogel was used as the shell composition to provide the controlled diffusion 
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barrier. It was shown that our coaxial mussel-inspired biofibers yielded biocompatible 
hydrogel fibers (as indicated by comprehensive in vitro and in vivo experiments) with 
favourable properties including controlled swelling, and enhanced mechanical properties, 
when compared against single fibers made from unmodified alginate. Notably, it was 
observed that these coaxial fibers were capable of releasing the two drugs in a slower 
manner, when compared to single fibers made from pure alginate, which was partly 
attributed to stronger interactions of drugs with dopamine-modified alginate (the core 
element of coaxial fibers) as observed from zeta-potential measurements. It was further 
shown that these drug-loaded coaxial fibers had optimal anticancer activity both in vitro 
and in vivo using various pancreatic cancer cell lines. Most remarkably, drug loaded 
coaxial fibers, particularly Doxorubicin-containing fibers, had higher anticancer effect in 
vivo compared to systemic injection of equivalent dosage of the drugs.  
 
In Chapter 3, with the aim of establishing a suitable implantable platform for multimodal 
chemo-photothermal cancer therapy, we have fabricated for the first time a coaxial 
composite hydrogel fiber using a wet-spinning method established in our laboratory. 
Particularly, the core-section of these fibers (Chemo-compartment) contained dopamine-
modified alginate along with a chemotherapeutic drug (Doxorubicin), while their shell 
section (Phothothermal compartment) was composed of UV-crosslinkable methacrylate-
modified algine together with Cu2−xSe Nanoparticles. It was hypothesized that specific 
biopolymeric composition of these fibres along with their corresponding core-shell 
geometry would allow controlled release of Doxorubicin (loaded in the core), while the 
Cu2−xSe nanoparticles (loaded in the shell) would facilitate heat generation upon near 
infra-red (NIR) laser irradiation. The results suggested that the fibres possessed a core-
shell morphology where nanoparticles were dominantly distributed in the shell section. 
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Furthermore, it was shown that addition of Doxorubicin and Cu2−xSe Nanoparticles to the 
coaxial fibres led to an increase in their corresponding tensile properties (when compared 
to unloaded coaxial fibres), an effect which was more prominently observed for fibres in 
their wet state. In addition, not only the coaxial composite fibres allowed controlled 
released of Doxorubicin in vitro over a span of 3 weeks, but they were also capable of 
generating heat in a tuneable manner (based on the length of the fibre) upon NIR 
irradiation, in both in vitro and in vivo conditions. Most remarkably, the coaxial drug-
loaded composite fibres in the presence of NIR radiation showed superior anti-cancer 
effect (both in vitro and in vivo) when tested against breast cancer cell lines, a 
phenomenon attributed to their synergistic chemo-photothermal effect. 
 
In chapter 4, with the purpose of fabricating a suitable platform for prolonged delivery 
of Gemcitabine (a chemotherapeutic drug), we have 3D printed a novel coaxial hydrogel 
patch. Particularly, the core-section of these patches contained dopamine-modified 
alginate methacrylate loaded with Gemcitabine, while their shell section was solely 
comprised of alginate methacrylate. Subsequently, these patches were further modified 
with CaCO3 cross linker and a PLA coating to facilitate prolonged release of the drug. 
The results showed that addition of CaCO3 to the formula enhanced the mechanical 
properties of the patches and significantly reduced their swelling ratio as compared to that 
for patches without CaCO3. Furthermore, addition of PLA coating to CaCO3-containing 
patches has further reduced their swelling ratio, which then significantly slowed down the 
release of Gemcitabine, to a point where 4 layered patches were capable of releasing 
Gemcitabine over a period of 7 days in vitro. Moreover, PLA coated CaCO3-containing 
patches showed a good level of biocompatibility when tested in vitro against pancreatic 
cancer cell lines. Remarkably, in vitro long term therapeutic effect of these GEM-loaded 
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patches were assessed, and the results showed that 3 layers- and 4 layers structures were 
successful in inhibiting the cancer cell growth for 14 days.  
 
Chapter 5 concludes the body of work that has been done in this thesis and provides 
recommendations for future works based on the obtained results. Of note, every chapter 
contains its own introduction, experimental chapter, results and discussion, conclusion, 
and a final supporting information.
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1.3. Introduction and Literature review 
 
 
Cancer is a disease that arises from mutated cells that have acquired the capacity to 
proliferate indefinitely and evade apoptosis which eventually leads to tumor formation 
and subsequent invasion to surrounding tissues (also known as metastasis).1-2 
Accordingly, advanced cancer is viewed as a “systemic” disease that requires systemic 
treatment and on account of such notion systemic administration (administered by 
intravenous injections) of chemotherapeutic drugs has been established as one of the 
standard methods to treat cancer. 3-5 Traditional systemic chemotherapy has many 
limitations in treating the disease including: low efficiency of delivering the drugs 
specifically to the tumor site at therapeutic concentrations, and the ensuing toxicity to 
healthy tissues.6-8 Consequently, local delivery systems have entered the fray to address 
the shortcomings of systemic delivery, by delivering the drug directly to the tumor site 
using an implantable system (Figure 1-1). 9-10 The implantable drug delivery system 
(DDS) contains one or more therapeutic agents while being placed around or inside the 
tumor to facilitate targeted delivery.11-12 These DDSs are intended to enhance drug uptake 
and efficacy since they (I) are delivered locally (directly at the site of the tumor) and 
therefore offer strategic and precise spatial control that significantly reduces the required 
drug dosage and often the side/off-target effects, (II) present temporal control over release 
profile of chemotherapeutic agents to maintain therapeutic concentrations over a longer 
duration of time and (III) protect the loaded drugs from degradation or clearance until 
they are released.4, 6, 13-16 In the past decade, a wide variety of biomaterials have been 
exploited to institute anti-cancer implantable DDSs, and the properties afforded by 
biopolymers (such as biocompatibility, biodegradability, and ease of processing), has led 
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to recent increased attention.9, 17-19 A significant advantage of biopolymeric implantable  
DDSs is that they do not demand surgical extraction after use, as they can be cleared 
naturally by the body.20   
 
Figure 1-1. Schematic of systemic drug delivery versus local drug delivery for treatment of 
malignant tumors, including various types of bio-polymeric implantable systems used for local drug 
delivery and different anti-cancer therapeutic modalities employed based on these implantable 
systems. 
 
Biopolymeric implantable DDSs are classified under two distinct categories, pre-formed 
systems or systems that are formed after the injection into the tumor site.21 Pre-formed 
implants have been made from commercially available and FDA (U.S. Food and Drug 
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Administration) approved synthetic biopolymers such as polycaprolactone (PCL), 
polylactic acid (PLA) and poly(lactic-co-glycolic) (PLGA) - or naturally occurring 
polymers including alginate, gelatin, silk and dextran. Pre-formed systems were typically 
fabricated through well-established fabrication methods such as casting, electrospinning 
and 3D printing.22-41 On the other hand, in-situ formed implants are realized by direct 
injection into the tumor site, typically using gels that solidify in response to either 
temperature or pH (Figure 1-1).42-57 Biopolymeric implantable DDSs have shown to be 
capable of releasing the therapeutic agents either actively (stimuli-responsive systems) or 
passively (non-stimuli responsive systems). Accordingly, stimuli-responsive systems 
showed a rapid change in dimension or physical properties, instigated by either internal 
stimuli within the body, such as temperature or pH, or external stimuli such as 
electromagnetic waves, ultrasound, visible-, infrared (IR)- and near infrared (NIR)-light 
(Figure 1-2).58-62  
 
Figure 1-2. Schematic showing different mechanisms of drug release from bio-polymeric 
implantable drug delivery systems (DDSs). 
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With non-stimuli responsive systems release is passive and controlled by diffusion, drug-
carrier affinity, degradation of polymer, and/or any combination of these 13, 63-64. 
Therefore, in these systems factors such as tortuosity of pores, steric interactions between 
drug and matrix, reversible chemical interaction of drug and matrix, and molecular weight 
of polymeric matrix determine the release profile of the therapeutic agent in question.13, 
65 Overall, application of the biopolymeric implantable DDSs for cancer therapy goes 
beyond delivery of anti-neoplastic agents (e.g. chemotherapeutic drugs), as recently they 
have been successfully applied to other cancer therapeutic modalities (Figure 1-1) 
including hyperthermia: local heating of tumors to a very high temperature using 
electromagnetic waves or NIR radiation;50 photo-dynamic therapy: utilization of 
photosensitizing agent and a particular type of light that produce reactive oxygen species 
to induce cancer cell death;56 gene therapy: treating the disease using small interfering 
RNAs (siRNA) and microRNAs (miRNA);66 and immunotherapy: aiding the immune 
system to eradicate the malignancy.67 Interestingly, these DDSs were also shown to be 
capable of taking on a combination of multiple therapeutic modalities such as 
chemotherapeutic drugs and gene therapy, to synergistically treat malignant tumors.68-69 
Nonetheless, implantable biopolymeric DDSs have been commonly used in two different 
ways to aid in the treatment of various cancers: they can either be used as neoadjuvant or 
adjuvant therapies, in which the tumor itself can be treated (neoadjuvant) or the site where 
the tumor was removed can be treated to prevent cancer reoccurrence (adjuvant).21  
 
In this section, we will review the most recent progress in biopolymer-based DDSs for 
abrogating various tumors. We will specifically focus on studies with preclinical in vivo 
evidences or those with clinical evaluations, as we believe these studies are of higher 
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value for transition of DDSs from concept to clinical application. We will further 
highlight various fabrication methods commonly deployed for making these DDSs and 
review the anti-tumor performance of some recent impressive examples. 
 
1.3.1.  Implantable anti-tumor DDSs   
 
1.3.1.1. Preformed Implants 
 
Owing to specific features of preformed implants, such as their structural integrity and 
defined geometric shapes, these implants endow predictable and adjustable long-term 
release and degradation profiles. In vivo implantation of these systems typically entails 
an invasive surgery.12, 17  
 
 
1.3.1.1.1. Cast implants 
 
Casting is considered one of the oldest fabrication methods and it can be further divided 
into different subcategories such as solvent casting/particulate leaching, gel casting or 
melt casting. Regardless of the sub category it involves pouring the polymer solution/melt 
into a cast and subsequently solidifying the precursor through heat/chemical or physical 
cross-linking/recrystallization.70-72 One of the main perks of casting is the flexibility in 
choice of material as it can be easily applied to thermoplastic biopolymers (such as PLA, 
PLGA or PCL) as well as natural/synthetic hydrogels. Moreover, it can be utilized for 
fabrication of either 2D films or 3D delivery systems. 22-24, 31, 73-75 However, casting comes 
up short in producing structures wherein porosity, mechanical properties and/or 
composition as well as the distribution of these is controllable. Nevertheless, on account 
of its simplicity it has been widely employed for fabrication of anti-cancer DDSs from 
various biopolymers. 24, 73, 76 
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Silk 
 
Silk fibroin, a protein based material, has been gaining a foothold in biomaterials science 
and oncology therapeutics.77-78 In addition to the use of silk materials for disease therapy 
for centuries, they are FDA approved for implantation as a bioresorbable scaffold.79 
Moreover, biodegradable materials based on silk fibroin isolated from Bombyx mori 
silkworm cocoons have been shown to induce minimal immune response in vivo.80-81 
Consequently, it was observed that this type of protein can be combined with various anti-
cancer drugs to bring about anti-tumor activity. For instance, recently, delivery of 
vincristine and Doxorubicin (DOX) from silk foams, for treatment of neuroblastoma in a 
mouse model, has been investigated.26 These implants were fabricated by lyophilization 
of silk solution inside a mold and subsequent thermal cross-linking at 121 ºC. The silk 
implants were placed intratumorally and the in vivo results revealed that silk foams loaded 
with vincristine, with and without DOX, significantly decreased neuroblastoma tumor 
growth, increased tumor drug availability and decreased ultimate plasma concentration 
compared to intravenous (IV) drug treatment. In another study, silk films loaded with 
DOX were used to suppress primary tumor growth as well as metastasis in breast cancer 
mice model (Figure 1-3). 24 The in vitro results revealed a direct correlation between 
absorption of DOX on silk films and silk crystallinity (beta-sheet content) that enabled 
controlled release of drug. The in vivo findings ensuing implantation of films at the 
primary tumor site indicated that silk films loaded with DOX had greater primary tumor 
response when compared to equivalent dosage of drug administered intravenously. In 
addition, drug loaded stabilized films showed reduction in metastatic dissemination as a 
result of locoregional control of the disease.   
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Figure 1-3. Preparation and in vivo anti-tumor performance of DOX loaded films. A) Strategies to 
generate Doxorubicin-loaded films that are water-insoluble with variable β-sheet content. B) Free-
standing Doxorubicin-loaded silk films in the dry state. C) Weight of primary tumours at the end of 
the study (week 6). D)  In vivo tumor cell-specific bioluminescence of representative mice from each 
treatment group at week 6. Plot symbols are defined in panel (C). E) Metastatic spread of cancer 
cells to organs at week 6. Plot symbols are defined in panel (C), Reprinted from 24, Copyright 




Gelatin a natural protein derived from hydrolytic degradation of collagen, has attracted 
much attention in the biomedical field owing to its biocompatibility and biodegradation 
in physiological environments.82-84 However, gelatin has a sol-gel transition temperature 
around 30 ºC, and so needs to be cross-linked to avoid dissolution at body temperature.85 
Yet, in the context of cancer drug delivery this property can be leveraged to allow 
controlled release of the drug in a temperature-dependent manner. For example, Zhang et 
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al., made a physically cross-linked gelatin hydrogel that was embedded with 
poly(ethylene glycol)-block-poly(caprolactone) (PEG-b-PCL) nanoparticles ,which were 
co-loaded with tetrandrine (Tet) and paclitaxel (PTX), and evaluated the performance of 
this implant (P/T-NPs-Gelatin) for treatment of gastric cancer in mice model.22 These 
hydrogel implants underwent a gradual gel-sol phase transformation at 37 ºC, which 
resulted in controlled release of drug loaded nanoparticles. In vivo results showed that 
P/T-NPs-Gelatin implants had the greatest inhibitory growth effect when compared to 
either intraperitoneal delivered P/T-NPs or free combinations of PTX and Tet. Similarly, 
a gelatin hydrogel loaded with gelatin/poly(acrylic acid) nanoparticles containing 
cisplatin (CDDP) was used for treatment of liver cancer in a murine hepatoma cancer 
model.28 It was found that implantation of the gelatin hydrogel containing CDDP-loaded 
nanoparticles on tumor tissue led to a remarkably higher efficacy in preventing tumor 
growth as well as prolonged lifetime of the mice compared to that of IV injected CDDP-
loaded nanoparticles. More importantly, bio-distribution results revealed that these 
gelatin hydrogel implants yielded a much higher drug concentration in tumor and far less 
accumulation in non-target organs when compared to that in the group which received 
systemic administered CDDP-loaded nanoparticles. Since gelatin has a variety of 
functional groups on its side chains, they can be exploited in various ways to crosslink 
the hydrogel either chemically or physically.85 Accordingly, Jaiswal et al., developed a 
hydrogel implant by in-situ polymerization and cross-linking of acrylic acid with 
polycaprolactone diacrylate in the presence of gelatin.27 It was shown that an increase in 
crosslinker concentration led to a slower degradation rate as well as drug release. 
Additionally, the semi-interpenetrating network of gelatin and poly-(acrylic acid) loaded 
with DOX was implemented as an adjuvant therapy by implanting it into the tumor cavity 
post tumor resection to prevent recurrence of breast tumors in mice models. It was 
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observed that use of this drug-loaded implant led to prevention of tumor recurrence after 
resection until day 25 as opposed to implants with no drugs which showed tumor relapse 




Dextran is a polysaccharide of microbial origin consists of glucose molecules connected 
via a 1-6 glucosidic linkage while side chains are connected in a 1-4 linkage.86 Aside from 
its biocompatibility and biodegradability, this polymer is resistant to protein adsorption 
and consequently it was deployed as drug delivery vehicles.87 Owing to abundance of 
hydroxyl groups in this polymer, one can partially oxidize them to produce aldehyde 
groups that can be crosslinked by addition of amine-containing polymers.88 For instance, 
based on a schiff-base interaction between dextran-aldehyde and polyamidoamine 
(PAMAM) dendrimers, an implantable hydrogel was made, which was embedded with 
poly(β-aminoester) nanoparticles containing anti-luciferase siRNA.23  This composite 
hydrogel was tested in vivo in a xenograft mouse model for human breast cancer, and 
showed no sign of inflammation after implantation. All mice subjected to these implants 
maintained healthy conditions indicating implant biocompatibility. Furthermore, 
nanoparticle loaded hydrogels promoted efficient luciferase silencing, with up to 70% 
reduction in luciferase expression after day 6, which was significant when compared to 
20% reduction of luciferase expression achieved by intratumoral injection of 
nanoparticles after the same period of time. Conde et al., loaded the same hydrogel with 
dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-intercalated nanobeacons, 
which acted as an on/off switch activated by the increase of multidrug resistance protein 
1 (MPR1) within the tumor microenvironment.68 These nanoparticles were specifically 
designed to detect and target MPR1 genes, a process that triggered concomitant 5-FU 
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release following nanobeacon opening. Consequently, in vivo implantation of these 
nanoparticle loaded hydrogels resulted in over 90% tumor reduction in a triple-negative 
breast cancer (TNBC) mice model as a consequence of 80% MPR1 silencing.  
In other work by this group, the same hydrogels were simultaneously loaded with gold 
nanospheres decorated with siRNAs and gold nanorods containing the anti-cancer drug 
bevacizumab(Avastin®), to bring about a “combinatorial” triple-combination therapy for 
tumor regression as well as recurrence prevention in a colon cancer mice model (Figure 
1-4).69  
 
Figure 1-4. Dextran-based hydrogel scaffold as prophylactic agent for in vivo local gene/drug 
delivery combined with phototherapy, before and after tumor resection in mice model of colorectal 
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cancer. A) Development of smart hydrogel-nanoparticle patch and subsequent implantation in mice 
model. B) Tumor burden following treatment as measured by luciferase activity, without tumor 
resection, C) and after tumor resection. D) Survival plot analysis of mice treated with hydrogel 
scaffolds for single therapies or triple therapy. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Materials 69, Copyright (2016). 
 
The gold nanospheres were designed to specifically silent a major oncogene driver (Kras) 
in colorectal cancer (CRC) progression, while the gold nanorods had the capacity to 
convert NIR radiation into heat causing release of the drug as well as photothermal 
therapy to ablate tumors. Accordingly, this triple therapy hydrogel (gene therapy, 
chemotherapy and phototherapy combination) synergistically abrogated the tumor, and 
following resection it completely prevented colon cancer recurrence. Furthermore, 
animals which received triple therapy have shown 100% survival for at least 170 days 
which was significantly higher compared to control groups that received monotherapies. 
Conde et al., also established a self-assembled hydrogel containing RNA-triple-helix to 
modulate miRNA in the tumor microenvironment.66 This system was comprised of RNA-
triple-helix conjugated in PAMAM G5 dendrimers (triplex nanoparticles) which formed 
the hydrogel upon mixing with dextran aldehyde. The RNA-triple-helix was formed by 
self-assembly of two miRNA oligonucleotides, an antagomiRNA used to inhibit an 
oncomiRNA and a miRNA mimic used as tumor suppressor. This nanoparticle loaded 
hydrogel were subsequently implanted in TNBC mouse models, which led to almost 90% 
tumor size reduction 13 days after hydrogel disk implantation, as well as a significant 
survival advantage in comparison to drug-loaded hydrogels. The highly selective and 
specific treatment of tumor cells has been shown to be the main advantage of this system 
over traditional chemotherapeutic drugs. 
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PLA and PLGA 
 
PLA is an FDA approved synthetic biocompatible polymer, belonging to poly (α-hydroxy 
acid) class and undergoes in vivo hydrolytic degradation through de-esterification.89 
However, long degradation times along with high crystallinity causing fragmentation can 
result in inflammatory reactions in vivo.  Numerous methods have been used to decrease 
crystallinity and subsequently hasten biodegradation.90 For instance, copolymerization of 
lactic acid and glycolic acid has produced PLGA with tunable degradation based on the 
ratio of lactic acid to glycolic acid.91-92 Hence, on account of desirable properties of PLGA 
this copolymer was extensively used in variety of clinical applications including drug 
delivery systems for cancer therapy.93 For instance, Wang et al., incorporated 
nanoparticles of RGD-modified PEGlated PAMAM dendrimer loaded with DOX (RGD-
PPCD) into PLGA/PLA solution containing PEG (polyethylene glycol; as drug release 
modifier) and then casted them into a cylindrical die.75 In vitro release studies revealed 
that the ratio of PLGA/PLA had an impact on the release of DOX, with an increase in 
PLA content decreasing the drug release rate. It was also observed that different amounts 
of PEG can influence the DOX release, as an increase in PEG led to significant increase 
in release rate of DOX. Furthermore, in vivo results indicated that PLG/PLA scaffolds 
containing RGD-PPCD nanoparticles could significantly reduce glioma tumor size in 
mice as opposed to their counterparts including PPCD implant, DOX implants and blank 
implants. These findings were assumed to be result of better penetration of RGD-PPCD 
nanoparticles into the tumor which highlighted beneficial role of RGD sequence in tumor 
retention of nanoparticles. PLGA was also utilized to fabricate a biopolymeric cylindrical 
implant, known as local drug eluter (LODER), that contained an siG12D (an siRNA 
against the mutated KRAS oncogene) for growth inhibition of pancreatic tumors in a 
mouse model.94 It was found that encapsulated siG12D in LODER was active and stable 
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for 155 days in vivo. Further, it was shown that these implants were capable of impeding 
the tumor growth and prolonging mouse survival time. This group also conducted a phase 
I and a phase II clinical trials for patients with unresectable locally advanced pancreatic 
cancer (LAPC). The siG12D LODER implant (implanted into the tumor using an 
endoscopic EUS biopsy needle) was combined with chemotherapy and the results showed 
that from twelve patients analyzed by CT scans, none showed tumor progression and most 
of them (10/12) demonstrated stable disease. Tumor marker CA19-9 was observed to 
decrease in 70% of patients and 18 month survival rate was 38.5%.95     
Recently, in a ground breaking study, researchers have tried to treat the pancreatic ductal 
adenocarcinoma (PDAC) by developing a tunable PLGA-based platform that enabled 
local delivery of anticancer drugs to the targeted tumor tissue (Figure 1-5).31 
Accordingly, a PLGA solution mixed with PTX was cast on top of a stainless steel disc 
containing a suture hole. The resulting PTX eluting device (PED) was sutured onto the 
tumor surface in mouse xenograft model (different PDAC cell lines with different 
sensitivity to PTX). The results suggested that thickness of the PLGA layer had a direct 
impact on PTX released, in that thicker layers yielded higher and longer release when 
compared against thinner layers. In vivo this implant showed up to 12-fold increase in 
suppression of tumor growth (PDAC-3 tumors with highest sensitivity to PTX), caused 
longer survival of mice and reduced retention in non-target organs in comparison with the 
group that received IV PTX. Finally, in another study, researchers have fabricated DOX 
loaded PLGA cylindrical millirods by casting the polymer and drug mixture into a Teflon 
tube via deploying heat/compression.96 The millirods were implanted in the center of VX2 
liver tumors in rabbits and the results showed that these implants were capable of 
significantly reducing the tumor size when compared to untreated controls. Furthermore, 
histological examinations revealed that necrosis happened throughout the tumor, 
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however, some viable tumor cells were observed advancing beyond the main front of the 
tumor due to their lack of exposure to therapeutic drug concentration. 
 
Figure 1-5. Design, characterization and in vivo anti-tumor performance of implantable paclitaxel 
eluting device (PED). A) Schematic of localized therapeutic approach with PED. B) Macroscopic 
visualizations of the local delivery device. C) Scanning electron microscopy images of PLGA 
coating on top of steel (“C” = coating and “S” = steel). D) Relative tumor growth curves of PDAC-3 
mouse xenografts after treatment with either paclitaxel intravenous or PED treatment. E) Survival 
plot showing longer median overall survival (28 day increase) for mice treated with PED compared 
to mice treated with I.V. injection of paclitaxel. F) Histological analysis of PDAC-3 tumors after 
treatment with PED showing higher areas of necrosis (N) compared to preserved tumor structure 
(T) in group treated with I.V. paclitaxel. Reprinted from 31, Copyright (2016), with permission from 
Elsevier. 
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PCL 
 
PCL is yet another biocompatible polyester that has semicrystalline structure with a glass 
transition temperature (Tg) of -60 ºC. Therefore it has highly flexible mechanical 
properties at room temperature which is the reason it was extensively exploited in various 
biomedical applications.97 This polymer has even slower degradation rate than PLA, due 
to presence of five hydrophobic –CH2 moieties in its repeating unit.98-99  Nevertheless, 
owing to its slow degradation as well as its compatibility with a wide range of drugs, it 
was shown to facilitate drug release up to several months and it was used to fabricated 
anti-cancer implantable DDSs.99For example, injection molding was used to fabricate 
PCL made needle-shaped conical implants that were loaded with 5-FU to abrogate breast 
tumors in a mouse model.100 Owing to the specific design of these implants they were 
capable of being injected directly into the tumor using a puncture needle that eliminated 
the need for invasive surgery. Moreover, in vivo tests revealed that these implants were 
capable of significantly preventing tumor growth as they could provide higher regional 
drug concentration compared with those in mice that did not receive any treatment or only 




PCPP-SA (20:80 molar ratio) is an extremely hydrophobic copolymer that possesses 
surface-controlled erosion and hence it was used to fabricate Gliadel wafers for treatment 
of brain tumors in several clinical studies.101-102  These wafers were fabricated in a two-
step process, where initially they were dissolved in an organic solvent along with 
carmustine (BCNU) and subsequently spray-dried into microparticles that were 
eventually made into wafers using compression molding.4 So far several preclinical in 
vivo studies were performed by loading these wafers with carmustine,103 or other anti-
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cancer agents such as PTX,104 4-Hydroperoxycyclophosphamide (4-HC) 105, DOX,106 3-
bromopyruvate (3-BrPA) and dichloracetate (DCA),107 and subsequently implanting 
them intracranially against malignant glioma. For instance, one study in rat brain revealed 
that carmustine loaded wafers were capable of releasing carmustine over a time span of 
five days and they were ultimately fully degraded 6-8 weeks after implantation 103. In 
another study PTX-loaded wafers were used for treatment of malignant glioma in rat brain 
and it was observed that PTX-loaded wafers improved the median survival of rats to 
different degrees depending on concentration of loaded PTX.104 Further, it was found that 
these wafers provided a much higher PTX concentration in the brain tissue proximal to 
the implant (75-125 ng taxol/mg brain tissue) than more distant sites (4 ng taxol/mg brain 
tissue). Fung et al., also carried out a pharmacokinetic study on interstitial delivery of 
carmustine, 4-HC, and PTX from the wafers in the monkey brain which showed high drug 
concentration (0.5-3.5 mM for carmustine, 0.3-0.4 mM for 4-HC, and 0.2-1.0 mM for 
PTX) within first 3 mm from the implant and fairly lower concentration at 5 cm from the 
implant (0.4 µM for carmustine, 3 µM for 4-HC, and 0.6 µM for PTX) after 30 days from 
implantation.105 Using area under concentration-time curve (AUC), it was also found that 
tissue exposure to carmustine by using implants were 4-1200 times higher than that 
achieved by IV administration of a higher dose. Lastly, another group of researchers 
investigated delivery of 3-BrPA and DCA using the wafers (both a as monotherapy or in 
combination with oral administration of temozolomide (TMZ) and radiation therapy 
(XRT)), in rat models with gliosarcoma.107 The results showed that intracranial 
implantation of 5% 3-BrPA wafers and 50% DCA wafers led to significant improvement 
in median survival of animals, 18 days for 5% 3-BrPA wafers and 17 days for  50% DCA 
wafers, when compared to the control group that did not receive any treatment (13 days). 
Furthermore, combination of 5% 3-BrPA wafers and TMZ markedly improved the 
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survival when compared to either therapy alone. Though triple combination therapy of 
wafers with TMZ and XRT did not show any statistical advantages in survival, however, 
5% 3-BrPA wafers given on day 0 in combination with TMZ and XRT resulted in long-
term survivorship of 30%.           
In addition, numerous clinical studies for treatment of malignant glioma with gliadel 
wafers (as adjunct to surgery and irradiation) showed notable increase in median survival 
time for patients with both primary and recurrent disease 108-111, which ultimately gained 
these wafers FDA approval in 1997 for the treatment of recurrent malignant glioma. 
However, complications still remain, some of the most common side effects of these 
wafers in clinical trials included: seizures, intracranial hypertension, impaired 
neurosurgical wound healing, meningitis, wafer migration and  poor drug penetration .112-
113              
 
Poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18) 
 
PGC-C18 is a super-hydrophobic, biocompatible copolymer of caproic acid and glycerol 
functionalized with stearic acid.114 Conjugation of hydrophobic side chains (stearic acid) 
imparts a large amount of hydrophobicity into this copolymer which makes it a suitable 
candidate for fabricating DDSs capable of delivery of anti-cancer drugs over an extended 
period of time.115 Consequently, Liu et al., fabricated PTX loaded PGC-C18 polymeric 
films for prevention of local tumor recurrence after resection in a mouse model with lewis 
lung carcinoma (LLC) tumor.74 In vitro drug release evaluation showed that the drug 
loaded film released the PTX over several weeks and in vivo results revealed that PTX 
loaded films prevented local tumor recurrence in 83.3 % of animals compared with 22.2 
% for systemically administered drug. Additionally, after 10 days, drug loaded films 
demonstrated a significantly greater PTX concentration (3000-fold) at the site of resection 
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when compared to that for systemic injection of PTX with equal concentration. The same 
group used these PTX loaded films to reduce locoregional recurrence of chondrosarcoma, 
in mice xenograft model, following macroscopically complete  tumor resection.73 Based 
on in vivo observations, it was found that in mice treated with PTX-loaded films 
locoregional recurrence was 17 %  which was much lower than this value for PTX IV 
treated mice (89 %). Furthermore, animals treated with PTX-loaded films showed longer 
median overall survival (81 days) compared to PTX IV treated animals (48 days), which 
was due to higher concentration of PTX in the local tissue. In another study, PGC-C18 
films loaded with anti-cancer agent 10-hydroxycamptothecin (HCPT) were used to 
prevent local growth and proliferation of LLC tumor in mice model.116 Drug-loaded films 
were applied to a collagen-based scaffold to form a flexible composite that can be 
administered to resection margins of soft tissue via application of a surgical stapler. In 
vitro, HCPT-loaded composites released the drug over a period of seven weeks and in 
vivo observations revealed that animals treated with HCPT-loaded composites had much 
higher freedom from tumor growth (86 %) compared to animals that received larger 
intravenous dose of HCPT (0 %). Moreover, histological analysis of tissues at the surgical 
site showed normal wound healing process indicating the nontoxic nature of this 
composite.            
 
1.3.1.1.2. Electrospun implants  
 
Electrospinning involves the usage of a strong electric field to create fibers (with diameter 
ranging from micrometers down to tens of nanometers) by extruding a polymer solution 
from an injection needle and depositing them on a collector plate.117-120 The electrospun 
fibers can vary in size and orientation (randomly distributed or aligned) based on the 
deployed processing parameters such as polymer solution flow rate, applied electric 
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voltage, collector configuration (stationary or rotary), needle-tip-to-collector distance and 
needle size.121-122 As a consequence of the many interesting properties of electrospun 
fibers, including high specific surface area and tunable porosity, they have been 
frequently utilized as implantable depots for drug delivery.117, 123-124  One of the 
outstanding features of electrospinning is its ability to create multiaxial fibers comprised 
of a core, which can be drug loaded, and a sheath, that can retard the release of drug from 
the core, and as a result these multiaxial fibers have recently gained attention for 
controlled drug delivery.125-131 Despite these properties, the use of electrospinning  is 
limited in terms of fabrication of 3D implants with complex shapes and geometries, and 
not all biopolymers are spinnable with this technique.121, 132 Nevertheless, over the past 
decade electrospun fibrous mats, fabricated from a variety of biopolymers, have been 
largely used as DDSs for abrogation of malignant tumors or preventing their reoccurrence 
in numerous studies.133  
 
PLA and PLGA 
 
PLA and PLGA were shown to be ideal choices of polymers for fabrication of electrospun 
fibers, mainly due to their solubility in volatile chlorinated and fluorinated solvents as 
well as their availability in a wide range of molecular weights, which allowed ease of 
electrospinning of these polymers.134-135  Electrospun PLA and PLGA mats have been 
frequently used as DDSs for cancer therapy.136 For example, electrospun PLA nanofibers 
that were loaded with DOX and used as local delivery systems against two types of 
secondary hepatic carcinoma (SHCC), namely nodular and diffuse SHCC (NSHCC and 
DSHCC), in mice.33 The in vivo results showed that targeting NSHCC tumors with DOX 
loaded fibers led to significant suppression of NSHCC growth and increased the median 
survival time of mice with DSHCC from 14 days to 38 days. In another study, Ding et 
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al., Loaded the poly-D,L-lactide (PDLLA) nanofibers with docetaxel (DTX) to prevent 
breast cancer reoccurrence in mouse model.36 It was shown that animals treated with drug 
loaded membranes had significant decrease in locoregional reoccurrence after primary 
tumor resection (16.7%) when compared to systemic administered DTX (75.0%) or local 
administered DTX (77.8%). Additionally these drug loaded membranes showed minimal 
signs of inflammation in the surrounding tissue indicating a high level of 
biocompatibility. Similarly, other researchers investigated the inhibitory effect of 
released DCA from PLA electrospun mats to suppress cervical carcinoma in tumor-
bearing mice.137 In vivo observations after 19 days showed a significant suppression of 
tumor growth in animals treated with drug loaded fibers as well as substantial reduction 
of tumor weight. This was assumed to be a result of synergistic necrosis of tumor cells by 
two different necroptosis mechanisms that were caused by high dosage of DCA. In a 
different study, (5-FU)-loaded PLLA nanofibrous membranes were developed for 
suppressing colorectal cancer in xenografted mice.138 In vivo it was shown that these 
membranes were more capable of supressing tumor growth than an intraperitoneal 
injection of 5-FU (at median lethal dose (LD50) concentration) due to prolonged and 
continuous release of 5-FU from the membranes. PLA fibers can also be loaded with 
multiple chemotherapeutic agents to treat cancer in a combinatorial manner. For instance, 
Zhang et al., evaluated the in vivo activity of PLA fibers containing 5-FU and oxaliplatin 
(Oxa) against colorectal cancer (CRC) in tumor-bearing mice.139 As a result, it was shown 
that drug loaded fibers can significantly inhibit tumor growth due to higher local drug 
dose, caused by a sustained drug release from the fibers. Additionally, histopathological 
studies of the excised tumor tissue showed large areas of necrotic regions in the tumors 
after treatment with drug loaded fibers which was in great correspondence with 
immunohistochemistry results of apoptosis related proteins (namely Bax and Bcl-2). 
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PLA fibers could also be arranged in a multilayer structure to bring about controlled 
release of the drugs. As an example, Liu et al., fabricated asymmetric multilayer PLA 
nanofibers (AMPN) loaded with Oxa or a combination of Oxa and cyclophosphamide 
monohydrate (OxCy) to prevent liver cancer recurrence in mice models with either 
subcutaneous or orthotopic hepatocellular carcinoma (HCC).41 Three different types of 
multi-layered electrospun mats were fabricated, two layered (M2), three layered (M3) and 
five layered (M5) (Figure 1-6).  
 
Figure 1-6. Drug loaded asymmetric multilayer PLA nanofibers (AMPN) for preventing liver 
cancer recurrence. A)  Graphical presentation of multilayer nanofibers and scanning electron 
microscopy image of five layered (M5) nanofibrous mat. The top layer (i) in M5 and M3 mats 
contained PLA films to allow one sided release of drugs. B) Schematic illustration of performance 
of drug-loaded AMPN mats in human body for prevention of tumor recurrence after HCC surgery. 
C) Tumor recurrence rate, D) average tumor volume, and E) survival time as a function of time, for 
treated animals, post “subcutaneous tumor” surgery. Reprinted from 41, Copyright (2015), with 
permission from Elsevier. 
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The five layered implants showed the slowest in vitro release rate of loaded Oxa which 
was followed by three layered implants and two layered implants. Insertion of Oxa loaded 
multilayered membranes into the cavity, formed as a result of “subcutaneous tumor” 
removal, substantially slowed the rate of tumor reoccurrence and it increased the survival 
rate of the rodents compared to control group. Interestingly, tumor growth suppression 
capacity was shown to have a direct relation with in vitro release rate of Oxa, as the five 
layered implants showed the highest inhibition of tumor growth. Furthermore, in 
orthotopic HCC models wrapping of AMPN mats (loaded with OxCy) around the left 
liver lobe following partial hepatectomy revealed appearance of normal liver tissue 
without visible tumor reoccurrence in comparison to control groups, which was further 
confirmed by histopathological observations of liver samples. Similarly, the same group 
successfully fabricated other multilayered PLA electrospun mats loaded with cisplatin or 
Oxa/DCA that prevented local liver cancer or cervical cancer reoccurrence in mice 
models, respectively.37, 39 Last but not least, to allow loading of hydrophilic drugs into 
PLA-based fibers, this polymer has been mixed with more hydrophilic polymers and 
subsequently electrospun to make fibers with improved hydrophilicity. For instance, 
cisplatin loaded mucoadhesive nanofibers made out of a mixture of PLA and polyethylene 
oxide (PEO) were fabricated to abrogate cervical/vaginal cancer in mice.38 Owing to the 
hydrophilicity properties of PEO these nanofibers showed good in vivo vaginal retention 
and upon implantation into the vagina of mice, cisplatin concentration was found to be 
much higher in vagina/cervix region that in the non-target organs, in contrast to the case 
of IV cisplatin. However, these nanofibers did not show superiority over IV cisplatin in 
treating vaginal tumors. Consequently, in a separate study the same group co-loaded the 
PLA/PEO nanofibers with cisplatin and curcumin (cis-cur) to prevent cervical cancer 
reoccurrence after surgery.34 After resection of subcutaneous vaginal tumors drug loaded 
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fibers were implanted at the site of tumor resection and it was shown that these fibers 
were better capable of preventing local cervical cancer reoccurrence when compared to 
IV drugs, which was further supported by histological analysis showing large area of 
necrosis induced by cis-cur/fibers only 4 days after tumor resection. Along similar lines, 
Xia et al., successfully enwrapped GEM into electrospun fibers via microsol 
electrospinning technology to form a stable core–shell fibrous structure.140 The shell 
section of the fibers was made out of PLA and the core section contained hyaluronic acid 
(HA). The GEM release rate can be adjusted by altering the thickness of the hyaluronan‐
sol inner fiber and the quantity of loaded GEM, and the release can be sustained for as 
long as three weeks. In vitro assays show that these electrospun fibers effectively inhibit 
pancreatic cancer cells and promote apoptosis. In vivo studies show that the fibrous 
membranes are better for inhibiting the growth of residual tumors than that of integrated 
tumors. Furthermore, immunohistochemistry results show that GEM‐loaded fibers 
promote a higher cell apoptosis rate than does systemically injected GEM in residual 
tumors. In addition, the local delivery of GEM with fibers significantly reduces liver 
toxicity. 
As highlighted in the beginning of this section, PLGA has also been used in fabricating 
anti-cancer fibrous DDSs. For example, Ranganath et al., fabricated submicron (F2) and 
nanoscale (F3) discs from PLGA(50:50) electrospun fibers loaded with PTX and used 
them for inhibiting growth of glioblastoma in a mouse model.141 Consequently, F3 
nanofibrous discs demonstrated a greater drug release rate in vitro and in vivo, in 
comparison to counterparts including F2 submicron fibrous discs and PTX-loaded PLGA 
microspheres entrapped in sodium alginate beads. As a result, F3 discs showed higher 
drug availability and subsequently enhanced diffusion rate as well as diffusion distance 
in the mouse brain tissue that is crucial considering that glioblastoma multiforme (GBM) 
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typically reoccurs within 2 cm of the resection site. Moreover, F3 discs were capable of 
inhibiting the tumor at its early stages of tumor growth as a consequence of high local 
drug concentration, which is critical to slow down the reoccurrence rate of glioma in post-
surgical chemotherapy. In another study carried out by Tseng et al., PLGA nanofibrous 
membranes were loaded with combination of drugs including BCNU, irinotecan and 
cisplatin to treat malignant glioma in tumor-bearing rats.142 Consequently, in rats treated 
with drug loaded fibers (BIC/PLGA), a substantially higher concentration of drugs was 
observed in brain tissue than in the blood throughout 8 weeks of study. Rats treated with 
BIC/PLGA membranes experienced a much lower tumor volume after 16 days, when 
compared to that in rats which received blank PLGA membranes. Furthermore, in the 
BIC/PLGA treated group a much longer median survival time was achieved (~60 days) 
in comparison to the group treated with non-drug loaded (blank) membranes (~22 days).   
PCL 
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Due to specific rheological and viscoelastic properties of PCL this polymer and its 
copolymers have been successfully utilized in electrospinning to bring about fibrous 
mats.143 Similar to PLA and PLGA, PCL fibers were also utilized as drug carriers for 
local delivery of anti-cancer drugs to tumor site. For instance, Chen et al., made 
nanofibers from combination of PCL and gelatin (PG), that contained DOX-loaded core-
shell nanoparticles of Cu9S5-mesoporous SiO2 (Cu9S5@mSiO2) and used them for 
synergistic chemo- and photothermal therapy of hepatoma tumors in mice (Figure 1-
7).144  
 
Figure 1-7. A nanofibrous PCL-based composite for synergistic chemo- and photothermal tumor 
therapy. A) Schematic showing preparation of composite fibers as well as their subsequent 
implantation procedure for dual therapy of tumors. B) Tumor volume as a function of time after 
different treatments. C) Images of mice with tumors and photograph of corresponding excised 
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tumors after 11 days of treatments. D) Mean tumor weights after 11 days of treatments. 
Reproduced from 144 with permission of The Royal Society of Chemistry. 
 
In vitro DOX release in PBS (phosphate-based buffer) revealed that these fibrous 
membranes possessed pH responsive release owing to intrinsic properties of 
Cu9S5@mSiO2 nanoparticles, also, it was shown that after 5 min laser irradiation the 
temperature of Cu9S5@mSiO2 PG fibers dramatically increased from 21 ºC to 54.6 ºC. 
Additionally, in vivo results showed that DOX-loaded Cu9S5@mSiO2 PG composite 
fibers under laser irradiation had a more efficient tumor suppression effect once compared 
against single photothermal therapy of tumors by Cu9S5@mSiO2 PG fibers or with single 
chemotherapy by Dox loaded Cu9S5@mSiO2 PG fibers. In another study the same group 
fabricated similar PG nanofibers instead loaded them with DOX-containing 
NaGdF4:Yb/Er@NaGdF4:Yb@mSiO2-PEG core-shell nanoparticles (upconverting 
nanoparticles; UCNPs) and indomethacin (anti-inflammatory drug) to abrogate hepatoma 
tumors in mice.35 This composite fiber not only was aimed for controlled-release of DOX 
but also enabled upconversion fluorescence/magnetic resonance dual-modality imaging 
via NaGdF4:Yb/Er@NaGdF4:Yb incorporated into composite fibers. In vivo anti-tumor 
efficacy showed that composite fibers containing DOX-loaded UCNPs and indomethacin 
had the highest tumor inhibition rate (96%) when compared to simple DOX-loaded fibers 
(61.8%). Moreover, owing to presence of indomethacin in composite fibers, they caused 
complete healing of surgical wound. At last, in an attempt to further prolong the drug 
release of PCL nanofibers, researchers fabricated cisplatin-loaded superhydrophobic 
electrospun nanofibers from mixture of PCL and Poly(caprolactone-co-glycerol-
monostearate) (PGC-C18) for prevention of local cancer reoccurrence post resection in 
mice model with lung carcinoma.145 Owing to hydrophobicity of these nanofibers they 
have shown a sustained release of drug over 90 days. Further, in vivo evaluation showed 
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that these fibers were capable of significantly increasing median reoccurrence-free 
survival rate to more than 23 days compared to the group treated with intraperitoneal 




Owing to superior biocompatibility and biodegradability of gelatin, this polymer was 
extensively utilized to fabricate electrospun fibers (either alone or as a blend component) 
for various biomedical applications including drug delivery.123, 146 For instance, Yang et 
al., fabricated core-shell fibers, in which the core was comprised of polyvinyl alcohol 
(PVA) containing folate-decorated micelles (FM) of poly(ε-caprolactone)-poly(ethylene 
glycol) loaded with DOX (for active targeting of solid tumors), and the shell contained 
genipin crosslinked gelatin (Figure 1-8).131  
 
Figure 1-8. Core-shell micelle-loaded nanofibers for efficient cancer therapy. A) Schematic 
representation of multi-axial fibers and their corresponding in vivo performance. B) Biodistribution 
(for different time points) in different organs of mice after receiving different treatments. C) Tumor 
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volume and D) survival rate of treated tumor-bearing mice as a function of time. Reprinted with 
permission from 131, Copyright (2015) American Chemical Society. 
 
These fibers showed delayed in vitro release of DOX when compared with micelles alone, 
and further in vivo studies in mice with  breast cancer revealed that DOX accumulation 
in tumors for FM (IV administrated) and FM-nanofiber groups (implanted near the tumor) 
were significantly higher than that in DOX treated (IV administrated) group. Moreover, 
during 21 days of treatment, groups treated with FM-nanofiber showed comparable tumor 
growth suppression in comparison to the groups that received four times injection of DOX 
or M or FM. Lastly, FM-nanofiber treated group experienced a higher survival rate when 
compared to other groups, owing to lower systemic drug exposure caused by local 
delivery of DOX using the nanofibers.      
 
1.3.1.1.3. 3D printed implants 
 
3D printing  is known as a process whereby three dimensional solid objects of any shape 
are constructed from a computer-aided design (CAD) model via layer-by-layer deposition 
of materials onto a computer-controlled built platform.119, 147 Technically, 3D printing 
encompasses various technologies such as inkjet printing, microextrusion printing, laser-
assisted printing, stereolithography and fused deposition modeling (FDM), and they all 
offer significant advantages over traditional fabrication methods as they endow reliability, 
reproducibility and flexibility in design (geometrically complex shapes).147-149 In the 
context of cancer studies 3D printing has been used to recreate the 3D microenvironment 
of tumors by printing a variety of hydrogels and this aspect of 3D printing will not be 
reviewed here.150-152 Herein, we solely focus on bipolymeric anti-cancer drug eluting 
implants fabricated using 3D printing technologies.  
3D printed DDSs are commonly fabricated via microextrusion or FDM printing.153 
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Microextrusion printing involves continuous extrusion of biomaterials (in the form of 
solution/paste) from a temperature-controlled micro-extrusion head to a building 
platform, using pneumatic pressure or piston-assisted system, for layer-by-layer 
fabrication of 3D constructs.119, 154 FDM deploys preformed filaments fed into a 
temperature-controlled extruder where they are heated and subsequently the semi-molten 
thermoplastic is deposited onto a platform in a layer by layer process.155-156 Such printing 
is directly affected by processing parameters such as nozzle diameter and temperature, 
feed rate and print head speed.157-158 Interlayer bonding significantly affects the final 
properties of the printed product and consequently solidification procedures should be 
carefully controlled to avoid separation of subsequent layers. The major disadvantages of 
extrusion and FDM printing include: slow printing speed, nozzle clogging and interlayer 
debonding.159 Even so, these methods have been successfully practiced on biopolymers 
such as PCL and PLGA to fabricate implantable anti-cancer DDSs. 
 
PLGA and PCL 
 
Owing to the thermoplastic nature of PCL and PLGA in conjunction with their favorable 
biocompatibility and biodegradability, they have been utilized to create 3D printed DDSs 
for cancer therapy. For example, most recently extrusion printing was used to fabricate a 
3D patch made from a mixture of PLGA (lactide:glycolide = 85:15) and PCL loaded with 
5-FU for growth suppression of pancreatic cancer (Figure 1-9).29 The patches were 
printed with three different pore shapes and geometries (latticed, slant and triangular) in 
different thicknesses and it was found that these features can greatly affect the drug 
release profile by altering the surface area:volume ratio (S:V) of the structure. 
Implantation of drug-loaded patches (P100;100 mg 5-FU and P150;150 mg 5-FU) 
underneath a pancreatic cancer tumor in mice, resulted in a substantial decrease in tumor 
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size when compared to non-drug loaded patch (P0) groups. 
 
Figure 1-9. 3D printed patch for local delivery of 5-FU for pancreatic growth suspension. A) 
Schematic showing sample preparation procedure. B) Schematic and photograph of printed 
patches with different geometries. C) Relative tumor size as a function of time in mice after 
implantation of drug loaded patches. D) Photographs of excised tumors and the patches 4 weeks 
after implantation. Reprinted from 29, Copyright (2016), with permission from Elsevier. 
 
In another study, Sun and his colleagues fabricated a PCL scaffold using a FDM printer 
and coated the structure with a mixture of chitosan, chitosan-modified montmorillonite 
clay and β-tricalcium phosphate (β-TCP) which was subsequently coated with DOX 
solution (DESCLAYMR_DOX) to inhibit growth of breast tumors in mice .30 These drug 
eluting implants showed a significant burst release of DOX in the first 24 h that was 
followed by four weeks of sustained release. Further, subcutaneous implantation of 
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DESCLAYMR_DOX in mice showed prolonged presence of DOX to a much larger 
extent at the treatment site which resulted in higher tumor growth inhibition when 
compared to subcutaneous injection of DOX (INJECTION_DOX). Also compared to 
INJECTION_DOX, DESCLAYMR_DOX showed decreased multi-organ metastasis as 
well as cardiotoxicity due to local delivery of DOX. In another instance, Wei et al., 
presented a facile method to prepare core-shell hydrogel fibers/scaffolds with controlled 
drug delivery and designed structures for the treatment of the residual breast cancer and 
prevention of local recurrence after surgery.160 Mixtures of polydopamine (PDA) and 
concentrated alginate inks as the shell layer, and DOX-loaded temperature-sensitive 
gelatin hydrogels as the core part were co-injected and coaxial 3D printed into core-shell 
hydrogel fibers and scaffolds. Under near infrared (NIR) irradiation, PDA with excellent 
photothermal effect could raise the temperature of core-shell fibers, which induced the 
gel-sol transition of the core gels, and subsequently resulted in the drug release from the 
loosened hydrogel network. Photothermal effects and the released therapeutic drugs could 
effectively kill breast cancer cells and inhibited the growth of tumor. In addition, the in 
vivo performance of the core-shell fiber scaffolds could be monitored by photoacoustic 
imaging. 
 
1.3.1.2. Injectable in-situ forming implants 
 
Injectable DDSs are typically made from a solution/semisolid mixture of polymer matrix 
and therapeutic agents that solidify in situ upon injection into the tumor site. 10, 17, 161 The 
solidification mechanism will differ based on the type of biopolymer used, however, the 
existing injectable DDSs can be generally categorized accordingly161-163: (I) in situ 
precipitation, wherein the polymer precipitates from a solution state as a consequence of 
solvent removal 164-165, sol-gel transition in response to temperature change42-43, 45 or pH 
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change44, 166; (II) in situ crosslinking, wherein the polymer chains undergo 
physical/chemical cross-linking upon injection as a result of covalent bonding  55, 57, 167-
170 , or non-covalent bonding of polymeric chains.52-53, 56 The injectable implants hold 
great advantages over preformed implants including elimination of invasive surgical 
intervention and their ability to fill any cavity, into which they are injected.171-173 Some 
of the disadvantages of these implants are the complicated and sometimes toxic 
crosslinking chemistry required as well as the fairly long gelation time upon injection.161 
Nevertheless, recently injectable DDSs, developed from a broad range of biopolymers, 
have been extensively used to inhibit the growth of malignant tumors or prevent their 




Polyethylene glycol (PEG) 
 
PEG is a FDA-approved synthetic hydrophilic polymer that has various structures 
including linear and branched (multi-arm or star-shaped).175 Aside from its desirable 
properties such as good biocompatibility and non-immunogenity, this polymer is capable 
of being chemically modified with various functional groups (via replacement of two 
hydroxyl groups in its repeating unit) to provide certain functionalities.176-177 
Consequently, PEG and its copolymers have been frequently used to bring about 
injectable DDSs based on either in situ precipitation or in situ crosslinking mechanisms. 
PEG-based injectable hydrogels established via in situ precipitation are often thermo-
gelling hydrogels that have been synthesized via copolymerization of PEG with other 
polymers to allow sol-gel transition of the hydrogel upon changes in temperature. For 
instance, DOX-loaded nanoparticles made from copolymer of poly(ε-caprolactone-co-
1,4,8,trioxa[4.6]spiro-9-undecanone)-poly(ethylene glycol)-poly(ε-caprolactone-co-
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1,4,8, trioxa[4.6]spiro-9-undecanone) (PECT) have formed the macroscale hydrogel upon 
thermo-sensitive self-aggregation of PECT/DOX nanoparticles at 37 °C in aqueous media 
(Figure 1-10).43   
 
Figure 1-10. Injectable thermosensitive nanoparticle-assembled hydrogel for peritumoral 
chemotherapy. A) Schematic showing design concept and in vivo mechanism of action of the 
hydrogels. B) Images of sol-gel transition of hydrogels at 37 °C. C) Tumor volume change and D) 
percentage of survival, as a function of time, for treated animals. Reprinted with permission from 
43, Copyright (2016) American Chemical Society. 
 
Peritumoral injection of PECT/DOX hydrogel into the breast tumors of mice showed a 
much higher intratumoural concentration of DOX when compared to other organs, which 
in turn led to greater suppression of tumor growth. In addition, survival rate increased in 
animals treated with PECT/DOX hydrogel compared to ones who received IV injection 
of DOX or PECT/DOX NPs, which was largely due to the fact that hydrogels were 
capable of locally releasing DOX within the tumor area, preventing distribution of DOX 
to other organs. Researchers developed another thermo-sensitive hydrogel from MPEG-
b-(PCL-PLLA) diblock copolymer  loaded with 5-FU that underwent an instantaneous 
sol-gel transition at body temperature.178 Intratumoral injection of this system into 
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melanoma tumors in mice showed higher tumor suppression effect and subsequent 
necrosis of tumor tissue which was comparable to that of mice who received three 
intratumoral injections of free 5-FU, each at equivalent concentrations to that of one 
hydrogel injection. Similarly, Phan et al., synthesized a thermo-sensitive triblock 
copolymer of poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-
caprolactone-co-lactide) (PCLA-PEG-PCLA) that was used to develop an injectable 
hydrogel containing nanoparticles of montmorillonite loaded with Gemcitabine (MMT-
GEM).179 Interestingly, the targeted injection of this composite hydrogel into a pancreatic 
tumor (in mice) led to enhanced anti-tumor efficacy when compared to control group of 
intratumorally injected GEM solution at equivalent concentrations.  
Triblock copolymers of PLGA and PEG (PLGA-PEG-PLGA) are specifically attractive 
thermo-responsive systems on account of their biodegradability and acceptable safety 
profile and they showed to undergo sol-gel transition at physiological temperature (37 
°C).180 As a result, this copolymer has been exploited as delivery systems for anti-cancer 
drug delivery purposes.181-182 As an example, incorporation of DOX into this thermo-gel 
did not interfere with its sol-gel transition (except at high concentration of DOX; 4 mg/ml) 
and after injection of this drug loaded hydrogel in the vicinity of a sarcoma-tumor in mice, 
significant suppression of tumor growth as well as strong apoptosis of tumor cells were 
achieved. 183  Similarly, Zhang et al., used the same DOX loaded PLGA-PEG-PLGA 
thermo-gel and injected it into hepatic-tumor in mice.184 Interestingly, similar anti-tumor 
efficacy was observed in this case and toxicity studies revealed that these drug loaded 
hydrogels caused mild lesions in major organ tissues (heart, liver, spleen lung and kidney) 
when compared with DOX control group. The same gel was also loaded with PTX, also 
known as OncoGel, and used as palliative therapy in pre-clinical in vivo studies in rats 
with metastatic spinal tumors,185 mice with breast carcinoma 186 and porcine model for 
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future application in non-resectable pancreatic ductal adenocarcinoma.187  Most 
importantly, a phase I clinical trial on patients with superficially accessible advanced solid 
tumors and a phase 2a clinical study on patients with inoperable esophageal cancer 
(OncoGel used in adjuvant to radiotherapy), showed that OncoGel administered 
intralesionally was well tolerated, retained its position at the site of injection and caused 
low systemic concentration of PTX.188-189 Other types of PEG-based thermo-gelling 
copolymers include triblock copolymer of poly(ethyleneglycol)-poly(ε-caprolactone)- 
poly(ethyleneglycol) (PEG-PCL-PEG, PECE) and triblock copolymer of poly(γ-ethyl-L-
glutamate)-poly(ethylene glycol)-poly(γ-ethyl-L-glutamate) (PELG-PEG-PELG). Both 
these copolymers form a gel quickly after being exposed to body temperature and they 
have been employed for local delivery of anti-cancer drugs in animal models.190-191 For 
instance, Lei et al., loaded PECE with PTX and injected it at the original tumor site in 
4T1 breast cancer -bearing mice, with the intention of preventing locoregional recurrence 
of primary tumor after resection.49 As a result, recurrence of the tumor was significantly 
inhibited by administration of PTX-loaded PECE hydrogels (9.1%) compared with 
systemic (77.8%) or local (75%) administration of PTX at an equivalent concentration. 
In addition, this hydrogel accelerated post-operative wound healing at the surgical 
incision site, indicating its superior biocompatibility. In another work, Cheng et al., 
loaded PELG-PEG-PELG thermo-gels with PTX and used it for local delivery of PTX to 
liver carcinoma in mice models.192 Interestingly, it was shown that by adjusting the length 
of each block in the copolymer a different sol-gel transition temperature could be 
achieved. Injection of PTX loaded PELG-PEG-PELG hydrogel beside the tumor revealed 
enhanced tumor growth suppression when compared to equivalent amounts of free PTX 
and higher anti-tumor activity that was confirmed by TUNEL staining of apoptotic cells. 
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As it was highlighted at the beginning of this section PEG can also be used to bring about 
injectable hydrogels based on in situ crosslinking. This normally involves 
functionalization of PEG with a variety of desirable functional groups, which are either 
mixed with a secondary polymer to facilitate the cross-linking, or can be used alone to 
enable radical/photo cross-linking of the PEG chains.193-194 For instance, Wang et al., used 
polydopamine nanoparticles (PDANPs) to cross-link thiol-terminated four-arm PEG (via 
thiol-ene reaction) and form a hydrogel that showed sensitivity towards NIR irradiation, 
owing to the presence of polydopamine (Figure 1-11).170 This feature was further used 
for controlled release of the drug as well as photothermal therapy of tumors. Upon 
intratumoral injection of 7-ethyl-10-hydroxycamptothecin (SN38) loaded gel into a lung 
cancer mouse model, it was found that PDA-SN38/PEG gel with NIR radiation had 
greater anti-tumor activity when compared with the PDANP-SN38 group, due to 
synergistic interactions of the chemo- and photothermal therapy. In addition, these gels 
caused no detectable pathological change in major organs indicating their minimal 
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systemic toxicity.  
 
Figure 1-11. Injectable polydopamine nanoparticle-knotted PEG hydrogel for on demand chemo-
photothermal therapy of tumors. A) Schematics showing preparation PDA/PEG hydrogel and 
subsequent SN38 release mechanism from the hydrogel upon NIR irradiation. B) Tumor volume 
change plot for different treated groups. C) Photograph of excised tumors and D) their 
corresponding average weight. Reprinted with permission from 170, Copyright (2017) American 
Chemical Society. 
 
In another study, a heparin functionalized four-arm PEG hydrogel was synthesized which 
was further processed post-synthesis into injectable microparticle aggregates.51 Owing to 
the presence of heparin in these hydrogel microparticles they have shown high affinity 
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towards DOX especially at higher concentrations, leading to slow in vitro release of this 
drug in PBS. Moreover, local injection of the DOX-loaded hydrogel microparticles into 
established human orthotopic breast tumors in mice showed significant reduction in tumor 
burden as well as breast cancer metastasis when compared to IV bolus-treated animals.  
Li et al., used acylhydrazone bonds to form a pH-sensitive injectable hydrogel from a 
mixture of dibenzaldehyde-terminated PEG (DF-PEG) and polyaspartylhydrazide 
(PAHy).44 In vitro, these hydrogels showed faster release of DOX in a buffer solution 
with acidic pH compared to a neutral pH due to cleavage of acylhydrazone bonds in acidic 
conditions. Furthermore, intratumoral injection of DOX-loaded hydrogel in fibrosarcoma 
tumor bearing mice showed a superior antitumor activity compared to control groups as 
well as negligible toxicity in vivo.  
Guest-host interactions have also been implemented to make PEG-based injectable 
hydrogels based on in situ crosslinking mechanism. For example, Kuang and his 
coworkers synthesized two types of nucleobase-terminated PEG (adenine and thymine) 
that upon mixing with α-cyclodextrin (α-CD) formed an injectable hydrogel based on 
guest-host interactions.52 Additionally, intratumoral injection of DOX loaded hydrogel 
into a cervical cancer  mouse model revealed that this hydrogel substantially restricted 
the tumor growth and caused no significant fluctuation in body weight (compared to 
control groups) which was assumed to be a consequence of slow and longer local release 
of DOX from this hydrogel. Similarly, the concept of guest-host interaction was used by 
another group to make an injectable biocompatible hydrogel by developing a mixture of 
methoxy polyethylene glycol (MPEG) conjugated with arginine-functionalized poly(L-
lysine) Dendron and α-CD (MPEG-PLLD-Arg), for delivery of MMP-9 short hairpin 
RNA plasmid (pMMP-9).54 In vitro, these hydrogels were capable of sustained release of 
pMMP-9 and after intratumoral injection of drug-loaded hydrogels in nasopharyngeal 
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carcinoma tumor-bearing mice, it was shown that MPEG-PLLD-Arg/pMMP-9 hydrogels 
enhanced retention of pMMP-9 in the tumor compared to standard pMMP-9-loaded 
Polyethylenimine (PEI-25K/pMMP-9). Moreover, one time injection of this new 
hydrogel had equivalent anti-tumor efficiency to seven injections of a conventional PEI-
25K/pMMP-9 that totalled the plasmid concentration in the hydrogel. 
Wu et al., designed another injectable hydrogel based on Schiff-base interaction of 
aldehyde-functionalized four-arm PEG (PFA) and 4-arm poly(ethylene glycol)-b-poly(L-
lysine) (PPLL) for co-delivery of metformin (ME) and 5-FU.57 In vitro drug release and 
degradation studies showed that this hydrogel released both ME and 5-FU in a pH-
sensitive manner. Moreover, a single subcutaneous injection of the drug loaded hydrogel 
(ME and 5-FU) beside the tumors of BALB/c mice bearing colon adenocarcinomas led 
to significant anti-tumor activity compared to that of single and combination bolus drug 
doses, and this was a result of p53-mediated G1 arrest and apoptosis of tumor cells caused 
by synergistic therapeutic effect of ME and 5-FU. Additionally, histological assessment 
of major organs in mice that were treated with blank (non-drug loaded) hydrogel revealed 
their excellent biocompatibility. And lastly, a photo-crosslinkable hydrogel made from 
polyethylene glycol dimethacrylate (PEG-DMA) was used for delivery of temozolomide-
loaded polymeric micelles (M-TMZ) to brain tumors in mice.169 Drug-loaded hydrogel 
was intracranially injected into a human glioblastoma bearing xenograft mouse model 
and subsequently photo-crosslinked in situ. It was shown that the unloaded hydrogel did 
not cause any apoptosis in the brain of the mice, while the drug loaded hydrogel markedly 
decreased the tumor weight when compared to all the other control groups. Furthermore, 
histological analysis of tumors (retrieved seven days post-treatment) using CD34 and 
Ki67 staining, revealed that mice treated with in situ cross-linked drug-loaded hydrogel 
showed no sign of cancer proliferating cells at the center of tumor but were present at the 
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periphery. 
   
Pluronic F-127 (poloxamer 407) 
 
Triblock copolymers of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene 
oxide) (PEO-PPO-PEO) have been of great interest in drug delivery due to their gelation 
phenomenon,195-200 however among them pluronic F127 is reported to be the least toxic 
one and it also showed inhibitory effect against P-glycoprotein, a major player in the 
multidrug-resistant phenotype in cancer.162, 201-202 As a result, this polymer has gained 
much interest as DDS against malignant tumors.203-209 For instance, three different types 
of thermo-sensitive F-127 hydrogels were developed with either paclitaxel (PTX) in the 
form of molecules (MOs), nanocrystals (NCs) and microcrystals (MCs).42 Interestingly, 
in vitro erosion and release studies showed very small release of PTX from PTX-NCs-
Gel and PTX-MCs-Gel whilst PTX-MOs-Gel showed the highest amount of release after 
14 days in PBS which was in direct correlation with their corresponding erosion rates. In 
addition, it was shown that PTX-MCs-Gel possessed the highest intratumoral drug 
concentration followed by PTX-NCs-Gel and PTX-MOs-Gel, respectively. Lastly, PTX-
NCs-Gel showed the highest anti-tumor efficacy against breast tumor xenografts in mice 
when compared with PTX-MCs-Gel and PTX-MOs-Gel, which was assumed to be a 
consequence of sustained release of drug from PTX-NCs-Gel. In a separate study, Chen 
et al., attempted to improve the mechanical properties of pluronic F-127 by 
copolymerzing it with hexamethylene diisocyanate (HDI-PF127) and subsequently 
mixing it with hyaluronic acid (HDI-PF127/HA).45 Hence, the mentioned hydrogel 
showed a sol-gel transition at 37 °C and after intratumoral injection of DOX-loaded gels 
in breast tumor-bearing mice, it was shown that DOX-loaded HDI-PF127/HA gel 
exhibited the highest tumor growth inhibition compared to DOX-loaded PF127/HA gel 
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due to its slower degradation rate and controlled DOX release. Finally, Guo et al., 
synthesized linoleic acid (CLA)-couple poloxamer (CLA-c-P) thermo-sensitive hydrogel 
to benefit pro-drug activity of CLA and further increase stability of the hydrogel.48 
Injection of PTX-loaded CLA-c-P hydrogel beside breast cancer tumor in mice model led 
to significant suppression of tumor growth when compared with control groups, as a result 
of the synergistic effect of CLA in conjugation with PTX. Moreover, significant reduction 
in expression of cell cycle signaling proteins (Cyclin A, Cyclin B, Cyclin D3 and CDK2) 
in combination with considerable increase in expression level of pro-apoptic protein 




Collagen one of the most abundant proteins in the human body, has been extensively 
explored for biomedical applications.210 Collagen can undergo self-assembly to form 
injectable fibrous hydrogel based on non-covalent bonding.211 Consequently, collagen 
has gained attention as an injectable DDS for a variety of cancers. For example, a collagen 
peptide modified dendrimer attached to DOX via a hydrazone bond (CP-Dox-den) was 
synthesized and embedded in collagen gel. 212 Subsequent injection of this gel underneath 
a breast cancer tumor (in mice) led to prolonged suppression of tumor growth. 
Additionally, CP-Dox-den/Col gel was even capable of suppressing metastasis in tumor-
bearing mice, as a result of sustained release of DOX from the gel over the period of the 
experiment. Peng et al., designed another injectable hydrogel from a mixture of collagen 
and Polyethylenimine (PEI) containing ld1-targeted siRNA for gastric cancer 
inhibition.213 Consequently, collagen/PEI-siRNA gels showed slower and sustained 
release of siRNA owing to better stability of these gels compared to collagen-siRNA gels. 
Additionally, in vivo anti-cancer studies using a gastric cancer xenograft mouse model 
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revealed that collagen/PEI-siRNA gel inhibited tumor growth to a greater degree 
compared with collagen-siRNA gels or siRNA/medium, which was further confirmed by 
immunostaining of treated tumor cells with cell-cycle antibodies (cyclin D1 and P21) and 
cell proliferation antigen (PCNA). Most recently, researchers developed an injectable 
hydrogel from a mixture of collagen and gold nanoparticles (AuNPs) containing a 
photosensitizer (PS) for non-invasive combinational photodynamic therapy (PDT) and 
photothermal therapy (PTT) of breast cancer in mice (Figure 1-12).56  
 
Figure 1-12. Collagen-based injectable hybrid hydrogel for synergistic photothermal therapy (PTT) 
and photodynamic therapy (PDT) of breast cancer tumor in mice model. A) Schematic 
representation of injectable hybrid hydrogel, containing gold nanoparticles (Au NPs) and 
photosensitizer (PS), and its corresponding in vivo anti-tumor mechanism. B) Tumor growth 
graphs of mice treated with different treatments. C) Tumor recurrence in different groups. 
Reprinted from 56, Copyright (2017), with permission from Elsevier. 
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This hydrogel was formed due to ionic interactions of negatively charged [AuCl4]- ions 
with positively charged collagen. Intratumoral injection of this hydrogel into tumor-
bearing animals followed by irradiation using laser light resulted in up to an 80% 
elimination rate of tumors. In addition, the dual therapy caused suppression of tumor 
recurrence for a longer period of time when compared to monotherapies, denoting 
superior synergistic anti-cancer effect of photodynamic therapy and photo thermal 
therapy. 
Cisplatin/Epinephrine (CDDP/epi) gel is also an injectable hydrogel based on collagen 
matrix and it was exploited in several clinical studies in patients with esophageal 
cancer,214  adenocarcinomas,215 squamous cell carcinomas 216 and hepatocellular 
Carcinoma.217 For instance, Monga et al., injected the CDDP/epi gel intratumorally (using 
endoscopy) in nine patients with esophageal cancer and it was found that this treatment 




Chitosan is a cationic linear polysaccharide composed of randomly distributed β-(1-4)-
linked D-glucosamine and N-acetyl-D-glucosamine units, and on account of its intrinsic 
properties such as, biocompatibility, biodegradability, penetration enhancer (opening 
epithelial tight-junction) and wound healing promoter, has received great deal of attention 
in medical and pharmaceutical applications.218-219 Injectable chitosan-based hydrogels are 
generally made by neutralization of chitosan amine groups that eliminates the repulsive 
inter-chain electrostatic forces and allows development of extensive hydrogen bonding 
and hydrophobic interactions between chains, which eventually leads to formation of 
hydrated gel-like precipitate.220 Furthermore, it was shown that pH sensitive chitosan gels 
can be transformed into thermally sensitive gels by addition of polyol salts such as β-
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glycerophosphate (GP).221  
Injectable chitosan-based gels have shown great promise in local delivery of anti-cancer 
drugs. For instance, a thermo-sensitive injectable hydrogel containing chitosan and β-
glycerophosphate (C/GP) loaded with liposomal doxorubicin (LipDOX) was developed 
and showed pH-dependent release of DOX in in vitro settings.222 In vivo results from 
intratumoral injection of this gel into liver tumor-bearing mice showed that 
LipDOX+C/GP had a better anti-tumor effect and less systemic cytotoxicity when 
compared with DOX+C/GP gels, due to more sustained release of DOX from 
LipDOX+C/GP which caused a larger therapeutic window. In another study, Hsiao et al., 
synthesized a chitosan derivative, which contained self-doped acid substituted polyaniline 
(PANI) side chain (NMPA-CS) that was capable of self-assembling into a micellar 
hydrogel upon local pH change (sol-gel transition at pH of 7).166 Interestingly, exposing 
NMPA-CS solution to NIR laser showed rapid increase in its temperature (to 54 °C) 
within 5 min of exposure and possessed excellent photostability. Subsequently, 
subcutaneous injection of this gel into the right flank of mice showed mild foreign-body 
reaction with slow degradation. Additionally, intratumoral injection of NMPA-CS in liver 
cancer-bearing mice followed by NIR radiation (5 min every 4 days) led to effective 
suppression of tumor growth and maintained no sign of tumor progression for the duration 
of study, as a consequence of successful photothermal therapy of these tumors. Shi and 
coworkers also made an injectable pH-sensitive hydrogel resulting from Schiff-base 
interaction of succinated chitosan (S-chi) and oxidized alginate (O-alg).167 This hydrogel 
showed faster in vitro release of DOX at lower pH in PBS and subsequent intratumoral 
injection of DOX loaded hydrogel (DOX-OS) in a xenograft mouse model of breast 
cancer resulted in greater and longer inhibition of tumor growth when compared to the 
DOX-treated control group. 
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Hyaluronic acid (HA) is a biocompatible, biodegradable non-sulfated glycosaminoglycan 
which has been largely used over the years for drug delivery purposes.223 Injectable 
hyaluronic acid-based hydrogels can be formed using various methods, including Schiff-
base reaction and covalent crosslinking with secondary agents.224  For instance, an 
injectable hydrogel based on physical cross-linking of hyaluronic acid/adipic acid 
dihydrazide (HA-ADH) and hyaluronic acid aldehyde (HA-CHO) was developed and 
subsequently loaded with two types of paclitaxel, namely microparticulate paxlitaxel 
(PTX) and 14 nm micelle form of PTX (Taxol).225 Consequently, in vitro PTX-gel 
showed slower release of paclitaxel compared to Taxol-gel as a result of larger particle 
size of PTX. In addition, treatment of ovarian cancer in a xenograft mouse model with 
these hydrogels revealed significant reduction in tumor burden compared to control 
group, however no significant difference between tumor burden of mice treated with 
PTX-gel or Taxol-gel was observed, which was assumed to be a result of limited 
dissolution of PTX. Cho et al., developed a similar hydrogel and loaded them with 
platinum incorporated HA nanoparticles (PtNPs) and upon injection of this gel into the 
peritoneal cavity of ovarian cancer -bearing mice found that PtNP/gel and PtNP were not 
capable of inhibiting tumor growth and proliferation at later time points due to pro-
tumorigenic effect of HA in the DDS.55 In a different study, Ueda et al., designed an 
injectable hydrogel from interferon-alpha (IFN-α)-incorporated hyaluronic acid-tyramine 
(HA-Tyr) through oxidative coupling of Tyr with hydrogen peroxide (H2O2) and 
horseradish peroxide (HRP). 226-227  The IFN-α-incorporated HA-Tyr gel was further 
combined with sorafenib (a small molecule tyrosine kinase inhibitor) for synergistic anti-
cancer effect in a renal carcinoma xenograft mouse model. It was found that IFN-α-
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incorporated HA-Tyr gel+sorafenib caused the highest inhibition of tumor growth, which 
was further confirmed by the ratio of apoptotic cells and Ki-67-positive cells in the treated 
tumors. This synergistic effect was attributed to induction of apoptosis in conjugation 




Alginate a naturally occurring anionic polysaccharide has been extensively studied in 
tissue engineering and drug delivery avenues on account of its ideal biocompatibility and 
adjustable gelation properties.228-229 Alginate-based injectable hydrogels can be made by 
exploiting a variety of chemistries including non-covalent bonding such as ionic bonds, 
schiff-base interactions and acylhydrazone Bonds.229 Ionic cross-linking of alginate 
chains with divalent cations such as Ca2+ provides a facile route to development of 
injectable formulations of this polymer. For instance most recently, Wang et al., 
developed an injectable alginate-calcium hydrogel with immobilized acetylated G5-NH2 
PAMAM dendrimer-encapsulated platinum nanoparticles (DAcEPts) in its matrix for 
non-invasive photothermal ablation of tumors.53  This hydrogel was capable of being 
degraded on-demand upon addition of a chelator (diethylene triamine pentacetic acid-
DTPA). Intratumoral injection of DAcEPts containing hydrogel (H/DAcEPts) in lung 
cancer -bearing immunocompromised mice followed by NIR irradiation led to significant 
decrease in tumor volume compared to controls after 30 days of treatment. Interestingly, 
in the DAcEPts treated group, tumor-site temperature did not stay stable due to leakage 
of these nanoparticles out of the tumor tissue, however, the H/DAcEPts treated group 
showed maintenance of  temperature at 47 °C after each NIR irradiation. Additionally, 
after two intratumoral injections of the DTPA chelator (at day 9 and day 12) the liberated 
DAcEPts nanoparticles leached form the tumor tissue, which in turn resulted in an 
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Poly(organophosphazene) is an inorganic/organic hybrid polymer that has immense 
potential for biomedical applications as a result of its hydrolytic degradability and non-
toxic degradation products.230-231 Furthermore, this hydrogel undergoes a sol-gel 
transition in psychological temperature that makes it a suitable candidate for anti-cancer 
injectable DDSs.   For example, Al-Abd et al., loaded the poly(organophosphazene) 
thermogel with DOX for local delivery of this drug to human gastric tumor xenografts in 
mice.232 Interestingly, it was observed that DOX loaded gel (POL) had 40% and 90% 
sustained drug release over 5 weeks in vitro and in vivo, respectively. In vivo results 
suggested that POL had similar efficacy in suppressing tumor growth as DOX loaded 
solution (SOL), however POL showed dramatically decreased systemic toxicity 
compared to SOL leading to higher survival rates of animals after 28 days of treatment. 
In a different study, Zhang et al., synthesized  poly(organophosphazene) nanocapsules 
loaded with superparamagnetic iron-oxide nanoparticle that transformed to a hydrogel 
(SPION-NHs) upon exposure to body temperature and it was further used for magnetic 
hyperthermia (MHT) and long-term magnetic resonance imaging (MRI).50 Intratumoral 
injection of SPION-NHs in human brain cancer tumor xenograft in mice showed higher 
retention of SPION nanoparticles in the tumor tissue compared with that in the group 
treated with PEGylated SPIONs solution. Moreover, it was shown that treatment cycles 
of multiple MHT using SPION-NHs has a direct effect on tumor regression as mice 
treated with one or two cycles of MHT demonstrated resumed tumor growth after 5 days 
of treatment, however, mice treated with four cycles of MHT showed significant tumor 
eradication. Finally, long-term MRI monitoring of tumors injected with SPION-NHs 
 
55 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
showed dissipation of SPIONs from the tumor site as a result of apoptosis of tumor cells. 
Similarly, the same group loaded the SPION-NHs hydrogel with tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) (T/S-NHs) to synergistically abrogate tumors 
by multiple MHT and anti-cancer potential of TRAIL.233 Accordingly, it was shown that 
chemical structure of poly(organophosphazene) (PPZ) had a direct effect on in vitro 
degradation and subsequent release of TRAIL and SPIONs from the hydrogel, as nonionic 
side group on PPZ (indicated as T/S-NHs-1) led to fastest degradation rate as well as 
fastest SPIONs and TRAIL release, while, hydrogel made from PPZ with ionic side 
groups (indicated as T/S-NHs-2 and T/S-NHs-3) showed much slower degradation rate 
and consequently slower TRAIL and SPIONs release. Additionally, intratumoral 
injection of T/S-NHs in a glioblastoma tumor xenograft in mice revealed that tumor 
growth was significantly inhibited in animals that received T/S-NHs-2 with two cycles of 




PLGA, an FDA approved thermoplastic biopolymer, has also been deployed to generate 
injectable DDSs for cancer treatment because of its quick in-situ precipitation in aqueous 
environment. For instance, Chen et al., incorporated the iron(III) oxide (Fe3O4) 
nanoparticles into a PLGA solution for magnetic-hyperthermia regression of tumors.165 
Intratumoral injection of this solution in a breast cancer xenograft mouse model followed 
by only single magnetic ablation showed complete disappearance of the tumor after 3 
days and without reoccurrence even after 1 month. The same group also developed 
another injectable DDS based on PLGA, which MoS2 nanosheets and DOX were 
incorporated into the implant for synergistic photothermal and chemotherapy of tumors 
(Figure 1-13). 164  Therefore, this implant showed controlled release of DOX in pH- and 
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NIR- responsive manner. Furthermore, intratumoral injection of this composite in a breast 
cancer tumor xenograft mouse model followed by only one time NIR irradiation (5 min) 
led to disappearance of tumor after 7 days and no tumor recurrence was observed within 
2 months from the treatment. Lastly, mice treated with PMD+NIR had 100 % of survival 
rate over a period of 50 days, which indicated high efficiency of this local synergistic 
treatment.  
                       
Figure 1-13. Multifunctional PLGA/MoS2/DOX (PMD) oleosol as injectable implant for synergistic 
chemo- and hyperthermia tumor therapy. A) Schematic illustration showing in vitro phase 
transformation of oleosol, oleosol microstructure, and in vivo dual mechanism of tumor therapy 
triggered by NIR irradiation. B) In vivo thermal images of PMD implanted mice after continuous 
NIR irradiation for different durations. C) Tumor volume change in mice with different 
treatments. D) Survival rate of mice following various treatments. Reprinted from 164, Copyright 
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1.3.2. Conclusion 
 
Despite a steady decrease in cancer mortality incidents over last few decades, the current 
standards of care in cancer treatment encounter major obstacles in efficiently treating the 
disease. Therefore, bio-polymeric implantable DDSs have been designed to overcome 
hurdles faced by conventional therapies, by means of local delivery of therapeutic agents 
directly to the tumor site and consequently they have shown immense promise in treating 
malignant tumors (or preventing the tumor recurrence) in animal models as well as some 
clinical cases. Not only do these DDSs possess intriguing properties (such as 
biocompatibility, biodegradability and trackability) but they are also capable of delivering 
a variety of anti-cancer therapeutic agents while exerting precise spatiotemporal control 
over their release. A variety of biopolymers were employed for fabrication of such DDSs, 
however natural hydrogels such alginate seems to have better biocompatibility and allow 
for a variety of chemical modifications to their structure. Moreover, among all fabricated 
geometries, coaxial structures with biopolymer-drug affinity features has never been 
studied for the purpose of cancer drug delivery. Consequently, in this thesis we aim to 
make coaxial hydrogel structures for cancer drug delivery, where the core section of these 
structures is comprised of dopamine-modified alginate along with chemotherapeutic 
drugs to confer affinity-controlled release, while a methacrylated-alginate is used as the 
shell composition to provide the controlled diffusion barrier. To fabricate these coaxial 
hydrogel structures we have specifically used two different fabrication technologies 
including (i) wet-spinning: as it facilitates high throughput and low cost production of 
coaxial fibers, (ii) 3D-printing: as it allows fast prdoction of patches with highly 
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1.3.3. Thesis Objectives  
 
This thesis aims to develop coaxial hydrogel structures with drug-affinity features to 
locally deliver therapeutics to cancer tumors. To this end, it was hypothesized that 
employment of dopamine-modified alginate in the core along with chemotherapeutic 
agents would confer affinity-controlled release, while employment of methacrylated-
alginate as the shell would provide a diffusion barrier for controlled release of the drugs. 
Consequently, dopamine-modified alginate and methacrylate-alginate were successfully 
synthesized and characterized using various techniques such as Fourier-transform 
infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (H NMR). 
Accordingly, rheological properties of the solutions made from synthesized polymers 
were assessed, and subsequently coaxial hydrogel fibers were made using a wet-spinning 
technoque. Two different chemotherapeutic drugs (Gemcitabine and Doxorubicin) where 
loaded in the core section of these coaxial fibers, either separately or simulataneously 
together. As a result, specific interactions of these two drugs with dopamine-modified 
alginate (core element) were assessed using zeta-potential measurements. Microstructural 
morphology (scanning electron microscopy; SEM), mechanical properties (both in static 
and dynamic conditions), swelling behaviour, and degradation of the fibers were 
evaluated. In vitro drug relese from the fibers were examined, and then they have been 
tested in vitro on two pancreatic cancer cell lines. Also, in vivo peformance of these drug-
loaded coaxial hydrogel fibers were assessed in mice with subcutanous pancreatic cancer 
tumors.  
 
Multimodal cancer therapies, such as chemo-photothermal therapy, are yet another 
therapeutic aspect that has been explored using biopolymeric local drug delivery systems 
to achieve a high tumor-synergistic therapy . Particularly, use of these systems for chemo-
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photothermal therapy implies that not only these systems must allow sustained release of 
the drug, but also they should generate heat instigated by an external stimuli. 
Consequently, with the aim of establishing a suitable implantable platform for multimodal 
chemo-photothermal cancer therapy, for the first time a coaxial composite hydrogel fiber 
was fabricated using a wet-spinning method. Particularly, the core-section of these fibers 
(chemo-compartment) contained dopamine-modified alginate along with a 
chemotherapeutic drug (Doxorubicin), while their shell section (phothothermal 
compartment) was composed of UV-crosslinkable methacrylate-modified algine together 
with Cu2−xSe Nanoparticles. It was hypothesized that specific biopolymeric composition 
of these fibers along with their corresponding core-shell geometry would allow controlled 
release of Doxorubicin (loaded in the core), while the Cu2−xSe nanoparticles (loaded in 
the shell) would facilitate heat generation upon near infra-red (NIR) laser irradiation. 
Accordingly, various physiochemical properties of the composite fibers was assessed 
including their microstructural morphology (scanning electron microscopy; SEM), 
elemental composition (Energy-dispersive X-ray spectroscopy; EDX), chemical 
composition and crystalline phase (Fourier-transform infrared spectroscopy; FTIR, X-ray 
diffractrometry; XRD), nanoparticle content (thermogravimetric analysis), mechanical 
properties (both in static and dynamic conditions), and their swelling behaviour. 
Furthermore, in vitro Doxorubicin release from the fibers was assessed. Also, the 
photothermal effect of the fibers upon NIR laser irradiation was assessed. Next, the fibers 
were tested in vitro agaisnt breast cancer cells, in presence or absence of NIR laser. Lastly, 
the fibers were tested in vivo in mice with subcutaneous breast cancer tumors to evaluate 
their synergistic chemo-photothermal therapy.  
 
Various fabrication technologies were employed to facilitate the making of biopolymeric 
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drug delivery systems, while each imposed their own set of advantages and 
disadvantages. Among them 3D printing technologies offer considerable advantages 
including reproducibility, and ability to design geometrically complex shapes. In 
addition, 3D printing is compatible with a variety of biopolymers including hydrogels 
such as alginate. As a result, with the purpose of fabricating a suitable platform for 
prolonged delivery of Gemcitabine (a chemotherapeutic drug), a novel 3D printed coaxial 
hydrogel patch was developed. Particularly, the core-section of these patches contained 
dopamine-modified alginate methacrylate loaded with Gemcitabine, while their shell 
section was solely comprised of alginate methacrylate. Subsequently, these patches were 
further modified with CaCO3 cross linker and a PLA coating to facilitate prolonged 
release of the drug. Accordingly, different properties of the fabricated patches were 
characterized including their microstructural morphology (scanning electron microscopy; 
SEM), mechanical properties (in both static and dynamic conditions), and their swelling 
behaviour. In vitro Gemcitabine release from different types of 3D printed coaxial patches 
was assessed. Lastly, to assess the therapeutic effect of Gemcitabine-loaded 3D printed 
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2. Coaxial mussel-inspired biofibers: Making of a robust 




Despite remarkable improvements in cancer treatments resulting in extended survival, 
this disease still remains one of the major causes of death worldwide 174. Although current 
standards of care that involve the use of chemotherapy provide encouraging results, they 
still cause severe systemic toxicity and also fail in preventing recurrence of the disease 4, 
235. Tremendous progress has been made in design of bio-polymeric implantable drug 
delivery systems for cancer treatment 236, among which hydrogels have emerged as 
promising platforms owing to their inherent biocompatibility, tunable physical properties 
and controllable degradability 237-238. Hydrogels are water-swollen hydrophilic polymer 
networks, held together by physical and/or chemical cross-links, and have been 
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successfully used as depots to protect and facilitate controlled release of drugs at the target 
sites 239-240. Controlled drug release profiles attainable with these systems are dictated by 
factors such as porosity, network swelling/degradation, the size of the molecule to be 
released and drug-polymer interactions 13, 238.  
Nevertheless, methods for incorporation of drugs into hydrogels generally fall into three 
categories: (I) physical encapsulation, where drugs are simply entrapped within the cross-
linked polymer network; (II) covalent conjugation, where drugs are covalently bound to 
the polymer network; and (III) affinity binding, where hydrophobic, ionic, or hydrogen 
bonding are utilized to retain drugs within the hydrogel network 241. Though, physical 
encapsulation renders a simplistic approach for designing drug loaded hydrogels, these  
systems often face uncontrolled drug diffusion out of the bulk hydrogel immediately after 
formation (burst release) 242. On the other hand, covalent conjugation of drugs to the 
hydrogel network yields a much slower drug release profile, where release is facilitated 
by cleavage of the covalent linkage or by complete hydrogel degradation 243. However, 
this strategy often involves chemical modification of drugs which not only can impact 
their FDA approval but could also alter their biological activity 244. Along those lines, 
affinity-based drug delivery has emerged as an alternative to achieve controlled release 
of small-molecule drugs, without compromising their activity 245. Affinity-controlled 
release is usually achieved by immobilizing a drug-binding ligand within a hydrogel 
matrix. Based on the type of drug molecule, a variety of ligands have been explored for 
affinity-controlled release, this includes heparin-like moieties, binding peptides, 
cyclodextrins, and thiols 246-248. Recently, inspired by marine mussels, researchers have 
utilized 3, 4-dihydroxyphenylalanine (DOPA) to confer affinity-controlled release to 
hydrogels 249-252. The catechol group of dopamine is shown to be capable of adhering to 
drug molecules by using a variety of mechanisms including hydrogen bonds, π-π 
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interactions, cation-π interactions and dynamic covalent bonds 253-255. For instance, Han 
et al., took advantage of interaction of polydopamine component with the proteins, via 
interaction with amine or thiol groups of the proteins, to achieve sustained release of 
epidermal growth factor from polyacrylamide-clay-polydopamine hydrogel 251. In 
another study, Wang et al., developed a polydopamine nanoparticle-knotted 
poly(ethylene glycol) hydrogel which successfully released the 7-ethyl-10-
hydroxycamptothecin (SN38- a chemotherapeutic drug) in a controlled manner, mainly 
due to strong π−π stacking interaction 249. Nevertheless, in the context of hydrogels for 
cancer drug delivery, dopamine has rarely been used to confer affinity-controlled release 
of chemotherapeutic drugs on hydrogels.  
Along the same lines, in this study, with the aim of developing a suitable hydrogel 
platform for local delivery of anti-cancer drugs, the well-established wet-spinning method 
was used to engineer novel coaxial biofibers. Specifically, dopamine-modified alginate 
hydrogel, along with the chemotherapeutic drugs, was used as the main core component 
to confer affinity-controlled release, while a methacrylated-alginate hydrogel was used as 
the shell composition to provide the controlled diffusion barrier (Figure 2-1).  
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Figure 2-1. Schematic illustration of coaxial mussel-inspired biofibers as 3D implantable textiles for 
local delivery of anti-cancer drug 
 
Here we investigated the use of two anti-cancer drugs, Gemcitabine (GEM) and 
Doxorubicin (DOX), as these drugs are in routine clinical use  solely or in combination 
with other drugs, to control the progression of cancer 256. It was demonstrated that the 
proposed hierarchical structure enabled the development of biocompatible hydrogel 
fibers (as indicated by both in vitro and in vivo experiments) with controlled swelling,  
and enhanced mechanical properties (as indicated by both static and dynamic tension 
tests), when compared to single fibers made from pure alginate. Particularly, it was 
observed that these coaxial fibers were capable of releasing the two drugs in a slower 
manner, when compared to single fibers made from pure alginate, which was partly 
attributed to stronger interactions of drugs with dopamine-modified alginate (the core 
element of coaxial fibers) as observed from zeta-potential measurements. Remarkably, it 
was shown that drug-loaded fibers, particularly Doxorubicin-containing fibers, had 
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higher anticancer effect in vivo compared to systemic injection of equivalent dosage of 
the drugs. Also, simultaneous loading of the two drugs in the coaxial fibers (DOX and 
GEM) also inhibited the growth of the tumors in animal models. Overall, these 
biocompatible and robust coaxial hydrogel fibers may be further used as neoadjuvant or 
adjuvant therapies for controlled delivery of chemotherapeutic drugs locally to the tumor 
sites with the aim of suppressing cancer growth, with reduced side effects. 
 




Alginic acid sodium salt from brown algae (medium viscosity), N-(3-
dimethylaminopropyl)-Nˊ-ethylcarbodiimide hydrochloride (≥99.0%), N-
hydroxysuccinimide, dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%), 
methacrylic anhydride, and IRAGACURE D-2959 were purchased from Sigma Aldrich. 
Calcium chloride (CaCl2) and sodium hydroxide (NaOH) were purchased from Chem-
Supply. Doxorubicin hydrochloride and Gemcitabine hydrochloride were purchased from 
Focus Bioscience. Simulated body fluid (SBF) was prepared as explained before. 19 D2O 
(100% - CIL) was supplied by Novachem. The MIA-PaCa-2 human pancreatic 
adenocarcinoma cell was kindly supplied by Gillian Lehrbach from the Garvan Institute 
of Medical Research (Aust). The PANC-1 human pancreatic adenocarcinoma cell line 
was purchased from ATCC. The CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay (MTS) was from purchased from Promega, Australia. DMEM-High glucose media 
and foetal calf serum (FCS) were purchased from Invitrogen, USA. Trypsin/EDTA was 
purchased from Life Technologies, Australia.  
 
 
73 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
2.2.2. Synthesis and characterization of alginate-dopamine 
 
Alginate-dopamine with different substitution degrees was synthesized via carbodiimide 
chemistry.257 Briefly, 1 g of alginic acid (5 mmol in terms of repeating unit) was dissolved 
in 100 ml of 0.1 M MES buffer with pH of 5.6. EDC and NHS were separately dissolved 
in 2 ml of MES buffer (1.25 and 2.5 mmol for 25% and 50%, respectively) and 
subsequently added to the alginic acid solution. while the reaction were allowed to 
continue for 30 min. Dopamine hydrochloride (at equal concentration to EDC and NHS) 
was separately dissolved in 2 ml of MES buffer and added to the mixture subsequently. 
The reaction were allowed to happen for 1 hr under nitrogen flushing. Afterwards the 
solution was dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD) for 7 days 
against acidic water (pH of 6) and subsequently precipitated in ethanol. The precipitated 
polymers were next lyophilized using a freeze-dryer. Incorporation of dopamine into 
alginate was further confirmed using FTIR (Shimadzu IRPrestige-21 infrared 
spectrometer) and HNMR (Bruker 400 MHz) spectroscopy. 
 
2.2.3. Synthesis and characterization of alginate-methacrylate 
 
Alginate-methacrylate was synthesized by using methacrylic anhydride.258 Briefly, 3 g of 
alginic acid was dissolved in 300 ml of distilled water (1% w/v) to which 24 ml of 
methacrylic anhydride (8% v/v) was added and the pH was maintained at 8 for 6 hrs using 
5.0 M NaOH solution. Afterwards, the solution was dialyzed (spectra/ por membrane 
tubing; MWCO 12–14 kD) for 7 days and precipitated in ethanol followed by freeze-
drying. Grafting of methacrylate groups onto the alginate backbone was further confirmed 
using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR (Bruker 400 
MHz) spectroscopy.  
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2.2.4. Rheology 
 
All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton 
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room 
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer 
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of 
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to 
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm, 
DYMAX BlueWave 75).  
 
2.2.5. Fabrication of dye loaded fibers  
 
After synthesis of alginate-dopamine and alginate-methacrylate, we have fabricated the 
dye-loaded (fluorescein sodium salt) fibers to evaluate the effect of dopamine grafting on 
subsequent release and encapsulation of the dye. Accordingly, 3% (w/v) of pure alginate, 
alginate-dopamine 25% and alginate-dopamine 50%, were separately dissolved in 
distilled water. Next 2 mM of fluorescein sodium salt were added to each solution to 
prepare the spinning mixtures. The single and core-shell fibers were fabricated using a 
coagulation bath of H2O/Ethanol (4:1) containing 2% CaCl2 (w/v). The single fibers were 
fabricated by simply extruding the dye-containing solutions (50 ml/hr) into the 
coagulation bath using a blunt needle (gauge 19). On the other hand, the core-shell fibers 
were fabricated using a novel coaxial spinneret with two input ports.259 Alginate-
dopamine/alginate-methacrylate solution (75/25 w/w, 3% w/v, containing 0.05% 
IRAGACURE  D-2959) containing the dye (2 mM) was extruded (50 ml/hr) through the 
centre outlet nozzle (gauge 19) into the coagulation bath, while alginate-methacrylate 
solution (3% w/v, containing 0.05% IRAGACURE  D-2959) was simultaneously being 
extruded (50 ml/hr) as the sheath of the fiber (gauge 15). Right after exiting the 
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coagulation bath, the core-shell fiber were irradiated with UV light (365 nm, DYMAX 
BlueWave 75) as they were being collected on the rotating drum. To measure the dye 
release from the fibers, 30 cm of fibers were immersed in 1 ml of SBF solution and the 
supernatant was collected at certain time points and replaced with fresh SBF. Eventually 
these supernatant were tested using UV spectrometer (Shimadzu, UV-1800) and the 
unknown concentrations were revealed using a calibration curve achieved previously.  
 
2.2.6. Fabrication of drug loaded fibers 
 
Drug loaded fibers were fabricated in the same manner as dye loaded ones with minor 
differences. Single alginate drug-loaded fibers were fabricated by initially dissolving the 
drug in distilled water (2 mM for DOX or 50 mM for GEM), next alginate was dissolved 
in the mixture at a 3% (w/v) concentration. Subsequently, the prepared mixture was 
extruded into the coagulation bath using a blunt needle. For core-shell fibers, the drugs (2 
mM for DOX or 50 mM for GEM) were first dissolved in distilled water, to which 3% 
(w/v) of alginate-dopamine/alginate-methacrylate mixture (75/25% w/w) and 0.05% 
(w/v)  IRAGACURE D-2959 were added (this solution was used as the core input). 
Separately, alginate-methacrylate was dissolved in distilled water (3% w/v) and 0.05% 
(w/v) IRAGACURE D-2959 was added to this mixture (this solution was used as the core 
input). These two solutions were simultaneously extruded through the coaxial nozzle into 
the coagulation bath and the fibers were subsequently irradiated with UV light (365 nm, 
DYMAX BlueWave 75) as they were collecting on the rotating drum. For dual-loaded 
fibers, the core constituent was loaded with 2 mM of DOX while the shell constituent was 
loaded with 50 mM of GEM. Of note, for the sole purpose of drug release studies, we 
have fabricated another type of core-shell fibers which is indicated as CS •. In these fibers 
the core only contained (3% w/v) alginate-methacrylate + 0.05% (w/v) IRAGACURE D-
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2959 + the drugs (2 mM for DOX or 50 mM for GEM), while the shell only contained 
(3% w/v) alginate-methacrylate + 0.05% (w/v) IRAGACURE D-2959.       
    
2.2.7. Characterization of fibers 
 
The morphology of fibers were examined using a JSM-6490LV SEM and Leica M205A 
microscope. For SEM imaging (in dry or wet state), the fibers were cut into small pieces 
and inserted into special sample holders. The sample holder containing the mounted fibers 
was then immersed into liquid nitrogen for about 45 s. Next, the sample holder was then 
quickly transferred to the LVSEM for examination. SEM images were taken in high 
vacuum mode at 15 kV operating voltage and a spot size setting of 60. The swelling 
properties of the hydrogel fibers were determined by examining their water uptake 
capacity. The hydrogel fibers were incubated in simulated body fluid (SBF) at 37°C and 
allowed to fully swell. The swelling ratio was calculated using the following equation: 
(Ws – Wd)/Wd, where Ws represents the weight of the swollen hydrogel fibers and Wd 
represents the weight of the dried hydrogel fibers at the beginning. The degradation rate 
of the fibers was measured by initially freeze-drying the fibers and subsequently weighing 
them (Wi). Next, the fibers were immersed in 5 ml of SBF at 37°C for in vitro degradation 
testing. The SBF was replaced every three days. At predetermined time points, the 
samples were removed, rinsed with distilled water, and lyophilized and weighed (Wd). 
The percent mass loss was calculated using the equation (Wi-Wd)/Wi x 100. The static 
mechanical properties of fibers were assessed using a mechanical tester (EZ-L tester from 
Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry and wet fibers, 
respectively. The dynamic mechanical properties of fibers was evaluated using a dynamic 
mechanical analysis (DMA 242 E Artemis, NETZSCH). Accordingly, by using a tension 
clamp the samples were exposed to a constant strain (0.1 %) of increasing frequencies in 
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the range of 0.1 to 10 Hz for 30 min, subsequently storage and loss modulus were recorded 
and Tan delta values were measured as a ratio of loss modulus to storage modulus. 
Furthermore, hydrodynamic diameter, poly-dispersity index (PDI), and zeta potential of 
various formulations were measured using a Zetasizer Nano ZS (Malvern Panalytical, 
UK). Accordingly, prepolymer solutions (with similar drug/polymer ratio as in fibers) 
were diluted to 100 ng mL−1 in ultrapure water for analysis of the zeta potential and 
hydrodynamic diameter, and poly-dispersity index (PDI).  
 
2.2.8. Release studies from drug loaded fibers  
 
To measure the drug release from the fibers (either DOX or GEM), 30 cm of drug loaded 
fibers were immersed in 1 ml of SBF solution and the supernatant was collected at certain 
time points and replaced with fresh SBF. For measuring the DOX release, fluorescence 
properties of DOX was measured (excitation 485 nm, emission 520 nm) using FLUOstar 
OPTIMA microplate reader. The absorbance values were eventually converted to 
concentrations using a previously achieved calibration curve for DOX. For measuring the 
GEM release, a high performance liquid chromatography (HPLC, Agilent 1260 infinity) 
was used. Briefly, Samples were filtered through a 0.2 μm syringe membrane filter unit 
before being injected (10 μL) onto a ZORBAX Eclipse Plus column (4.6 × 100 mm, 5 
μm particle size). Using an isocratic elution with a water/acetonitrile (95/5), draw and 
eject speed of 200 μL/min, pressure 300 bar, Gemcitabine was detected with the UV-
Visible detector at 272 nm. The absorption values were converted to concentrations using 
a previously observed calibration curve. The release results were plotted as mean value 
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2.2.9. In vitro cell studies 
 
All cell lines were authenticated using short tandem repeat (STR) profiling at the Garvan 
Institute of Medical Research. Cells (MIA-PaCa-2 or PANC-1) were cultured in DMEM-
High glucose media containing 10% fetal calf serum (FCS) at 37 °C, 95% humidity and 
5% CO2 in a Heracell incubator (Kendro Laboratory Products, Germany). When 80% 
confluence was reached, cells were detached by incubation with 5 mM trypsin/EDTA and 
harvested after centrifugation in a Heraeus Megafuge 1.0 (Thermo Scientific, USA) at 
1200 rpm for 5 min at RT. Cells were resuspended in media, and viable cells counted 
using a hemocytometer and trypan blue staining. Cells were confirmed free of 
mycoplasma contamination. MIA-Paca-2 and Panc-1 cells were seeded (8 × 104, 6 × 104, 
and 4 × 104 cells/well for 24, 48, and 72 hr time points, respectively) in 24-well flat 
bottomed plates in complete media (1 mL) containing 1% penicillin/streptomycin and 
kept in the incubator for 24 h prior to addition of empty or drug loaded fibers (1 cm 
lengths). After each time point the fibers were removed from the wells and subsequently 
40 µL of MTS agent was added and allowed to react with the cells for 3 hrs. The 
absorption of each solution was measured at 490 nm on a microplate reader (SPECTRA 
max, PLUS). For live cell staining, at each time point the media was removed from the 
wells and subsequently the cells were washed with PBS. Next 500 µL of PBS solution 
(Containing 2.5 µL of Calcein AM and 1 µL of Propidium Iodide; Sigma Aldrich) was 
added to the wells and the plates were incubated for 15 min, after which the staining 
mixture was removed from the wells and replaced with fresh PBS. Immediately after the 
IncuCyte ZOOM system (Essen BioScience, USA) at 10 × magnification, with green (live 
cells) and red (dead cells) filters, was used to image the cells.  
To confirm the long-term therapeutic effect on inhibition of cancer cell growth, the effect 
of the medium supernatant of the drug loaded or empty fiber on the viability of the human 
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pancreatic cancer cell line, MIA PaCa-2, PANC-1, and BxPC3 cell lines, was assessed 
using a cell counting kit-8 method (Sigma, St. Louis, MO, USA) based on the 
manufacturer’s guideline. The BxPC3 cells were cultured in DMEM (Gibco), while 
PANC-1 and MIA-PaCa-2 cells were cultured in RPMI-1640 medium (Gibco) 
supplemented with 10% v/v fetal bovine serum (Gibco), 100 U/mL penicillin, and 100 
μg/mL streptomycin (Invitrogen) at 37 °C in 5% CO2 in a humidified incubator. Cells 
were plated at a density of 3 × 103 cells per well in a 96-well culture plate and incubated 
for 24 h before drug treatment. To assess the therapeutic effect of the drug released from 
the fibers, the fibers (1 cm) incubated in complete culture media at 37 °C in 5% CO2 in 
a humidified incubator and then the supernatant was collected at determined intervals (1-
, 5-, 8-, 11-, 14-, 17-, and 20-days). At day 1 after cell seeding, we changed the media to 
corresponding supernatants. Cell viability at each time point was determined using a cell 
counting kit-8 assay (CCK-8; Sigma Aldrich) according to the manufacturer’s guideline.  
 
2.2.10. In vivo Studies 
 
To confirm the in vivo effects of the CS-fibers, a subcutaneous tumor model was 
established using MIA-PaCa-2 and BxPC3-Luc cells. MIA-PaCa-2 and BxPC-3-Luc cells 
were harvested (2×106) and resuspended in PBS mixed with Matrigel (1:1 ratio). To 
prepare the xenograft tumors were developed in 6-week-old male nude mice by injecting 
MIA-PaCa-2 and BxPC-3-Luc cells subcutaneously into the right posterior flank of mice, 
respectively. All mouse experiments within the guidelines of the protocol were reviewed 
by the Institutional Animal Care and Use Committee of Asan Institute for Life Science 
(IRB No. 2013-0939). Tumor growth was recorded twice a week in three dimensions 
using a digital caliper. Tumor volume was calculated as [(length × width × height) / 2] 
and reported in mm3. Tumors were grown in for 11-12 days until average tumor volume 
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100mm3. Mice were randomly divided into 4 groups at day 11 or 12 after subcutaneous 
cancer-cell inoculation; Group I: implanted with a drug-free CS fibers; Group II: 
implanted with Gemcitabine loaded CS fibers; Group III: implanted with Doxorubicin 
loaded CS fibers; and Group IV: implanted with Gemcitabine and Doxorubicin loaded 
CS fibers. For MIA-PaCa-2 tumor bearing mice three extra groups were added where 
equivalent dose of I) Doxorubicin or II) Gemcitabine or III) dual drugs 
(Doxorubicin+Gemcitabine) in saline solution were once injected into tail vein of 
animals. All experimental groups started with n=6 mice at the time of treatment initiation. 
To insert the CS fibers in the mouse, CS fibers (12mg each) were cut into 5mm length. 
The CS fibers were sterilized in 70% alcohol solution and then washed in the PBS solution 
twice. After washing, the fibers have adhesiveness. Wetted fibers were directly attached 
under the solid tumor. Tumor growth was observed over a period of 2 weeks. The 
therapeutic effect and anticancer activity of local drug delivery were determined by tumor 
volume and tumor weight change. Also, tumor growth was estimated using an in vivo 
imaging system (IVIS) of luciferase transduced BxPC-3 cell lines. The BxPC-3-Luc cells 
used in this experiment expressed a bioluminescent signal, and the correlation between 
cell numbers and bioluminescent signals was confirmed before the experiment.  
 
2.2.11. Optical imaging of the subcutaneous pancreatic tumor 
 
Mice were intraperitoneally injected with D-luciferin (0.3 mg; Perkin Elmer Inc.). Whole 
body luminescence imaging with an IVIS Spectrum (Caliper Inc., Alameda, CA) was 
performed every 2 minutes until radiance values reached the maximum. The region of the 
interested (ROI) level was measured with the radiance (photons/s/cm2/sr) using an 
analysis program, Living Image 4.4 (Caliper Life Sciences, PerkinElmer Inc.). 
Immunohistochemical staining: After sacrificing the mice at day 14, the tumors were 
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removed and fixed in 4% neutral buffered paraformaldehyde and embedded in paraffin. 
Paraffin blocks were cut into 4 µm sections and were reviewed histologically after 
hematoxylin and eosin staining. Paraffin sections were deparaffinized and then 
rehydrated. After microwave antigen retrieval, non-specific binding sites were blocked 
with PBS containing 10% normal goat serum. The sections were further incubated with 
the primary antibodies against Ki-67 (Dako, Glostrup, Denmark). The samples were 
mounted using Prolong Gold antifade mountant with DAPI (Thermo Fisher Scientific, 
Massachusetts, USA). Images were obtained using an EVOS-fluorescence microscope 
(Thermo Fisher Scientific, Massachusetts, USA).  
 
2.2.12. In vivo toxicity 
 
Retro-orbital blood collection was performed for hematology determinations in tubes 
with anticoagulants (EDTA-2 K) at day 3 and 14. Hematology determinations included 
white-blood-cell (WBC) count and differential leucocyte count (neutrophils, 
lymphocytes, monocytes) using an Advia 120 Hematology Analyzer (Bayer Healthcare, 
Myerstown, PA, USA).  
 
2.2.13. Statistical analysis  
 
Statistical significance was determined using a two-way ANOVA with a Sidak post-test 
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05 
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 
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2.3. Results and Discussion  
 
2.3.1. Chemical characterization of polymers 
 
For coaxial fiber fabrication, we first synthesized alginate-dopamine (theoretical 
substitution degree of 50 % - in terms of alginate repeating units) using standard 
carbodiimide chemistry 260. We then synthesized alginate-methacrylate using methacrylic 
anhydride 261. Fourier-transform infrared spectroscopy (FTIR) and proton nuclear 
magnetic resonance (1H NMR) were employed to investigate successful synthesis of 
alginate-dopamine and alginate-methacrylate. Accordingly, FTIR spectrum of both 
alginate-dopamine and alginate-methacrylate (Figure 2-S1a, supporting information) 
showed the characteristic peaks of alginate associated with C-O stretching vibration (1030 
cm-1), COO- symmetric and asymmetric stretching vibration (1415 and 1600 cm-1, 
respectively), and –OH stretching vibrations (3325 cm-1). More specifically, alginate-
dopamine spectrum showed appearance of peaks at 1544 cm–1, and 1220 cm–1 assigned 
to the N–H deformation and C–N stretching vibrations 262-263. In addition, significant 
reduction in intensity of COO- bands (1415 and 1600 cm-1) further indicated the 
successful attachment of dopamine to the alginate back bone via carbodiimide chemistry. 
Successful synthesis of alginate-dopamine was further confirmed using HNMR via 
appearance of catechol protons at around 7 ppm (Figure 2-S1b-ii, supporting 
information) 264. Further, the relative integration of catechol protons (6.6-7 ppm) to 
anomeric protons of the glucose ring of alginate (4.9 ppm) were used to determine the 
degree of substitution which was measured to be 16 % (in terms of alginate repeating 
units). It should be noted that alginate-dopamine was synthesized with the designated 
degree of substitution (theoretical substitution degree of 50 %) based on preliminary 
release experiments using a model dye; fluorescein sodium salt (Figure 2-S2, supporting 
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information), which revealed that degree of substitution of alginate-dopamine have a 
significant effect on the dye release profile and total amount of dye released.  
Along similar lines, alginate-methacrylate was characterized via FTIR spectroscopy 
(Figure S1a, supporting information). It exhibited –CH stretching vibration band (2980–
2850 cm−1) and the appearance of two shoulders one around 1712 cm−1 and the other at 
1161 cm−1 , associated with C=O and C-O groups of the esters resulting from the grafting 
of the methacrylate units.265 Additionally, HNMR (Figure 2-S1b-iii, supporting 
information) also proved the grafting of methacrylate groups by appearance of double 
peaks (vinyl) in the double bond region (5.5-6.5 ppm). Furthermore, the relative 
integration of methyl protons (of methacrylate groups) to anomeric protons of the glucose 
ring of alginate (4.9 ppm) were used to determine the degree of substitution which was 
40% (in terms of alginate repeating units).  
 
2.3.2. Rheology of polymers  
 
To evaluate spinability of the synthesized hydrogels, their rheological properties were 
investigated using a rheometer (Figure 2-2a & 2b). Accordingly, modification of alginate 
with dopamine increased the viscosity of the solution (Figure 2-2a-iii) at lower shear 
rates when compared to pure unmodified alginate (Figure 2-2a-iv), likely due to 
noncovalent interactions including π-π stacking of dopamine moieties 251. Also, a more 
pronounced shear thinning effect was observed for alginate-dopamine samples over the 
entire shear rate range, when compared to that of pure unmodified alginate. This could 
possibly be associated to the attached dopamine in further hindering the entanglement of 
neighbouring alginate polymeric chains.  
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Figure 2-2. (a) Viscometry of 3% (w/v) solution of i) alginate-methacrylate, ii) alginate-dopamine/ 
alginate methacrylate (75/25 w/w), iii) alginate-dopamine, and iv) pure alginate. (b) Oscilatory 
rheology of 3% (w/v) solutions (containing 0.05% (w/v) IRAGACURE D-2959) of i) alginate-
methacrylate, and ii) alginate-dopamine/ alginate methacrylate (75/25 w/w). Microscopy images 
showing (c & d) Top view of freshly made core-shell mussel-inspired fibers (CS) loaded with DOX 
in the core (scale bars 2 mm and 1 mm, respectively). 
 
Furthermore, modification of alginate with methacrylate groups led to a significant 
decrease in viscosity of the resulting solution in comparison to pure alginate (Figure 2-
2a-i), a phenomenon attributed to disruption of the alginate backbone by the 
methacrylation chemistry 266. For coaxial fiber fabrication, effective cross-linking of the 
core component is vital to assure stability of the fibers 267. Consequently, alginate-
dopamine was physically mixed with alginate-methacrylate (75/25% w/w) to allow the 
formation of a dual cross-linked core constituent by combining chemical and physical 
crosslinking methods 268. As a result, the viscosity of the mentioned alginate-
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dopamine/alginate-methacrylate solution was also assessed (Figure 2-2a-ii) and the 
result showed a similar trend to that of alginate-dopamine solution (Figure 2-2a-iii), yet 
with a slightly lower viscosity over the entire shear rate range, associated with small 
portion of alginate-methacrylate in this solution (25% w/w). Furthermore, oscillatory 
experiments (as a function of time) revealed that upon UV irradiation (365 nm for 5 sec) 
the storage modulus of the alginate-methacrylate hydrogel increased significantly from 
lower values (~ 1 Pa) up to 13000 Pa, indicating the formation of methacrylate bonds in 
the cross-linked hydrogel (Figure 2-2b-i). Subsequently, the alginate-dopamine/alginate-
methacrylate mixture showed a much lower increase in the storage modulus (levelling off 
at around 3500 Pa) in correspondence with the low volume of UV cross-linkable element 
in the mixture (Figure 2-2b-ii).  
 
2.3.3. Morphology of the core-shell fibers 
 
Next, the core-shell mussel-inspired fibers (CS) were fabricated through a custom made 
coaxial nozzle based on a previously described wet-spinning method 269-270. 
Subsequently, the core-shell morphology of the CS fibers was further assessed using 
optical microscopy and scanning electron microscopy (SEM) (Figure 2-2c, d & Figure 
2-3). The core-shell boundaries of the Doxorubicin-loaded fibers could be clearly 
observed in these images (Figure 2c-d), as indicated by higher density of red colour 
(associated with DOX) in the middle region as compared to the adjacent area. The CS 
fibers were then allowed to dry off and their subsequent swelling in SBF was further 
investigated by recording them using a microscope camera.  
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Figure 2-3. SEM images of core-shell mussel-inspired fibers (CS), (a & b) SEM image of CS fibers 
at dry state. (c & d) SEM images of CS fibers fully swollen in SBF. 
 
Accordingly, the fibers demonstrated a time-dependent swelling behaviour as it took them 
almost 60 hr to completely swell. Cross-section morphology of the CS fibers, in dry and 
swollen state, was also studied using scanning electron microscopy (SEM) and the results 
are shown in Figure 2-3. The core-shell borders of the fibers were only detectable once 
the fibers were fully swollen (Figure 2-3c&d). Remarkably, the shell showed a more 
compact structure with smaller pores, as compared to the core, which was a consequence 
of dual crosslinking mechanism (ionic and covalent bonds) that was imposed on alginate-
methacrylate in the shell region. This pore size difference between the core and the shell 
could also be attributed to limited diffusion of CaCl2 crosslinking agent into the core, as 
well as, higher concentration of alginate-methacrylate in the shell. It should be mentioned 
that the thickness of the shell layer can be controlled by using a larger shell nozzle. 
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 Of note, SEM images of single fibers made from unmodified alginate (Alg) was also 
taken as a point of reference (Figure 2-S3, supporting information). 
2.3.4. Swelling and degradation of the core-shell fibers 
 
Considering the direct correlation between the drug release profile, the swelling 
behaviour, and degradation of the hydrogels, we have measured the swelling ratio and 
degradation rate of the fibers in SBF (Figure 2-4). 
 
 
Figure 2-4. (a) Final swelling ratio of single fibers made from pure alginate (Alg), and CS fibers in 
SBF. (b) In vitro degradation profiles of Alg and CS fibers in SBF as a function of time. (n = 4, 
mean ± SD) (****P = 0.0001, **P ≤ 0.01) 
 
 As a result, CS fibers showed to have significantly less swelling (18.05) when compared 
to Alg fibers (33.07) as shown in Figure 4a, which could be due to dual cross-linked 
network in the coaxial fibers 238. The gradual swelling behaviour of CS fibers (loaded 
with DOX in the core) in SBF was also recorded over a span of 60 hr.  The obtained 
swelling data for CS fibers in this study were almost 20 times less than this value reported 
for similar fibrous hydrogel structures 271. In addition, the degradation rate results 
revealed that CS fibers possessed a slower mass loss rate over a period of 14 days 
compared to that of Alg fibers (Figure 2-4b). More specifically, after 14 days Alg fibers 
experienced a 63.6 ± 9.1% of mass loss, while CS fibers showed a 43.9 ± 3.6% of mass 
loss. This is possibly due to the dual cross-linked hydrogel network in the CS fibers.   
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2.3.5. Mechanical properties of the core-shell fibers 
 
Given the effect of mechanical properties on release of drugs from hydrogels272, we have 
measured the tensile properties of the fibers in both static and dynamic conditions (Figure 
2-S4 supporting information and Figure 2-5, respectively). Initially, mechanical 
properties of the fibers were assessed using a static tension test (both in dry and wet states) 
and compared them to that of Alg fibers (Figure 2-S4, supporting information). In dry 
state, CS fibers showed higher modulus (2.78 ± 0.03 GPa) and tensile strength (85.44 ± 
9.6 MPa) compared to those for single Alg fibers (1.26 ± 0.08 GPa and 68.5 ± 2.6 MPa, 
respectively). These observations was more pronounced for the fibers in the wet state, as 
CS fibers had a modulus of 0.21 ± 0.07 MPa and tensile strength of 0.64 ± 0.02 MPa, 
while single Alg fibers possessed a modulus and tensile strength of 0.06 ± 0.01 MPa and 
0.07 ± 0.02 MPa, respectively. This implied that the proposed core-shell structure 
provides greater stability in aqueous environments, making them more practical for 
biomedical applications. It is worth noting that in this study the elastic modulus of wet 
CS fibers (0.21 MPa) were almost 10 times higher than that observed for fibers produced 
by microfluidic systems (0.02 MPa) 273.  
In order to gain a better insight into viscoelastic properties of fibers, an oscillating tension 
test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz was conducted 
(Figure 2-5). Remarkably, CS fibers showed a significantly higher storage modulus 
(2996 ± 78.1 MPa), over the entire frequency range, when compared to that of single Alg 
fibers (261.45 ± 5.4 MPa) (Figure 2-5a). For both fibers (Alg and CS) the storage 
modulus values were higher than the loss modulus values, which indicated the domination 
of elastic response over a viscous behaviour for the two types of samples. However, after 
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measuring the damping factor (Tan δ - calculated from the ratio of E˝/Eˊ) for the fibers, 
CS fibers demonstrated a significantly lower value (0.031) than that of single Alg fibers 
(0.053), which was associated with higher elasticity of CS fibers over single Alg fibers 
(Figure 2-5d). Consequently, the observed mechanical properties data suggested that CS 
fibers possessed a more robust structure (as compared to single Alg fibers), probably due 
to the dual cross-linked network (chemical and physical) arrangement. Also, the CS fibers 
were robust enough to be fabricated into a woven structure (using a traditional weaving 
technique) as a potential 3D implantable patch (Figure 2-S5, supporting information). 
 
Figure 2-5. Dynamic mechanical analysis of hydrogel fibers, single fibers made from pure alginate 
(Alg) or core-shell fibers (CS), by using a tension clamp. The samples were exposed to a constant 
strain (0.1 %) of increasing frequencies in the range of 0.1 to 10 Hz for 30 min. (a) Storage modulus 
and (b) Loss modulus of fibers at different frequencies. (c) Storage and loss modulus at the 
frequency of 10 Hz. (d) Tan delta (damping factor) at the frequency of 10 Hz (n = 3, mean ± SD) (*P 
= 0.05, **P ≤ 0.01). 
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2.3.6. Drug release from the core-shell fibers 
 
Next, in vitro drug release studies were carried out using two specific chemotherapeutic 
drugs (GEM and DOX, as described in the section 2.2.8) and the results are shown in 
Figure 2-6. Specifically, we have compared the release of drugs from core-shell mussel-
inspired fibers (CS) to those obtained from single fibers made from unmodified alginate 
(Alg), as well as core-shell fibers in which both core and shell were made entirely out of 
UV-crosslinkable alginate-methacrylate (CS •). Of note, the comparison between the 
normal CS fibers and the specially made CS • fibers, was for the purpose of understanding 
the specific role of alginate-dopamine (in the core of CS fibers) in the obtained drug 
release profiles.  
 
Figure 2-6. In vitro drug release studies from hydrogel fibers including single fibers made from 
pure alginate (Alg), core-shell mussel-inspired fibers (CS), and core-shell fibers in which both core 
and shell were entirely made of UV-crosslinkable alginate-methacrylate (CS•). (a)  Release profile of 
Gemcitabine (GEM). (b) The first 2 hr of GEM release. (c) Release profile of Doxorubicin (DOX). 
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(d) The first 10 hr of DOX release (n = 3, mean ± SD) 
 
Consequently, Figure 2-6a&b shows the GEM release data from the above mentioned 
fibers. Accordingly, CS fibers was able to slow down the release of GEM down to almost 
42% when compared to that of Alg fibers (~ 93%). Of note, CS • fibers also succeeded to 
slow down the release of GEM (~ 68%) in comparison to Alg fibers (~ 93), however it 
seemed like CS fibers succeeded to further slowdown the release possibly due to 
interactions of the drug with the dopamine moieties. Nevertheless, release of GEM from 
CS fibers reached a plateau level after 10 hr. Next, release of DOX from the fibers was 
evaluated (Figure 2-6c&d). Accordingly, DOX release profile from CS fibers exhibited 
three distinct stages: starting with a burst release of the drug over the first 10 h (~ 24%), 
followed by a slower release of the drug up to day 8 (~ 42%), and then an even slower 
release rate that lasted up to day 19 (~ 46%), which was followed by a plateau region up 
to day 21 (~ 49%). This was in total contrast to single Alg fibers releasing almost the 
entire DOX in the first 10 h of the experiment. Of note, the Dox release profile obtained 
from these CS fibers is comparable to other studies in the field 274-276.  
Of note, CS • fibers also showed to slow down the release of DOX when compared to that 
of Alg fibers. Accordingly, DOX release profile from these fibers exhibited two distinct 
stages: starting with a burst release of the drug over the first 10 h (~ 59%), followed by a 
slower release of the drug up to day 5 (~ 67%), which was followed by a by a plateau 
region up to day 8 (~ 69%). Similar to Gemcitabine, the differences between the obtained 
DOX release profiles of CS fibers and CS • fibers could be associated to the possible 
intermolecular interactions of DOX with dopamine moiety in the CS fibers.  
Consequently, to investigate this hypothesis and with the aim of scrutinizing the obtained 
drug release profiles, a dynamic light scattering (DLS) analysis was conducted (Table 2-
S1, supporting information). Correspondingly, the measurements were carried out for 
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pure unmodified alginate, as well as, dopamine-modified alginate (main component of 
the core section in CS fibers), and methacrylate-modified alginate (main component of 
the core section in CS • fibers), to better understand their interactions with the drug 
molecules. The results revealed that modification of alginate with dopamine led to an 
increase in hydrodynamic diameter of the polymer from 110.9 ± 0.24 nm to 192.8 ± 1.83 
nm, which was attributed to addition of catechol moieties and possible aggregation of 
polymeric chains due to π−π stacking of aromatic rings 277. Modification of alginate with 
methacrylate groups also led to an increase in hydrodynamic diameter of the polymer to 
205.7 ± 0.40. Compared to pure alginate and alginate-methacrylate, alginate-dopamine 
had a higher negative zeta potential value (-33.2 ± 0.86 as compared to -28.8 ± 0.36 and 
-29.9 ± 0.78, respectively), that was ascribed to acidic nature of catechol groups 278. Of 
note, addition of drugs (DOX or GEM) to pure unmodified alginate or alginate-
methacrylate did not cause any major change in their corresponding hydrodynamic 
diameters or zeta potentials, implying the weak interactions of these drugs with pure 
alginate and alginate-methacrylate, which translated into quicker release of these two 
drugs from those fibers. It should also be noted that slower release of drugs from CS • 
compared to Alg fibers, could have been due to smaller porosity of these fibers indicated 
from their cross-sectional SEM images (Figure 2-S6, supporting information). On the 
other hand, incorporation of drugs into alginate-dopamine was associated with 
remarkable changes in hydrodynamic dimeter and zeta potential of this polymer. 
Specifically, hydrodynamic diameter of alginate-dopamine increased significantly from 
192.8 ± 1.83 nm to 422.0 ± 0.24 and 388.0 ± 0.35 nm, after addition of DOX and GEM, 
respectively. The zeta potential value of alginate-dopamine increased from -33.2 ± 0.86 
mV to -37.2 ± 0.69 and -34.0 ± 0.69 mv, after addition of DOX and GEM, respectively. 
The observed data suggested that both drugs could possibly had non-covalent 
 
93 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
hydrophobic interactions (π−π interactions) with alginate-dopamine which led to 
significant increase in hydrodynamic diameter values. However, DOX seemed to also 
have better ionic interactions with alginate-dopamine, as the value of zeta potential 
increased significantly (-33.2 ± 0.86 mV to -37.2 ± 0.69 mV) for this drug, whereas, 
addition of GEM did not generate such changes. Altogether, the obtained data showed 
that alginate-dopamine had better interactions (physical or chemical) with the drugs, 
when compared to pure unmodified alginate or alginate-methacrylate, a phenomenon 
which was also observed in drug release studies. Also, the results confirmed that DOX 
had stronger interactions with alginate-dopamine, as compared to GEM, which further 
contributed to longer release profile of this drug from CS fibers. In addition, the 
differences between the obtained release profiles of GEM and DOX from CS • fibers 
could be attributed to larger molecular size of DOX when compared to that of GEM.    
 
2.3.7. In vitro biocompatibility of fibers       
 
With the aim of evaluating anti-cancer efficacy of the drug loaded CS fibers, in vitro 
cellular experiments were carried out using two different human pancreatic cancer cell 
lines (MIA-PaCa-2 & PANC-1) and the results are shown in Figure 2-7. The empty CS 
fibers (indicated as control) were shown to be biocompatible and maintained high cell 
viability for both cell lines. GEM loaded fibers were able to reduce the viability of the 
MIA-PaCa-2 cells down to 26.6% ± 0.5, 72 h post treatment (Figure 2-7a). Remarkably, 
DOX loaded CS fibers were able to reduce the viability of cancer cell line as early as 24 
h post treatment and they showed a higher anti-cancer effect (4.2 ± 3.7) after 72 hr of 
treatment (Figure 2-7b). Following the observed results we have loaded the two drugs 
(GEM+DOX) simultaneously in core section of the CS fibers, indicated as dual treated, 
to investigate any possible synergistic anti-cancer effect of this drug combination. 
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Accordingly, the obtained results suggested that the dual loaded CS fibers were also 
effective in reducing the viability of cancer cells 72 h post treatment down to 13.8 ± 1.8 
(Figure 2-7c). Lastly, a live/dead staining of the corresponding cells further proved that 
empty CS fibers (indicated as control) had a good level of biocompatibility after 72 hr of 
treatment as implied from high density of the live cells (shown in green), whereas all 
drug-containing CS fibers were capable of reducing the viable cells in correspondence 
with MTS cell viability results (Figure 2-7g).  
 
Figure 2-7. In vitro biocompatibility of fibers (1 cm) including empty CS fibers (Control), 
Gemcitabine loaded CS fibers (GEM treated), Doxorubicin loaded CS fibers (DOX treated), and 
dual-loaded CS fibers (GEM-, DOX-, Dual-treated). (a-c) MTS cell viability assay of MIA-PaCa-2 
human pancreatic adenocarcinoma cells when treated with the fibers. (d-f) MTS cell viability assay 
of PANC-1 human pancreatic adenocarcinoma cells when treated with the fibers. (g) & (h) 
Corresponding live/dead cell staining of treated MIA-PaCa-2 and PANC-1 human pancreatic 
adenocarcinoma cells, respectively. Values are the mean (±SEM) of quadruplicate. *P = 0.05, **P ≤ 
0.01, ***P = 0.001, ****P = 0.0001. 
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Furthermore, in order to assess the anti-cancer effect of CS fibers on a more resilient 
pancreatic cancer cell line we have tested these fibers on PANC-1 human pancreatic 
cancer cell lines. The results showed a similar trend to MIA-PaCa-2 cells lines, however 
herein the cells had a higher level of viability after 72 hr post treatment specially in cells 
treated with GEM loaded fibers (56.6 ± 4.7) as shown in Figure 2-7d. Otherwise, cells 
treated with DOX- and Dual-loaded CS fibers had 13.3 ± 2.6 and 12.6 ± 2.8, respectively 
(Figure 2-7e & f). At last, live/dead staining of these cells further verified the obtained 
MTS cell viability results with DOX- and Dual-loaded fibers having the least number of 
viable cells 72 hr post treatment (Figure 2-7h). Of note, the difference in sensitivity to 
chemotherapy is well documented for MIA-PaCa-2 and PANC-1 cells,279 and has been 
attributed to differences in ERK activity 280. Moreover, the significant difference between 
anti-cancer performances of GEM loaded fibers compared to DOX-containing fibers 
could be a result of controlled release of DOX from the fibers and also different 
mechanism of action of this drug compared to GEM 281-283. Overall, the in vitro results 
suggested that CS fibers possessed a high level of cell biocompatibility, while DOX and 
dual-loaded CS fibers had superior anti-cancer efficacy when compared to GEM loaded 
fibers. Moreover, in these short-term in vitro assessments, no statistical difference was 
observed between the DOX- and dual-loaded fibers. This could be associated with 
mechanism of action of Gemcitabine, as it requires cellular uptake and intracellular 
phosphorylation.284-285 A process that is time-dependent, and also requires prolonged and 
high intercellular concentration of Gemcitabine. This further validates the importance of 
long-term in vitro studies to evaluate the therapeutic effect of the drug loaded CS fibers.   
          
2.3.8. In vitro therapeutic effect of fibers  
 
Next, with the aim of evaluating the long-term therapeutic effect of CS fibers on inhibition 
of cancer cell growth, a 20 days cell counting assay (CCK-8) was conducted using three 
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different human pancreatic cancer cell lines including MIA-PaCa-2, PANC-1, and 
BxPC3-Luc cells (Figure 2-8).  
 
 
Figure 2-8. Therapeutic effect of CS fibers on inhibition of cancer cell growth. The viability of (a) 
MIA-PaCa-2, (b) PANC-1, and (c) BxPC3-Luc human pancreatic adenocarcinoma cells at the 
different time points treated with Empty CS fibers (Control), Gemcitabine-loaded CS fibers (GEM 
treated), Doxorubicin-loaded CS fibers (DOX treated), and dual-loaded CS fibers (GEM-, DOX-, 
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Dual-treated). Values are the mean (±SEM) of quadruplicate. 
 
Consequently, in MIA-PaCa-2 cell lines the empty CS fibers (indicated as control) 
showed a high level of biocompatibility throughout the test period and did not hinder the 
cancer cell growth, whilst, drug-loaded fibers were capable of slowing down the cell 
growth to different degrees (Figure 2-8a). Accordingly, Dual-loaded fibers showed a 
higher degree of cancer cell growth prevention which lasted for almost 14 days before the 
cells became highly viable again. This was in contrast to DOX- and GEM-loaded fibers 
which showed a short term inhibition of cell growth lasting only for 5 days. Regardless, 
in correspondence with previous MTS cell viability results the DOX-loaded fibers had 
better inhibition of cancer cell growth when compared to the GEM-loaded counterparts. 
Next, PANC-1 cells were tested and similar results were obtained where Dual-loaded 
fibers showed the most inhibition of cell growth that was followed DOX- and GEM-
loaded fibers, respectively (Figure 2-8b). At last, BxPC3-Luc cells further verified the 
previous observations where Dual-loaded fibers prevented the cancer cell growth the 
longest which was followed by Dox-loaded and GEM-loaded fibers (Figure 2-8c). Worth 
noting that based on these results Dual-loaded fibers showed a notable synergistic anti-
cancer effect (as compared to GEM- or DOX-loaded fibers), which was not observed in 
the previous short-term MTS cell viability experiments. This further validates the 
importance of long-term in vitro studies in the context of cancer drug delivery as these 
chemotherapeutic drugs tends to show their therapeutic effects only after weeks of 
treatment. Overall, the obtained results suggested that these drug loaded fibers can inhibit 
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2.3.9. In vivo therapeutic effect of fibers 
 
Next, in vivo experiments were carried out for a period of 2 weeks using a murine 
subcutaneous xenograft tumor model using two pancreatic cancer cell lines including 
MIA-PaCa-2, and BxPC3-Luc cancer cells (Figure 2-9 & 2-10, respectively). Following 
tumor formation the drug loaded CS fibers were implanted under the tumor region, 
through a small incision in the middle of the back of the mice, and after two weeks the 
animals were sacrificed and their tumor size were measured.  
 
 
Figure 2-9. In vivo performance of drug loaded CS fibers in MIA-PaCa-2 mice xenografts 
compared to intravenous injection of same drugs at equal dose (n= 5 in each group, *P = 0.05, **P ≤ 
0.01, ***P = 0.001, ****P = 0.0001). (a) Schematic representation of localized therapeutic approach 
with drug loaded CS fibers in mice xenograft model (MIA-PaCa-2 tumors). (b) Tumor volume at 
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day 0 and day 14 after the treatment. (c) Tumor weight at day 14 after the treatment. (d) Body 
weights of mice in different groups after treatment. (e) Images of hematoxylin and eosin (H&E) 
staining along with KI-67 staining of pancreatic-cancer tissue (MIA-PaCa-2 tumors) sections from 
treated mice. The scale bar in images with 4x, 10x, and 20x magnification is 1000 µm, 400 µm and 
200 µm, respectively. 
 
The obtained data showed that tumors treated with DOX- and dual-loaded (DOX+GEM) 
CS fibers showed significant inhibition of tumor growth compared to GEM-loaded or 
empty CS fibers. Accordingly, MIA-PaCa-2 tumor volume increased 79 ± 83% and 28 ± 
14% in mice treated with DOX-loaded and dual-loaded CS fibers, respectively, while 
mice treated with empty and GEM-loaded CS fibers experienced 323 ± 157% and 275 ± 
21% increase in the tumor volume, respectively (Figure 2-9b). Moreover, slightly higher 
anti-cancer efficacy of dual-loaded fibers, as compared to DOX-loaded fibers, could have 
possibly been associated to synergistic effect of the two drugs 286. Most significantly, 
DOX- and dual-loaded CS fibers were able to inhibit the tumor growth to a much higher 
degree when compared to injection of equal dosages of DOX and DOX+GEM (277 ± 
55% and 194 ± 49% increase in the tumor volume, respectively), which was a testament 
to importance of local delivery of drugs in a controlled manner. Of note, weak therapeutic 
effect from GEM loaded fibers was attributed to faster release of this drug from the fibers 
that prevented steady phosphorylation of GEM by cancer cells leading to its reduced 
therapeutic effect 287. Also, all treated mice did not experience any significant weight loss 
throughout the study, which indicated that all treatments were well tolerated and did not 
cause any major toxicity (Figure 2-9d). To further evaluate the anti-cancer effect of drug 
loaded CS fibers, H&E and Ki67 (proliferating cells marker) staining of tumor tissues 
post-treatment were evaluated (Figure 2-9e). In correspondence with the observed 
results, the DOX- and dual-loaded fibers yielded significant levels of apoptosis as 
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confirmed by H&E staining of tumor tissues post-treatment, which suggests that the level 
of drugs to which tumors were exposed were sufficient to shrink the tumors and prevent 
their growth. Similar results were observed from Ki67 staining of the tumor tissues, as 
tumors treated with empty or GEM loaded fibers showed the highest density of red 
pigments (as opposed to DOX- or Dual-loaded fibers), indicating the higher population 
of proliferating cells in tumors treated with these two samples. Furthermore, with the aim 
of evaluating the cytotoxicity of empty or drug loaded CS fibers, various parameters in 
the blood of the mice were analysed (Table 2-S2, supporting information). The 
obtained results for mice treated with drug loaded or empty fibers showed no significant 
difference from the haematological values (i.e. white blood cell, red blood cell, 
hemoglobin, platelet, neurophil and lymphocyte count) of a normal mouse, suggesting 
that CS fibers did not produce any significant changes in the haematology of mice, 
implying that CS fibers may be a safe delivery platform for in vivo use.  
In order to further assess the anti-cancer performance of drug-loaded CS fibers, a second 
series of animal studies were conducted using murine subcutaneous xenograft tumor 
model using BxCP3-Luc light-producing pancreatic cancer cell lines (Figure 2-10). 
Similarly, BxCP3-Luc tumor volume increased 77 ± 53% and 47 ± 46% in mice treated 
with DOX-loaded and dual-loaded CS fibers, respectively, whilst mice treated with empty 
and GEM-loaded CS fibers experienced 622 ± 589% and 376 ± 138% increase in the 
tumor volume, respectively (Figure 2-10b). In these tumor models after 14 days of 
treatment, GEM-loaded fibers were able to slightly decrease the tumor volume when 
compared to empty fibers, which was also observed in luciferase images of the growing 
tumors (Figure 2-S8, supporting information). The slight difference between BxCP3-
Luc and MIA-PaCa-2 tumors responses to GEM-loaded fibers was associated to higher 
sensitivity of BxCP3-Luc cell lines to Gemcitabine 288. 
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Figure 2-10. In vivo performance of drug loaded CS fibers in BxPC3-Luc mice xenografts (n= 6 in 
each group, *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 0.0001). (a) Schematic representation of 
localized therapeutic approach with drug loaded CS fibers in mice xenograft model (BxPC3-Luc 
tumors). (b) Tumor volume at day 0 and day 14 after the treatment. (c) Tumor weight at day 14 
after the treatment. (d) Body weights of mice in different groups after treatment. (e) Images of 
hematoxylin and eosin (H&E) staining along with KI-67 staining of pancreatic-cancer tissue 
(BxPC3-Luc tumors) sections from treated mice. The scale bar in images with 4x, 10x, and 20x 
magnification is 1000 µm, 400 µm and 200 µm, respectively. 
 
Also, similar to MIA-PaCa-2 tumor models, in the BxCP3-Luc tumors dual-loaded fibers 
failed to show any significantly higher anti-cancer efficacy, when compared to DOX-
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loaded fibers, which could have been a result of quick release of Gemcitabine from these 
fibers. Additionally, animals treated with empty or drug-loaded fibers maintained their 
body weight for the whole duration of the study, which showed that these fibers did not 
cause a systemic toxicity and could potentially serve as a safe in vivo treatment modality 
(Figure 2-10d).Lastly, H&E and Ki67 staining of excised tumor tissue, revealed that 
empty fibers did not cause apoptosis in tumor tissue and they have not interfered with 
proliferation of cancerous cells, whilst DOX- and Dual-loaded fibers caused the most 
apoptosis of cancer cells and left the least amount of proliferating cells (Figure 2-10e).  
Overall, the in vivo findings showed that CS fibers are well tolerated in the animals and 
they did not cause any major toxicity. Also, in MIA-PaCa-2 tumor models it was shown 
that drug loaded fibers (especially DOX- and Dual-loaded fibers) had better anti-cancer 
performance when compared to intravenous injection of the equal dosages of the drugs. 
In addition, in both tumor models, it was observed that continuous and slow release of 
DOX from the CS fibers can inhibit the tumor growth more effectively (DOX- and Dual-
loaded fibers), when compared to quick release of GEM from CS fibers. The results also 
showed that dual-loaded fibers could also be effective in inhibiting the tumor growth.    
2.4. Conclusions 
 
In this study, coaxial mussel-inspired biofibers loaded with chemotherapeutic drugs were 
fabricated for the first time, where the core consisted of alginate-dopamine and the shell 
contained UV cross-linkable alginate-methacrylate. This was done with a view to 
improve both the drug affinity and diffusion, and facilitate high loading capacity and 
controlled release to function as novel implantable drug delivery system. We propose that 
the efficient intermolecular interactions between the chemotherapeutic drugs (DOX and 
GEM) and catechol moieties of the DOPA in the core imparted excellent control on the 
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release of DOX over a period of 21 days. These CS fibers elicited no significant undesired 
toxicity as evidenced from both in vitro and in vivo experiments. DOX- and dual-loaded 
(DOX+GEM) fibers achieved significant anti-cancer effect on human pancreatic cancer 
cells-xenografted tumor models, while GEM loaded fibers showed minimal anti-cancer 
effect at doses much higher than DOX. Most remarkably, in MIA-PaCa-2 tumor bearing 
mice, Dox- and dual-loaded CS fibers were able to significantly prevent the tumor growth 
(79% and 28% increase in tumor volume, respectively), when compared to intravenous 
injection of equivalent dosages of the same drugs (277% and 194% increase in the tumor 
volume, respectively). Enhanced inhibition of tumor growth in DOX-containing fibers 
was attributed to prolonged release of the drug from these fibers, and considering the 
systemic side effects of DOX, the CS fibers could be beneficial for local delivery of this 
drug and subsequently reducing its cardiotoxicity. Lastly, in this study we did not observe 
any significantly higher anti-cancer efficacy from dual-loaded fibers, as compared to 
DOX-loaded fibers, which could be associated with quick release of GEM from the fibers. 
In conclusion, this study showed that mussel-inspired coaxial biofibers, as a novel 
implantable platform, provided an effective and safe strategy towards local delivery of 
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2.5. Supporting information 
 
2.5.1. Analysis of dye loaded fibers 
 
Degree of substitution of alginate-dopamine was shown to have a significant effect on the 
dye release profile and total amount of dye released. Accordingly, fibers made from 
alginate-dopamine 50% had the slowest release (51 µgr), followed by the fibers made 
from alginate-dopamine 25% (32 µgr) and pure alginate (22 µgr), respectively (Figure 
S2, supporting information). Noting, these observations were likely due to strong 





Figure 2-S1. Physiochemical characterization of as-synthesized polymers including, (a & b) FTIR 
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Figure 2-S2. Preliminary dye release (fluorescein sodium salt, 2mM) studies from single fibers 
made from pure alginate (Alg), alginate-dopamine 25% (alg-dopamine 25%), alginate-dopamine 
50% (Alg-dopamine 50%) (a) Release profile of dye loaded fibers. (b) Cumulative dye released 
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Figure 2-S3. Morphology of single fibers made from pure alginate (Alg) using SEM imaging, (a) in 
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Figure 2-S4. Mechanical properties of fibers following a static tensile test, pure alginate 
fibers (Alg) or core-shell mussel-inspired fibers (CS), (a) Stress-strain curve for fibers in dry 
state. (b & c) Tensile strength and modulus of fibers in dry state (n = 3, mean ± SD). (d) 
Stress-strain curve for fibers in wet state. (e & f) Tensile strength and modulus of fibers in 
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Figure 2-S6. Morphology of wet CS• fibers where both core and shell were made from UV-
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Figure 2-S8. Therapeutic effect of drug loaded CS fibers in subcutaneous BxPC3-Luc tumor model. 
(a) Quantitative imaging data of BxCP3-Luc tumor growth presented as mean ± SD. (b) In vivo 
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Table 2-S1. Hydrodynamic dimeter, poly-dispersity index (PDI), and zeta potential of various 
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Table 2-S2. Hematologic parameters from MIA-PaCa-2  tumor bearing mice in various treatment 
groups. Data are presented as average ± SD (n = 5). WBC: white blood cell, RBC: red blood cell, 
HGB: hemoglobin, HCT: hematocrit, PLT: platelet, Neut: neutrophils, Lymp: lymphocytes, Mono: 
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3. Coaxial mussel-inspired hydrogel fibers containing 
Cu2−xSe Nanoparticles: Toward building an implantable 





Conventional cancer therapies involve systemic administration of drug (or drug 
combinations) with the aim of inhibiting tumor growth and inducing cancer cell death.237 
However, this approach is bound to certain limitations including low efficiency of 
delivering drugs to their parenchymal target, which ensues undesired toxicity to healthy 
tissues.289 To surmount these issues, local delivery of drugs directly to the tumor site, via 
biopolymeric implants, has generated remarkable localized therapeutic effects with less 
undesired casualties.236 Notably, most recently researchers have begun to explore the use 
of biopolymeric implants for the delivery of multimodal cancer therapies, such as chemo-
photothermal therapy, with the aim of achieving synergy and therefore a high tumor 
response.290-292 Particularly, use of these implants for chemo-photothermal therapy allows 
for sustained release of the drug, but also the generation of heat instigated by an external 
stimuli. In brief, photothermal therapy involves the use of photo-absorbing agents to 
transform optical radiation to heat at the tumor site with the aim of ablating cancer cells.293 
   
Recently, hydrogels have attracted much attention for cancer drug delivery owing to their 
unique features including their tunability (both physically and chemically).236, 294 To 
obtain sustained and prolonged drug release from hydrogels these polymeric carriers 
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could be further functionalized with various functional moieties to facilitate drug-polymer 
interactions.295 This could include usage of functional moieties such as thiols,241, 296-297 
heparins (or heparin-mimetic molecules),298-301 cyclodextrins,302-304 amphiphilic 
moieties192, 305-307. Inspired by marine mussels, in Chapter 2 we have used dopamine to 
modify the alginate hydrogel to form dopamine-polymer conjugates, which showed 
enhanced drug-polymer interactions when loaded with Doxorubicin and Gemcitabine.308  
In addition, in the cotext of cancer therapy, dopamine possess peculiar properties 
including NIR-responsive hyperthermia,309-311 and intrinsic anti-tumor effects.312-313 
Nevertheless, controlled release of drugs from hydrogels is also affected by tortuosity of 
the release path, which is detrmined by factors such as porosity and network 
swelling/degradation.238 In line with this, modification of biopolymers with methacrylate 
groups and their subsequent photocrosslinking has been proven as an effective way to 
control physical properties of the hydrogels including their mechanical properties, 
porosity, swelling behaviors, and  degradation rate.314 As a result, combination of mussel-
inspired properties with photocrosslinking capabilities in a hydrogel system might yield 
a powerful platform for controlled delivery of chemotherapeutic drugs.  
Within the framework of hydrogels photothermal therapy is often achieved through a 
composite approach whereby photo-sensitive particles, such as gold nanopaprticles,211 
graphene nanosheets,315 and MXene nanosheets290, are incporated into the hydrogel 
network. Along these lines, copper selenides (Cu2–x Se) nanoparticles have emerged as 
powerful photothermal agents owing to unique set of characteristics including 
biodegradability, ease of chemical midifications, photoacoustic imaging, X‐ray computed 
tomography (CT) imaging, and single‐photon emission computed tomography (SPECT) 
imaging.316-319 Consequnetly, Cu2–xSe nanoparticles could be ideal additives for 
fabricating a composite hydrogel with photothermal capabilities.  
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In this chapter, with the aim of establishing a suitable implantable platform for 
multimodal chemo-photothermal cancer therapy, we have fabricated for the first time a 
coaxial composite hydrogel fiber using a wet-spinning method established in our 
laboratory.259 Particularly, the core-section of these fibers (Chemo-compartment) 
contained dopamine-modified alginate along with a chemotherapeutic drug 
(Doxorubicin; DOX), while their shell section (Phothothermal compartment) was 
composed of UV-crosslinkable methacrylate-modified algine together with Cu2−xSe 
Nanoparticles (NPs). It was hypothesized that specific biopolymeric composition of these 
fibers along with their corresponding core-shell geometry would allow controlled release 
of Dox (loaded in the core), while the Cu2−xSe nanoparticles (loaded in the shell) would 
facilitate heat generation upon near infra-red (NIR) laser irradiation. Accordingly, a 
comprehensive characterization of the physiochemical properties of the resulting fibers 
were conducted which included their microstructural morphology (scanning electron 
microscopy; SEM), elemental composition (Energy-dispersive X-ray spectroscopy; 
EDX), chemical composition and crystalline phase (Infrared spectroscopy; FTIR. X-ray 
diffractrometry; XRD), nanoparticle content (thermogravimetric analysis), tensile 
properties in both static and dynamic conditions (mechanical tester and dynamic 
mechanical analysis, respectively), and their swelling behaviour. The results suggested 
that the fibers possessed a core-shell morphology whereby nanoparticles were dominantly 
distributed in the shell section. Furthermore, it was shown that addition of DOX and 
Cu2−xSe nanoparticles to the coaxial fibers led to an increase in their corresponding tensile 
properties (when compared to unloaded coaxial fibers), an effect which was more 
prominently observed for fibers in their wet state. In addition, the coaxial composite fibers 
not only allowed controlled released of DOX in vitro over a span of 3 weeks, but they 
were also capable of generating heat in a tunable manner (based on the length of the fiber) 
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upon NIR irradiation, in both in vitro and in vivo conditions. Most remarkably, the coaxial 
drug-loaded composite fibers in the presence of NIR radiation showed superior anti-
cancer effect (both in vitro and in vivo) when tested against breast cancer cell lines, a 
phenomenon attributed to their synergistic chemo-photothermal effect. Overall, coaxial 
mussel-inspired hydrogel fibers containing Cu2−xSe nanoparticles provided a safe and 
efficacious implantable platform for multimodal chemo-photothermal therapy that could 
potentially be used to control the progression of cancer locally at the tumor site.  
 
3.2. Experimental section 
 
3.2.1. Materials  
 
Alginic acid sodium salt from brown algea (medium viscosity), N-(3-
Dimethylaminopropyl)-Nˊ-ethylcarbodiimide hydrochloride (≥99.0%), N-
Hydroxysuccinimide, Dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%), 
Methacrylic anhydride, and IRAGACURE D-2959 were purchased from Sigma Aldrich. 
Calcium chloride (CaCl2) and Sodium hydroxide (NaOH) were purchased from Chem-
Supply. Doxorubicin hydrochloride was purchased from Focus Bioscience. Simulated 
body fluid (SBF) was prepared as explained before.19 D2O (100% - CIL) was supplied 
by Novachem. Water soluble HS‐PEGylated Cu2‐xSe Nanoparticles were kindly supplied 
by Dr. Zhen Li  of Soochow University and they were synthesized by a previusouly 
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3.2.2. Synthesis and characterization of alginate-dopamine 
 
Alginate-dopamine was synthesized via carbodiimide chemistry.257 Briefly, 1 g of alginic 
acid (5 mmol in terms of repeating unit) was dissolved in 100 ml of 0.1 M MES buffer 
with pH of 5.6. EDC and NHS were separately dissolved in 2 ml of MES buffer (2.5 
mmol) and subsequently added to the alginic acid solution. while the reaction were 
allowed to continue for 30 min. Dopamine hydrochloride (at equal concentration to EDC 
and NHS) was separately dissolved in 2 ml of MES buffer and added to the mixture 
subsequently. The reaction were allowed to happen for 1 hr under nitrogen flushing. 
Afterwards the solution was dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD) 
for 7 days against acidic water (pH of 6) and subsequently precipitated in ethaol. The 
precipitated polymers were next lyophilized using a freeze-dryer. Incorporation of 
dopamine into alginate was further confirmed using FTIR (Shimadzu IRPrestige-21 
infrared spectrometer) and HNMR (Bruker 400 MHz) spectroscopy. 
 
3.2.3. Synthesis and characterization of alginate-methacrylate 
 
Alginate-methacrylate was synthesized by using methacrylic anhydride.258 Briefly, 3 g of 
alginic acid was dissolved in 300 ml of distilled water (1% w/v) to which 24 ml of 
methacrylic anhydride (8% v/v) was added and the pH was maintained at 8 for 6 hrs using 
5.0 M NaOH solution. Afterwards, the solution was dialyzed (spectra/ por membrane 
tubing; MWCO 12–14 kD) for 7 days and precipitated in ethanol followed by freeze-
drying. Grafting of methacrylate groups onto the alginate backbone was further confirmed 
using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR (Bruker 400 
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All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton 
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room 
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer 
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of 
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to 
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm, 
DYMAX BlueWave 75). 
 
3.2.5. Fabrication of core-shell fibers  
 
In this study 4 different formulation of core-shell fibers were made: i) Empty core-shell 
fibers (CS), ii) DOX loaded core-shell fibers (DOX-CS), iii) Cu2−xSe Nanoparticle loaded 
core-shell fibers (NPs-CS), and iv) DOX and Cu2−xSe Nanoparticle loaded core-shell 
fibers (NPs-DOX-CS). As mentioned in the introduction, two different solutions were 
used to prepare the core-shell fibers. Accordingly, the core aqueous solution contained 
3% (w/v) of alginate-dopamine/alginate-methacrylate mixture (75/25% w/w) and 0.05% 
(w/v) IRAGACURE D-2959. On the other hand, the shell aqueous solution contained 3% 
(w/v) of alginate-methacrylate and 0.05% (w/v) IRAGACURE D-2959.  Of note, for 
DOX-containing fibers the drug (2 mM) was added to the core solution, while for NPs-
containing fibers the nanoparticles (1.6 mg/ml) were added to the shell solution.  For fiber 
fabrication a coaxial wet-spinning technique (previously established in our laboratory) 
has been used.270 Briefly, those two solutions were simultaneously extruded through the 
coaxial nozzle into the coagulation bath, H2O/Ethanol (4:1) containing 2% CaCl2 (w/v), 
and the fibers were subsequently irradiated with UV light (365 nm, DYMAX BlueWave 
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75) as they were collecting on the rotating drum (10 rpm). Noting, Cu2−xSe Nanoparticles 
were loaded into the shell to further facilitate their exposure to the NIR laser. Of note, in 
the core solution, alginate-dopamine was physically mixed with alginate-methacrylate to 
allow the formation of a dual cross-linked core constituent by combining chemical and 
physical crosslinking methods. 
 
3.2.6. Characterization of fibers 
 
Scanning electron microscopy (SEM) observations with energy dispersive X-ray 
spectroscopy (EDX) analysis were performed using a JEOL JSM-6490LV microscope 
coupled with an Oxford instruments X-max 80mm2 SDD energy dispersive spectrometer. 
All maps were acquired using the Oxford Instruments AZtec software suite. SEM images 
were taken in high vacuum mode at 15 kV operating voltage and a spot size setting of 60. 
For SEM imaging, the fibers were first allowed to completely swell in SBF, then they 
were cut into small pieces and inserted into special sample holders. The sample holder 
containing the mounted fibers was then immersed into liquid nitrogen for about 45 s and 
immediately afterwards a razor blade was used to fracture the fibers and expose their 
cross-section. Subsequently, the sample holder was then quickly transferred to the 
LVSEM for examination.  
Fourier transform infrared (FTIR) spectra were measured between 700 and 4000 cm–1 on 
a Shimadzu IRPrestige-21 infrared spectrometer with internal beam equipped with 
standard detector with mirror speed of 2.8. The spectra were obtained using attenuated 
total reflection (ATR) on the fibers with resolution of 8 and number of scans of 30, on a 
transmittance mode. The crystalline structures of samples were analyzed by XRD (GBC, 
MtriX SSD) using Cu Kα radiation (λ = 0.154 nm), with the generator working at 40 kV 
and 30 mA. The weight percentage of the nanoparticles in the fibers was obtained by 
thermogravimetric analysis (TGA, Mettler Toledo-SDTA851) on 10 mg of samples with 
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heating rate of 5 °C/min under a nitrogen atmosphere, between temperatures of 27°C–
900°C. 
The static mechanical properties of fibers were assessed using a mechanical tester (EZ-L 
tester from Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry and wet 
fibers, respectively. The dynamic mechanical properties of fibers was evaluated using a 
dynamic mechanical analysis (DMA 242 E Artemis, NETZSCH). Accordingly, by using 
a tension clamp the samples were exposed to a constant strain (0.1 %) of increasing 
frequencies in the range of 0.1 to 10 Hz for 30 min, subsequently storage and loss modulus 
were recorded and Tan delta values were measured as a ratio of loss modulus to storage 
modulus. Lastly, the swelling properties of the hydrogel fibers were determined by 
examining their water uptake capacity. The hydrogel fibers were incubated in simulated 
body fluid (SBF) at 37°C and allowed to fully swell. The swelling ratio was calculated 
using the following equation: (Ws – Wd)/Wd, where Ws represents the weight of the 
swollen hydrogel fibers and Wd represents the weight of the dried hydrogel fibers at the 
beginning.  
 
3.2.7. Release studies from drug loaded fibers  
 
To measure the drug release from the fibers, 30 cm of drug loaded fibers were immersed 
in 1 ml of SBF solution and the supernatant was collected at certain time points and 
replaced with fresh SBF.320 For measuring the DOX release, fluorescence properties of 
DOX was measured (excitation 485 nm, emission 520 nm) using FLUOstar OPTIMA 
microplate reader. The absorbance values were converted to DOX concentrations using a 
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3.2.8. In vitro photo-thermal effect studies 
 
The photo-thermal effect of the fibers were evaluated in vitro by immersing either 2 cm 
or 4 cm of the fibers in 1 ml of SBF solution (in a 1.5 ml eppendorf), and irradiating them 
with an 808 nm laser (power density of 1.0 W·cm−2) for 600 s. The temperature change 
in the solutions were monitored using an infrared camera (Micro—EPSILON/TIM160) 
that was operated with thermoIMAGER TIM software.  
 
3.2.9. In vitro cell studies 
 
NIH-3T3 mouse fibroblast cells and 4T1 mouse breast cancer cells were cultured in the 
standard cell media at 37 °C in a 5% CO2 atmosphere. 2 ×104 cells/well were seeded into 
24 well plates and incubated for 24 hr in different culture medium supplemented with 
10% FBS and 1% Penicillin-Streptomycin  (i.e. NIH-3T3: DMEM high sugar medium 
containing L-glutamine, no sodium pyruvate; 4T1: RPMI-1640 medium). Then, with the 
aim of evaluating the cytotoxicity of the samples, cells were washed with PBS and 
incubated with 1 cm fibers per well for 12 hr or 24 h hr at 37 °C. Following incubation, 
cells were washed with PBS and subsequently 500 μL MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide) with a concentration of 0.5 mg/mL was added and 
allowed to react with the cells for 4 h before the addition of 500 μL dimethyl sulfoxide to 
dissolve the precipitates. The absorption of each solution was measured at 490 nm on a 
microplate reader (Thermo, Varioskan Flash). With the purpose of live/dead imaging of 
the cells, 4T1 cells were seeded in 12 well plates (2 × 105 cells per well) and incubated 
with 1 cm fibers per well. Cells were then irradiated once with an 808 nm laser for 10 
min, under power densities of 1.0 W·cm–2. The LIVE/DEADTM viability/cytotoxicity kit 
for mammalian cells (ThermoFisher Scientific) was used to stain the live cells (green 
fluorescence) and the dead cells (red fluorescence), which were subsequently imaged 
using a fluorescence microscope (Leica M205 FA). 
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3.2.10. In vivo tumor therapy  
 
All animal experiments were carried out according to the protocols approved by the 
Soochow University Laboratory Animal Center (Permit number: 2171075). The tumor 
models used were established by subcutaneous injection of 50 μL 4T1 cell suspension 
(≈5 × 106 cells) into the flank region of the right back of 6‐week‐old male BALB/c mice 
(for the photothermal therapy treatment). The tumor therapy studies were carried out 10 
d after the inoculation with tumor cells. Briefly, puncture needle (needle gauge 12) was 
used to deliver the dry fibers adjacent to the tumor site. Five groups (n = 5) of mice were 
referred as (a) tumor–bearing mice only treated with NIR laser (Control); tumor–bearing 
mice irradiated with the NIR laser after injection with (b) core-shell fibers  (CS), (c) DOX 
loaded core-shell fibers (DOX+CS), (d) NPs loaded core-shell fibers (NPs+CS), NPs and 
DOX loaded core-shell fibers (NPs+DOX+CS). The dose was either 2 cm or 4 cm of the 
fiber per mice. After 24 hr post implantation, an 808 nm laser was once used for the 
photothermal therapy and the power density was 1.0 W·cm−2, the irradiation time was 10 
min. The tumor sizes and body weights were measured every two days, and the tumor 
volume was expressed by L × W2/2, where L and W represent the length and width of the 
tumor, respectively.    
 
3.2.11. Statistical analysis  
 
Statistical significance was determined using a two-way ANOVA with a Sidak post-test 
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05 
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 
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Given the role of rheology in determining the spinnability of a solution,321 rheological 
evaluations of all spinning solutions were carried out (Figure 3-1). Based on the viscosity 
measurements (Figure 3-1a), all solutions showed a shear thinning behaviour as their 
viscosity consistently dropped by increasing the shear rate. Moreover, at the same 
concentration, the core solution (alginate-dopamine/alginate-methacrylate mixture; 
75/25% w/w) showed a higher viscosity when compared to that of shell solution (alginate-
methacrylate). This was likely due to noncovalent interactions including π-π stacking of 
dopamine moieties in alginate-dopamine that led to its higher viscosity.251  
 
 
Figure 3-1. Rheometry of the spinning solutions including (a) Viscometry of 3% (w/v) solution of i) 
alginate-methacrylate, ii) alginate-methacrylate + NPs, iii) alginate-dopamine/ alginate 
methacrylate (75/25 w/w), and iv) alginate-dopamine/ alginate methacrylate + DOX. (b) Oscilatory 
rheology of 3% (w/v) solutions (containing 0.05% (w/v) IRAGACURE D-2959) of i) alginate-
dopamine/ alginate methacrylate (75/25 w/w), ii) alginate-dopamine/ alginate methacrylate + DOX, 
iii) alginate-methacrylate, and iv) alginate-methacrylate + NPs. 
 
Also, methacrylation chemistry often leads to disruption of the alginate backbone 266, 
which can ultimately reduce its viscosity. Of note, addition of both DOX and NPs to their 
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corresponding solutions led to a slight increase in their viscosity values, a phenomenon 
that could be attributed to intermolecular interactions of these entities with their 
polymeric carrier.322 To further evaluate the UV crosslinking-ability of the spinning 
solutions, oscillatory experiments (as a function of time) upon UV irradiation were 
conducted and the results are presented in Figure 3-1b. Accordingly, the shell solution 
(with or without NPs) experienced a significant jump in its storage modulus upon 
initiating the UV irradiation, an indication of UV cross-linking of alginate-methacrylate 
in the solution. On the other hand, the core solution (with or without DOX) only 
experienced a slight increase in its storage modulus values, a consequence of low volume 
of alginate-methacrylate in this solution. Subsequently, the core and shell solutions were 
used to fabricate the core-shell fibers using a coaxial wet-spinning technique, as discussed 
in section 2.5.  
 
3.3.2. Physiochemical characterization of fibers  
 
In order to study the morphology of the resulting fibers and evaluate the dispersion of 
NPs in the shell section, SEM microscopy with energy dispersive X-ray spectroscopy 
(EDX) analysis was employed (Figure 3-2). Consequently, the cross-section SEM image 
of the fully swollen fiber (Figure 3-2a) showed two distinctly different pore distribution, 
associated with the core and shell section of these fibers. Thus, the shell section appeared 
to have a less porous structure, as compared to the core section, and its thickness was 
roughly around 100 µm. This was largely associated with higher concentration of 
alginate-methacrylate in the shell section, as well as limited diffusion of CaCl2 
crosslinking agent into the core. On the other hand, the core section showed more porosity 
with a pore size distribution varying along the fibers diameter. Similarly, this could have 
been a result of limited diffusion of CaCl2, along with minimized penetration of UV light 
to centre of the fibers.323-325 Next, with the aim of investigating the presence of NPs in the 
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fibers, EDX elemental mapping was implemented on the obtained SEM image (Figure 
2b). The results showed the distribution of carbon and oxygen as the major component of 
the organic fibers, whereas the inorganic Cu and Se were only observed at the edges of 
the fiber associated with the Cu2−xSe nanoparticles loaded into the shell. Furthermore, Cu 
and Se mapping showed the homogenous distribution of nanoparticles in the shell section 












Figure 3-2. (a) SEM image of the NPs-CS fibers, (b) EDX elemental mapping of the corresponding 
SEM image. 
 
Next, with the aim of scrutinizing the composition of the resulting CS fibers, FTIR and 
XRD analysis were utilized (Figure 3-3). The FTIR spectra (Figure 3-3a) of both CS and 
NPs-CS fibers showed characteristic peaks associated with alginate-dopamine and 
alginate-methacrylate. Accordingly, the characteristic alginate peaks associated with C-
O stretching vibration (1030 cm-1), COO- symmetric and asymmetric stretching vibration 
(1415 and 1600 cm-1, respectively), and –OH stretching vibrations (3325 cm-1) were 
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observed in both spectra.326 Moreover, in both spectrums the peak at 1257 cm-1 was 
associated to C-N stretching of phenyl amines in alginate-dopamine,327 and the peak at 
2920 cm-1 was due to methyl group of alginate-methacrylate.328 Of note, for NPs-CS 
fibers, characteristic peaks of Cu2−xSe were out of the range of our measurements (below 
700 cm-1),329-330 however appearance of C-S stretching vibration (small peak at 720 cm-
1) was attributed to the thiol groups in the nanoparticles.331 Also, NPs-CS fiber FTIR 
spectrum showed a significant decrease in intensity of COO- peaks (at 1415 cm-1 and 
1600 cm-1), and a slight shift in corresponding carboxylic acid C=O peak from 1712 cm-
1 to 1720 cm-1. These findings could potentially point out to a possible thioesterification 
reaction between the thiol groups in the nanoparticles and the carboxylic acid groups in 
alginate backbone.332  
 
Figure 3-3. (a) FTIR and (b) XRD analysis of the CS and NPs-CS fibers. 
 
To further investigate the presence of nanoparticles in NPs-CS fibers, XRD analysis of 
the fibers was conducted (Figure 3-3b). The XRD spectrum of CS fibers did not show 
any specific peak implying the amorphous nature of these fibers. On the other hand, the 
NPs-CS fibers showed three sharp peaks at 2θ of approximately 26.6 ⸰, 44.7 ⸰, and 52.8 ⸰ 
associated to (111), (220), and (311) planes of cubic berzelianite (Cu2‐xSe, JCPDS Card 
No. 06–0680), respectively.316 Lastly, with the aim of measuring the exact NPs content 
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in the NPs-CS fibers, TGA analysis of the fibers were carried out (Figure 3-4). 
Consequently, the CS fibers showed 3 different stages of thermal degradation: (i) the loss 
of volatile products through dehydration (from room temperature to 200°C), (ii) thermal 
degradation of polymeric content (200°C - 600°C), and (iii) carbonization process (above 
600°C).333 The NPS-CS fibers showed a similar trend in their TGA graph, except they 
created more residue at 900°C associated with Cu2‐xSe nanoparticles. The difference 
between final residue content of CS and NPs-CS fibers was used to measure the NPs 
content which was equal to 5% (weight %). 
 
Figure 3-4. (a) TGA and (b) DTGA thermographs of CS and NPs-CS fibers. 
 
3.3.3. Mechanical properties in static conditions 
 
A static tensile test was employed to evaluate the mechanical properties of the fibers in 
both dry and wet state (Figure 3-5). The results for dry fibers (Figure 3-5a,c) showed 
that CS fibers possessed a modulus of 2.0 ± 0.2 GPa and a tensile strength of 81.9 ± 20.5 
MPa. The obtained values for the CS fibers in dry state exceeded that of other core-shell 
hydrogel fibers that were reported in the literature,334-335possibly due to double-
crosslinking (physical and chemical) mechanism in our fibers. Addition of DOX to the 
fibers (DOX-CS) slightly increased the modulus and tensile strength values to 2.4 ± 0.3 
GPa and 113.2 ± 4.4 MPa, respectively. In a similar manner, addition of NPs to the fibers 
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(NPs-CS) further enhanced the modulus and tensile strength values to 3.1 ± 0.3 GPa and 
145.5 ± 3.2 MPa, respectively. These observations along with the rheometry results, 
further reinforced the idea of DOX and NPs interacting with their corresponding polymer 
carriers. Ultimately, simultaneous incorporation of DOX and NPs into the fibers (NPs-
DOX-CS) yielded the highest modulus and tensile strength values, 3.4 ± 0.2 GPa and 210 
± 1.0, comparable numbers to those obtained from other core-shell fibers reported in the 
literature.336-337 Mechanical properties of the fibers in wet state were also evaluated and 
the results are presented in Figure 3-5d,f. These results showed a similar trend to that of 
fibers in dry state, in that NPs-DOX-CS fibers possessed a significantly higher modulus 
and tensile strength values (0.4 ± 0.05 GPa and 1.6 ± 0.03 MPa, respectively) when 
compared to that of CS fibers (0.15 ± 0.07 GPa and 0.26 ± 0.01 MPa, respectively). In 
fact the obtained tensile values for NPs-DOX-CS fibers in wet state were greater than 
those for other core-shell hydrogel fibers that were reported in the literature.338-339 
 
Figure 3-5. Mechanical properties of fibers following a static tensile test, (a) Stress-strain curve for 
fibers in dry state. (b & c) Modulus and tensile strength of fibers in dry state (n = 3, mean ± SD). (d) 
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Stress-strain curve for fibers in wet state. (e & f) Modulus and tensile strength of fibers in wet state 
(n = 3, mean ± SD) (*P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 0.0001). 
 
3.3.4. Mechanical properties in dynamic conditions 
 
With the aim of gaining a better insight into viscoelastic properties of the fibers an 
oscillating tension test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz 
was conducted (Figure 3-6).  
 
Figure 3-6. Dynamic mechanical analysis of hydrogel fibers by using a tension clamp. The samples 
were exposed to a constant strain (0.1 %) of increasing frequencies in the range of 0.1 to 10 Hz for 
30 min. (a) Storage modulus and (b) Loss modulus of fibers at different frequencies. (c) Storage and 
loss modulus at the frequency of 10 Hz. (d) Tan delta (damping factor) at the frequency of 10 Hz (n 
= 3, mean ± SD) (**P ≤ 0.01, ****P = 0.0001). 
 
Accordingly, for all fiber formulations the storage modulus values exceeded the loss 
modulus values over the entire frequency range (Figure 3-6c), which indicated the 
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dominance of elastic response over a viscous behaviour in all the samples. Most 
significantly, NPs-DOX-CS had a remarkably higher storage modulus value (7.5 ± 0.5 
GPa) when compared to that of CS fibers (0.9 ± 0.2 GPa). This in turn translated into a 
significantly lower damping factor (Tan δ - calculated from the ratio of E˝/Eˊ) for NPs-
DOX-CS fibers (0.0065 ± 0.0007) compared to that of CS fibers (0.0315 ± 0.0021), as 
shown in Figure 3-6d. These findings suggested that NPs-DOX-CS are mechanically 
strong fibers (in both dry and wet conditions) with high level of elasticity, making them 
ideal candidates for fabricating implantable 3D structures using textile manufacturing 
techniques.340-341      
      
3.3.5. Swelling behaviour and DOX release study        
    
The swelling behaviour of fibers (in simulated body fluid; SBF) were assessed and the 
results were presented in Figure 3-7a. Consequently, all fiber formulations showed a 
large swelling ratio (> 10) befitting of their hydrogel nature,342 however NPs-DOX-CS 
fibers showed a statistically significant decrease in their swelling ratio (12.4 ± 0.6) when 
compared to that of CS fibers (15.5 ± 0.5). The decrease in swelling ratio of the NPs-
DOX-CS was in agreement with previously observed rheological and mechanical analysis 
of the fibers, implying to additional interactions of NPs and DOX entities with their 
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Figure 3-7. (a) in vitro swelling ratio of the fibers upon immersion in simulated body fluid (SBF), (b) 
in vitro release profile of Doxorubicin from drug loaded fibers. (**P ≤ 0.01) 
 
Furthermore, release of DOX from the NPs-DOX-CS fibers was assessed and the results 
were shown in Figure 3-7b. Consequently, DOX release profile from the fibers exhibited 
three distinct stages: starting with a burst release of the drug over the first 10 h (35.9 ± 
3.3%), followed by a slower release of the drug up to day 8 (57.7 ± 8.0%), and then an 
even slower release rate that lasted up to day 19 (65.7 ± 4.6%), which was followed by a 
plateau region up to day 21 (66.8 + 3.8%). The obtained DOX release profile further 
validated the rationale behind the specific composition and structure of the fibers, as they 
succeeded in prolonged release of the drug over a span of 21 days, longer than that of 
other hydrogels recently reported in the literature.343-347 Also, given the possible 
interactions of DOX with the core polymeric carrier (as supported by the rheological and 
mechanical evaluations), one can expect even a longer DOX release profile at 
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3.3.6. In vitro photo-thermal effect 
 
With the aim of evaluating the photo-thermal conversion capability of the fibers, an initial 
in vitro assessment was performed (Figure 3-8), where 4 cm of the fibers (immersed in 
SBF) were irradiated with 808 nm laser (power density of 1.0 W·cm−2) for 10 min. 
Accordingly, CS and DOX-CS fibers only raised the medium temperature up to 29°C and 
33°C (respectively) after 10 min of laser treatment. On the other hand, under similar 
circumstances, NPs-CS and NPs-DOX-CS fibers were capable of raising the medium 
temperature up to 65°C and 72°C (respectively), a clear indication of photo-thermal effect 
of fibers loaded with NPs. In addition, a separate set of experiments were conducted using 
2 cm of the fibers (Figure 3-S2, supporting information), and the results showed a 
similar trend where NPs-CS and NPs-DOX-CS were capable of increasing the 
temperature up to 54°C and 61°C, respectively. These observations showed that NPs-
containing fibers possessed a photo-thermal conversion capability that was directly 
correlated with length of the fibers. Accordingly, a whole variety of temperature profiles 
can be achieved by simply adjusting the fiber length, and this could be a distinguishing 
feature of these fibers. 
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Figure 3-8. In vitro photo-thermal conversion effect of 4 cm of the fibers in SBF. (a) Infrared 
thermal images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for 
10 min, under power densities of 1.0 W·cm–2. 
 
3.3.7. In vitro biocompatibility 
 
First, the biocompatibility of all fiber formulations were tested against 4T1 breast cancer 
cells and the results are shown in Figure 3-9a. Based on the obtained results CS fibers 
reduced the cell viability down to 71.7% ± 5.0 after 12 hr of treatment. This was followed 
by a further reduction in cell viability down to 45.2% ± 1.9 after 24 hr of treatment. 
Similar trend was observed for other fiber formulations, to a point where DOX-NPs-CS 
fibers showed a cell viability of 45.9% ± 5.6 and 18.1% ± 0.2 after 12 and 24 hr of 
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Figure 3-9. In vitro biocompatibility evaluation of the fibers including (a) MTT cell viability assay 
of 4T1 breast cancer cells, (b) MTT cell viability assay of NIH-3T3 fibroblast cells, and (c) 
Live/dead staining of 4T1 cells treated with different fiber formulations in absence (- NIR) or 
presence (+NIR) of laser irradiation (808 nm laser for 10 min, under power densities of 1.0 W·cm–
2). The scale bar in microscopy images is 100 µm. Values are the mean (±SEM) of quadruplicate. 
****P = 0.0001. 
These results suggested that empty CS fibers possessed some level of toxicity towards the 
4T1 breast cancer cell line. Consequently, with the aim of further evaluating the 
biocompatibility of the samples, a second set of in vitro experiments were conducted 
where fibers were tested against NIH-3T3 fibroblast cells (Figure 3-9b). As opposed to 
4T1 cell line results, the NIH-3T3 cells showed viability of 95.0% ± 2.1 and 83.6% ± 2.1 
after 12 and 24hr of treatment, respectively. Furthermore, NIH-3T3 cells treated with 
NPs-CS fibers showed similar levels of viability (87.6% ± 5.6 and 86.2% ± 4.6 for 12 and 
24 hr treatment, respectively) to that of CS fibers, indicating that addition of NPs to the 
fibers did not cause any major toxicity. Additionally, DOX containing fibers (DOX-CS 
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and NPs-DOX-CS) caused a significant reduction in cell viability, compared to that of 
control samples, associated with antineoplastic action of the drug. These observations 
showed that CS fibers possessed a high level of toxicity against the breast cancer cells, 
whereas no such effect was observed when they were tested against healthy fibroblast 
cells. This could be associated with anti-cancer action of dopamine in the CS fibers, 
caused by dopamine-instigated oxidative DNA cleavage of cancer cells.312-313, 348-349  
Lastly, the photothermal therapeutic effect of the fibers, in presence of NIR laser, was 
tested against 4T1 breast cancer cells (as described in section 3.2.9) and the live/dead 
confocal images of the treated cells are shown in Figure 3-9c. The results demonstrated 
that 4T1 cells could not be completely killed in the absence of NIR light. In contrast, NPs-
DOX-CS fibers were capable of completely killing the cells upon NIR laser irradiation, 
through synergistic effect of hyperthermia and chemotherapy. Overall, the obtained 
results revealed that CS fibers possessed certain level of toxicity towards cancer, but not 
towards healthy cells. Besides, the NPs-containing fibers (NPs-CS and NPs-DOX-CS) 
were capable of killing the cells with a higher efficiency, due to their hyperthermia effect. 
 
3.3.8. In vivo photo-thermal effect 
 
Next, the photo-thermal conversion effect of the fibers was assessed by implanting 4 cm 
of fibers subcutaneously in animal models, and subsequently exposing them to 808 nm 
laser irradiation (power density of 1.0 W·cm−2) for 10 min (Figure 3-10). Consequently, 
the results showed that NPs-CS and NPs-DOX-CS fibers were capable of increasing the 
temperature of irradiation site up to 57°C and 65°C, respectively. Whereas, all the other 
fibers (CS and DOX-CS) did not show any significant raise in their temperature when 
compared to that of control samples. Furthermore, we have repeated the same experiment 
with 2 cm of the fibers (Figure 3-S3, supporting information), to compare the data with 
previously obtained in vitro observations. Accordingly, the fibers did not show any 
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significantly different temperature profiles, indicating the length-dependence photo-
thermal conversion effect of the fibers. Most importantly, the obtained in vivo 
temperatures in this study (50 ºC to 65 ºC) were perfectly in range of previously reported 
temperature for the death of tumor cells and tumor-encapsulating blood vessels.350  
 
Figure 3-10. In vivo photo-thermal conversion effect of 4 cm of the fibers. (a) Schematic 
representation of subcutaneous implantation of the fibers in mice model, (b) Infrared thermal 
images and (c) corresponding temperature curves upon exposure to 808 nm NIR laser for 10 min, 
under power densities of 1.0 W·cm–2. 
 
 
3.3.9. In vivo tumor eradication 
 
Lastly, in vivo experiments were carried out by implanting 4 cm of the fibers next to a 
subcutaneous tumor model in mice, and subsequently irradiating them with NIR laser (as 
described in section 3.2.10). Accordingly, tumor volume values were recorded throughout 
the experiment (Figure 3-11a) and 24 days post-treatment the following tumor volume 
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values were obtained: i) 1184.3 ± 175.3 mm3 for control, ii) 1121.4 ± 320.7 mm3 for CS, 
iii) 1037.0 ± 280.0 mm3 for DOX-CS, iv) 463.2 ± 534.8 mm3 for NPs-CS, and v) 196.6 
± 393.2 mm3 for NPs-DOX-CS. Among all samples, mice treated with NPs-DOX-CS 
fibers showed a significantly lower tumor volume value 24 days post-treatment (as 
compared to control group), indicating that these fibers inhibited the tumor growth, and 
even in some cases completely eradicated the tumor as further shown in Figure 3-11c.  
 
Figure 3-11. In vivo tumor eradication performance of different fibers in 4T1 tumor‐bearing mice 
(4 cm fibers, n= 6 in each group, *P < 0.05), upon exposure to 808 nm NIR laser (power density of 
1.0 W·cm−2) for 10 min, 24 hr post fibers implantation. (a) Tumor volumes, and (b) Body weights of 
mice in different groups at every time point throughout the experiment. (c) Representative 
photographs of mice bearing 4T1 tumors before and after treatments. 
 
In contrast, under similar circumstances, NPs-CS fibers were only capable of preventing 
the tumor growth for a short period of time (approximately 8 days), which was followed 
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by a partial regrowth of the tumors. This was probably due to synergistic photo-
thermal/chemotherapeutic effect of NPs-DOX-CS fibers which led to their prolonged 
higher anti-cancer efficacy. It is assumed that the heat generated by the photothermal 
therapy might have reduced the tumor interstitial fluid pressure (TIFP) by interrupting the 
highly packed order of the cancer cells in the tumors, hence enhancing uptake of 
macromolecular therapeutics in tumor tissue.351 Also, photothermal therapy can interrupt 
the growth of fibrous or connective tissue around the tumor (desmoplasia) leading to 
enhanced drug uptake.352 Regardless, all treated mice did not experience any significant 
weight loss throughout the study, which indicated that all treatments were well tolerated 
and did not cause any major toxicity (Figure 3-11b). Noting, Zhang et al., previously 
evaluated the hemo-compatibility and bio-distribution of these copper selenide 
nanoparticles in animal models, and it was shown that these nanoparticles caused minimal 
toxicity to the animals.353     
Furthermore, a separate set of experiments (under similar conditions) were also conducted 
where animal were treated with 2 cm of the fibers, and the results were shown in Figure 
S4. Correspondingly, a similar trend was observed in the treated animals where NPs-
DOX-CS fibers showed the highest level of tumor growth prevention (Figure 3-S4a, 
supporting information). However, 2 cm of these fibers was not capable of completely 
eradicating the tumor as depicted in Figure S4b. This further shed light on association 
between the length of these fibers and their corresponding anti-cancer efficacy. In 
conclusion, the in vivo results suggested that NPs-DOX-CS fibers could be potentially 
applied as implants for preventing the tumor growth, in which their anti-cancer efficacy 
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3.4. Conclusion  
 
In this chapter, for the first time, a coaxial mussel-inspired composite fiber was fabricated 
for local chemo-photothermal combinational cancer therapy. Particularly, the core-
section of these fibers (Chemo-compartment) contained dopamine-modified alginate 
along with a chemotherapeutic drug (Doxorubicin; DOX), while their shell section 
(Phothothermal compartment) was composed of UV-crosslinkable methacrylate-
modified alginate together with Cu2−xSe nanoparticles (NPs). First, successful fabrication 
of the coaxial fibers was assessed through a series of physiochemical characterization 
methods including SEM, EDX elemental mapping, FTIR, XRD, and TGA. We have 
further shown that these fibers possessed good mechanical properties, in both static and 
dynamic conditions, and they were capable of releasing DOX over a span of 21 days. 
Also, NPs-containing fibers demonstrated a photo-thermal conversion capability upon 
NIR laser irradiation (both in vitro and in vivo), in which the obtained temperature profiles 
could be directly tuned by adjusting the length of the fibers. Noting, the fibers only start 
to chemically degrade at temperatures above 200ºC (TGA test; Figure 3-4) which below 
the highest achieved temperature in both in vitro (70ºC) and in vivo (65ºC) studies. As a 
result, the increase in temperature during laser irradiation does not cause degradation of 
the fibers. In addition, the glass transition temperature of alginic acid cross-linked with 
calcium chloride is above 75°C 354-356, and it has been shown previously that hydrogel 
swelling ratio stays constant at temperatures below this.357 This implies that an increase 
in temperature during laser irradiation did not interfere with the drug release profile. 
Furthermore, during in vivo studies only one term of laser irradiation was used which 
lasted for 10 min and this would not have a major impact on the obtained drug release 
profile.   
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Next, It was shown that CS fibers possessed a specific cancer cell killing capability in 
vitro, as they consistently yielded low levels of viability in breast cancer cells (4T1 mouse 
breast cancer cells), while not showing such effect in healthy cell lines (NIH-3T3 mouse 
fibroblast cells). Besides, it was shown that NPs-DOX-CS fibers were capable of 
completely eradicating the cancer cells in vitro upon NIR laser irradiation (808 nm laser 
for 10 min, under power densities of 1.0 W·cm–2). Most remarkably, in vivo experiments 
revealed that in presence of NIR laser, NPs-DOX-CS fibers were capable of effectively 
preventing the tumor growth up to 24 days, without causing any major toxicity to the 
animals. In addition, the in vivo anti-cancer efficacy of NPs-DOX-CS fibers was shown 
to have a direct correlation with the length of the implanted fibers. To conclude, the 
coaxial mussel-inspired composite fiber, containing DOX (in the core) and NPs (in the 
shell), could be a safe and effective implant for combinational chemo-photothermal 









3.5. Supporting information 
 
3.5.1. HNMR and FTIR analysis of the synthesized polymers 
 
For coaxial fiber fabrication, we first synthesized alginate-dopamine (theoretical 
substitution degree of 50 % - in terms of alginate repeating units) using standard 
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carbodiimide chemistry. We then synthesized alginate-methacrylate using methacrylic 
anhydride. Fourier-transform infrared spectroscopy (FTIR) and proton nuclear magnetic 
resonance (1H NMR) were employed to investigate successful synthesis of alginate-
dopamine and alginate-methacrylate. Accordingly, FTIR spectrum of both alginate-
dopamine and alginate-methacrylate (Figure 3-S1a, supporting information) showed 
the characteristic peaks of alginate associated with C-O stretching vibration (1030 cm-1), 
COO- symmetric and asymmetric stretching vibration (1415 and 1600 cm-1, respectively), 
and –OH stretching vibrations (3325 cm-1). More specifically, alginate-dopamine 
spectrum showed appearance of peaks at 1544 cm–1, and 1220 cm–1 assigned to the N–H 
deformation and C–N stretching vibrations. In addition, significant reduction in intensity 
of COO- bands (1415 and 1600 cm-1) further indicated the successful attachment of 
dopamine to the alginate back bone via carbodiimide chemistry. Successful synthesis of 
alginate-dopamine was further confirmed using HNMR via appearance of catechol 
protons at around 7 ppm (Figure S1b-ii, supporting information). Further, the relative 
integration of catechol protons (6.6-7 ppm) to anomeric protons of the glucose ring of 
alginate (4.9 ppm) were used to determine the degree of substitution which was measured 
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Figure 3-S1. Physiochemical characterization of as-synthesized polymers including, (a & b) FTIR 
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Figure 3-S2. In vitro photo-thermal conversion effect of 2 cm of the fibers in SBF. (a) Infrared 
thermal images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for 
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Figure 3-S3. In vivo photo-thermal conversion effect of 2 cm of the fibers. (a) Infrared thermal 
images and (b) corresponding temperature curves upon exposure to 808 nm NIR laser for 10 min, 
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Figure 3-S4. In vivo tumor eradication performance of different fibers in 4T1 mice xenografts (2 cm 
fibers, n= 6 in each group), upon exposure to 808 nm NIR laser (power density of 1.0 W·cm−2) for 
600s, 24 h post fibers implantation. (a) Tumor volumes of mice in different groups at every time 
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4. 3D-printed coaxial hydrogel patches with mussel-inspired 




The therapeutic modalities for cancer are very much dependent on the type and state of 
the disease, and so far a variety of treatments have been exploited in the clinic.3 More 
specifically, such treatments are aimed to address one or more of the following issues 
associated with cancer: (i) to shrink inoperable solid tumors to make them operable, (ii) 
to prevent recurrence of a tumor after surgical resection, and (iii) to eliminate circulating 
cancer cells in the peripheral blood in patients with metastasis.2 Along these lines, 
systemic administration of relevant drugs has been used prevalently to resolve some of 
the above-mentioned issues, and it even yielded some promising results in the clinic.240 
However, as discussed in Chapter 1 (Section 1.3), systemic administration of drugs is 
often linked to undesirable consequences such as high-dose requirement, poor 
bioavailability, and adverse side effects.358 This started a scientific movement towards 
discovering various ways where the drugs could be delivered locally to the tumor site, 
with the aim of rectifying drawbacks of systemic administration.4 Consequently, 
biopolymers entered the fray as candid materials to institute implantable drug delivery 
systems, designed for local delivery of therapeutics to the diseased site.359 Thus, various 
fabrication technologies were employed to facilitate the making of these biopolymeric 
drug delivery systems, while each imposed their own set of advantages and 
disadvantages.359 Among them 3D printing technologies offer considerable advantages 
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including reproducibility, and ability to design geometrically complex shapes.360 In 
addition, 3D printing is compatible with a variety of biopolymers ranging from 
hydrophobic thermoplastic polymers (such as polycaprolactone; PCL, and polylactic 
acid; PLA) to hydrophilic hydrogels (such as alginate, chitosan, and gelatine).160, 361 For 
instance, Yi et al. fabricated 3D printed patches made from a mixture of PLGA 
(lactide:glycolide = 85:15) and PCL loaded with Fluorouracil (5‐FU), which was aimed 
for growth suppression of pancreatic cancer.29 Accordingly, it was shown that the specific 
geometry (latticed, slant, or triangular) and number of layers could directly affect the 
release profile of 5-FU. Moreover, these patches were capable of releasing 5-FU over a 
period of 4 weeks and when tested in mice with subcutaneous MIA-PaCa-2 pancreatic 
tumors they induced significant reduction in relative tumor size compared to that of empty 
implanted patches. In another instance, 3D printed scaffolds made from PCL were used 
for local delivery of Doxorubicin (DOX) to inhibit breast cancer tumor growth.30 
Consequently, the results showed that these scaffolds were capable of releasing DOX 
over a period of 14 days, and when tested in mice with subcutaneous MDA-MB-231 
breast cancer tumors they were capable of inhibiting tumor growth to a higher degree with 
less systemic toxicity compared to that of mice who received equivalent dosage of the 
drug systemically.30 Based on the existing evidence in the literature, most of the 3D 
printed cancer drug delivery systems are made from hydrophobic thermoplastic polymers, 
which indicated the infancy of research in the field of 3D printed hydrogels for cancer 
drug delivery.359, 362-366  
In Chapter 2 we have previously investigated the application of coaxial mussel-inspired 
hydrogel fibers for delivery of two chemotherapeutic drugs (Gemcitabine and 
Doxorubicin) and the in vitro release studies showed that these coaxial fibers were 
capable of releasing Doxorubicin over a period of 21 days.367 However, they did not yield 
 
149 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
a sustained release of Gemcitabine (GEM) as they released the entire loading in a 10 hr 
time span. The quick release of Gemcitabine from those fibers, as compared to 
Doxorubicin, was associated with its smaller molecular size. Along similar lines, it is 
suggested that controlling a hydrogel swelling behaviour could decrease its pore size 
distribution, which can mediate a slower drug release rate from the gel.342 One of the 
common approaches to control the swelling of hydrogels is to implement crosslink agents 
that allow physical or chemical crosslinking of the polymeric chains.368 For instance, 
alginate-based hydrogels have been shown to undergo ionic crosslinking with calcium 
carbonate (CaCO3), which directly affected their pore size distribution in a concentration-
based manner.369 Another approach to control the swelling of hydrogels is to subject them 
to a hydrophobic polymeric coating that could spatially confine the hydrogel 
boundaries.370 For instance, drug-loaded alginate disks were successfully coated with 
PCL, which subsequently led to a reduced swelling of the disks and instigated a slower 
release of the drug.371 
In this chapter, with the purpose of fabricating a suitable platform for prolonged delivery 
of Gemcitabine (a chemotherapeutic drug), we have 3D printed a novel coaxial hydrogel 
patch. Particularly, the core-section of these patches contained dopamine-modified 
alginate methacrylate loaded with Gemcitabine, while their shell section was solely 
comprised of alginate methacrylate. Subsequently, these patches were further modified 
with CaCO3 cross linker and a PLA coating to facilitate prolonged release of the drug. 
Accordingly, different properties of the fabricated patches were characterized including 
their microstructural morphology (scanning electron microscopy; SEM), tensile 
properties in both static and dynamic conditions (mechanical tester and dynamic 
mechanical analysis, respectively), and their swelling behaviour. The results showed that 
addition of CaCO3 to the formula enhanced the mechanical properties of the patches and 
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significantly reduced their swelling ratio as compared to that for patches without CaCO3. 
Furthermore, addition of PLA coating to CaCO3-containing patches has further reduced 
their swelling ratio, which then significantly slowed down the release of Gemcitabine, to 
a point where 4 layered patches were capable of releasing Gemcitabine over a period of 
7 days in vitro. Moreover, PLA coated CaCO3-containing patches showed a good level 
of biocompatibility when tested in vitro against two pancreatic cancer cell lines (MIA-
PaCa-2 and Panc-1). Lastly, a 14 days cell counting assay (CCK-8) was conducted using 
MIA-PaCa-2 cells to measure long term therapeutic effect of GEM-loaded patches, and 
the results showed that 3 layers- and 4 layers structures were successful in inhibiting the 
cancer cell growth for the entire duration of study. Overall, our proposed approach for 
achieving a sustained release of Gemcitabine from 3D-printed hydrogel patches has been 
shown to be effective, and with future development, these patches might become useful 
as neo-adjuvant or adjuvant therapies in cancer patients.                 
4.2. Experimental section 
 
4.2.1. Materials  
 
Alginic acid sodium salt from brown algea (medium viscosity), N-(3-
dimethylaminopropyl)-Nˊ-ethylcarbodiimide hydrochloride (≥99.0%), N-
hydroxysuccinimide, dopamine hydrochloride (98 %), MES hydrate (≥ 99.5%), 
methacrylic anhydride, calcium carbonate (CaCO3; <50µm size), d-(+)-gluconic acid δ-
lactone (GDL), and IRAGACURE D-2959 were purchased from Sigma Aldrich. Sodium 
hydroxide (NaOH), ethanol (96%), and chloroform were purchased from Chem-Supply. 
Poly(DL-lactide) (PURASORB  PDL 20) was purchased from Corbion. Gemcitabine 
hydrochloride was purchased from Focus Bioscience. Simulated body fluid (SBF) was 
prepared as explained before.19 D2O (100% - CIL) was supplied by Novachem. 
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4.2.2. Synthesis and characterization of alginate-methacrylate 
 
Alginate-methacrylate was synthesized using methacrylic anhydride as described 
previously.258, 261 Briefly, 3 g of alginic acid was dissolved in 300 ml of distilled water 
(1% w/v) to which 24 ml of methacrylic anhydride (8% v/v) was added and the pH was 
maintained at 8 for 6 hrs using 5.0 M NaOH solution. Afterwards, the solution was 
dialyzed (spectra/ por membrane tubing; MWCO 12–14 kD) for 7 days and precipitated 
in ethanol followed by freeze-drying. Successful attachment of methacrylate groups onto 
the alginate backbone was further confirmed using FTIR (Shimadzu IRPrestige-21 
infrared spectrometer) and HNMR (Bruker 400 MHz) spectroscopy.  
 
4.2.3. Synthesis and characterization of alginate-methacrylate-dopamine 
 
Alginate-methacrylate-dopamine was synthesized using carbodiimide chemistry.257 
Briefly, 1 g of alginate-methacrylate (5 mmol in terms of repeating unit) was dissolved in 
100 ml of 0.1 M MES buffer with pH of 5.6. EDC and NHS were separately dissolved in 
2 ml of MES buffer (2.5 mmol) and subsequently added to the alginate methacrylate 
solution. while the reaction were allowed to continue for 30 min. Dopamine 
hydrochloride (at equal concentration to EDC and NHS) was separately dissolved in 2 ml 
of MES buffer and added to the mixture subsequently. The reaction were allowed to 
happen for 1 hr under nitrogen flushing. Afterwards the solution was dialyzed (spectra/ 
por membrane tubing; MWCO 12–14 kD) for 7 days against acidic water (pH of 6) and 
subsequently precipitated in ethaol. The precipitated polymers were next lyophilized 
using a freeze-dryer. Incorporation of dopamine into alginate-methacrylate was further 
confirmed using FTIR (Shimadzu IRPrestige-21 infrared spectrometer) and HNMR 
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4.2.4. Rheology 
 
All rheology experiments were conducted on a Physica MCR 301 Rheometer (Anton 
Paar) in parallel plate geometry (50 mm disk, 0.097 mm measuring distance) and at room 
temperature (23 °C). Flow experiment was performed to evaluate the viscosity of polymer 
solution (shear rate varying from 1 to 100 s−1). Oscillatory experiments as a function of 
time (at constant shear strain of 1 % and constant frequency of 1 Hz) were performed to 
measure the storage and loss modulus of the hydrogels upon UV irradiation (365 nm, 
DYMAX BlueWave 75). 
 
4.2.5. 3D printing of coaxial hydrogel structures  
 
In this study 2 different formulations of core-shell structures were made: i) without 
CaCO3 (-CaCO3), ii) with CaCO3 (+CaCO3). Two different solutions were used to prepare 
the core-shell structures. Accordingly, the core aqueous solution contained 6% (w/v) of 
alginate-methacrylate-dopamine and 0.05% (w/v) IRAGACURE D-2959. On the other 
hand, the shell aqueous solution contained 6% (w/v) of alginate-methacrylate and 0.05% 
(w/v) IRAGACURE D-2959. Of note, for structures with CaCO3, 144 mM of CaCO3 and 
36 mM of GDL were added to both core and shell solutions, based on previously reported 
values.369 Also, for GEM-containing patches Gemcitabine hydrochloride (50 mM) was 
added to the core solution. Structures in different geometries (Figure 4-S1, supporting 
information) were printed via a GeSiM BioScaffolder (Model 3.1) using a coxial nozzle 
with a core diameter of 400 µm and a shell diameter of 800 µm. The print parameters as 
input to the proprietary GeSiM software are listed in table 1. A UV light (365 nm, 
DYMAX BlueWave 75) was used to facilitate photo-crosslinking of the structures for 
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4.2.6. PLA coating of 3D printed patches 
 
The previously 3D printed patches containing CaCO3 were allowed to dry overnight in 
room temperature, and subsequently dip coated into a 15% (w/v) solution of Poly(DL-
lactide) in chloroform followed by overnight drying at room temperature. The dried 
coated patches were used for further processing.     
 
4.2.7. Characterization of printed structures  
 
The morphology of 3D printed patches were investigated using Leica M205A 
stereomicroscope. Scanning electron microscopy (SEM) observations were performed 
using a JEOL JSM-6490LV microscope. SEM images were taken in high vacuum mode 
at 15 kV operating voltage and a spot size setting of 60. For SEM imaging, the patches 
were first allowed to completely swell in SBF, then they were cut in half using a razor 
blade to expose their cross-section and subsequently inserted into special sample holders. 
The sample holder containing the mounted structure was then immersed into liquid 
nitrogen for about 45 s. The sample holder was then quickly transferred to the LVSEM 
for examination. The static tensile properties of strands were assessed using a mechanical 
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tester (EZ-L tester from Shimadzu) at 10 mm.min-1 via 50 N and 10 N load cells for dry 
and wet strands, respectively. The dynamic mechanical properties of strands was 
evaluated using a dynamic mechanical analysis (DMA 242 E Artemis, NETZSCH). 
Accordingly, by using a tension clamp the samples were exposed to a constant strain (0.1 
%) of increasing frequencies in the range of 0.1 to 10 Hz for 30 min, subsequently storage 
and loss modulus were recorded and Tan delta (damping factor) values were measured as 
a ratio of loss modulus to storage modulus. The static compressive properties of the 
patches in wet state were assessed using a mechanical tester (EZ-L tester from Shimadzu) 
at 10 mm.min-1 via a 50 N load cell. Lastly, the swelling properties of the hydrogel 
patches were determined by examining their water uptake capacity. The hydrogel patches 
were incubated in simulated body fluid (SBF) at 37°C and allowed to fully swell. The 
swelling ratio was calculated using the following equation: (Ws – Wd)/Wd, where Ws 
represents the weight of the swollen hydrogel patches and Wd represents the weight of 
the dried hydrogel patches at the beginning. 
  
4.2.8. Release studies from drug loaded patches 
 
To measure the Gemcitabine release from the patches, each patch was immersed in 5 ml 
of SBF solution. The supernatant was collected at certain time points and replaced with 
fresh SBF. For quantifying the Gemcitabine release, a high performance liquid 
chromatography (HPLC, Agilent 1260 infinity) was used. Briefly, Samples were filtered 
through a 0.2 μm syringe membrane filter unit before being injected (10 μL) onto a 
ZORBAX Eclipse Plus column (4.6 × 100 mm, 5 μm particle size). Using an isocratic 
elution with a water/acetonitrile (95/5), draw and eject speed of 200 μL/min, pressure 300 
bar, Gemcitabine was detected with the UV-Visible detector at 272 nm. The absorption 
values were converted to concentrations using a previously observed calibration curve. 
The release results were plotted as mean value of three repeated tests.  
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4.2.9. In vitro cell studies  
 
All cell lines were authenticated using short tandem repeat (STR) profiling at the Garvan 
Institute of Medical Research. Cells (MIA-PaCa-2 or PANC-1 cells obtained from 
ATCC) were cultured in DMEM-High glucose media containing 10% fetal calf serum 
(FCS) at 37 °C, 95% humidity and 5% CO2 in a Heracell incubator (Kendro Laboratory 
Products, Germany). When 80% confluence was reached, cells were detached by 
incubation with 5 mM trypsin/EDTA and harvested after centrifugation in a Heraeus 
Megafuge 1.0 (Thermo Scientific, USA) at 1200 rpm for 5 min at RT. Cells were 
resuspended in media, and viable cells counted using a hemocytometer and trypan blue 
staining. Cells were confirmed free of mycoplasma contamination. MIA-Paca-2 and 
Panc-1 cells were seeded 4 × 104 cells/well in 24-well flat bottomed plates in complete 
media (1 mL) containing 1% penicillin/streptomycin and kept in the incubator for 24 hr 
prior to addition of empty or drug loaded patches. After 72 hr the patches were removed 
from the wells and subsequently 40 µL of MTS agent was added and allowed to react 
with the cells for 3 hrs. The absorption of each solution was measured at 490 nm on a 
microplate reader (SPECTRA max, PLUS). For live cell staining, at 72 hr time point the 
media was removed from the wells and subsequently the cells were washed with PBS. 
Next 500 µL of PBS solution (Containing 2.5 µL of Calcein AM and 1 µL of Propidium 
Iodide; Sigma Aldrich) was added to the wells and the plates were incubated for 15 min, 
after which the staining mixture was removed from the wells and replaced with fresh PBS. 
Immediately after the IncuCyte ZOOM system (Essen BioScience, USA) at 10 × 
magnification, with green (live cells) and red (dead cells) filters, was used to image the 
cells.  
To confirm the long-term therapeutic effect on inhibition of cancer cell growth, the effect 
of the medium supernatant of the drug loaded or empty patches on the viability of the 
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human pancreatic cancer cell line, MIA-PaCa-2 cell line, was assessed using a cell 
counting kit-8 method (Sigma, St. Louis, MO, USA) based on manufacturer’s guideline. 
MIA-PaCa-2 cells were cultured in RPMI-1640 medium (Gibco) supplemented with 10% 
v/v fetal bovine serum (Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(Invitrogen) at 37 °C in 5% CO2 in a humidified incubator. Cells were plated at a density 
of 3 × 103 cells per well in a 96-well culture plate and incubated for 24 hr before drug 
treatment. To assess the therapeutic effect of the drug released from the patches, the 
patches incubated in complete culture media at 37 °C in 5% CO2 in a humidified 
incubator and then the supernatant was collected at determined intervals. At day 1 after 
cell seeding, we changed the media to corresponding supernatants. Cell viability at each 
time point was determined using a cell counting kit-8 assay (CCK-8; Sigma Aldrich) 
according to the manufacturer’s guideline.  
 
4.2.10. Statistical analysis 
 
Statistical significance was determined using a two-way ANOVA with a Sidak post-test 
or paired multiple t-test (GraphPad Prism V 6.0; San Diego, CA, USA). P values < 0.05 
were considered statistically significant. *P = 0.05, **P ≤ 0.01, ***P = 0.001, ****P = 
0.0001. Values are reported as the average ± standard deviation.  
 
4.3. Results and discussion 
 
4.3.1. Chemical characterization of the synthesized polymers 
 
Initially the chemical structure of the synthesized polymers were assessed using Fourier 
Transform Infrared (FTIR) and Proton nuclear magnetic resonance (HNMR) 
spectroscopies and results are shown in Figure 4-1. Accordingly, the FTIR spectra of 
both alginate-methacrylate and alginate-methacrylate-dopamine (Figure 1a) showed the 
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characteristic peaks of alginate at 1035 cm-1, 1408 cm-1, 1606 cm-1, and 3350 cm-1 
associated with C-O stretching vibration, COO- symmetric and asymmetric stretching 
vibration, and –OH stretching vibrations, respectively.372 More specifically, both spectra 
also showed two more peaks at 1165 cm-1, and 1712 cm-1 attributed to C=O and C-O 
groups of the esters resulting from the grafting of the methacrylate units.265  
 
 
Figure 4-1. Chemical characterization of as-synthesized polymers including, (a) FTIR and (b & c) 
HNMR spectra of i) alginate-methacrylate, and ii) alginate-methacrylate-dopamine. 
 
Additionally, alginate-methacrylate-dopamine spectrum showed appearance of three new 
peaks (due to attachment of dopamine) at 1210 cm-1, 1470 cm-1 and 2850-2950 cm-1 
assigned to C–N stretching vibrations, N–H deformation, and C-H stretching vibrations, 
respectively.262-263 Also, HNMR analysis of alginate-methacrylate (Figure 4-1b) proved 
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the grafting of methacrylate groups by appearance of double peaks (vinyl) in the double 
bond region (5.5-6.5 ppm).265 Furthermore, the relative integration of methyl protons (of 
methacrylate groups) to anomeric protons of the glucose ring of alginate (4.9 ppm) were 
used to determine the degree of substitution which was 42% (in terms of alginate 
repeating units). In a similar manner, HNMR analysis of alginate-methacrylate-dopamine 
(Figure 4-1c) showed the mentioned double peaks in the double bond region (5.5-6.5 
ppm) associated with methacrylate groups, along with appearance of catechol protons at 
around 7 ppm associated to the dopamine. 264 Further, the relative integration of catechol 
protons (6.6-7 ppm) to anomeric protons of the glucose ring of alginate (4.9 ppm) were 
used to determine the degree of substitution which was measured to be 18 % (in terms of 
alginate repeating units). Overall, these results suggested that alginate-methacrylate and 




Considering the essential role of polymer rheology in subsequent properties of the 3D 
printed structure,373 viscoelastic properties of all printing solutions were assessed using a 
rheometer and the results are shown in Figure 4-2.  
 
Figure 4-2. Rheometry of printing solutions including (a) Viscometry of 6% (w/v) solution of i) 
alginate-methacrylate, ii) alginate-methacrylate-dopamine, iii) alginate-methacrylate + CaCO3, and 
iv) alginate-methacrylate-dopamine + CaCO3. (b) Oscilatory rheology of 6% (w/v) solutions 
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(containing 0.05% (w/v) IRAGACURE D-2959) of i) alginate-methacrylate-dopamine, ii) alginate-
methacrylate-dopamine + CaCO3, iii) alginate-methacrylate, and iv) alginate-methacrylate + 
CaCO3. 
Accordingly, both alginate-methacrylate (Figure 4-2a i) and alginate-methacrylate-
dopamine (Figure 4-2a ii) solutions demonstrated shear thinning behaviour as their 
viscosities gradually decreased with increase in the shear rate, yet alginate-methacrylate-
dopamine solution showed a higher viscosity throughout the measurement range which 
was speculated to be a result of noncovalent interactions of dopamine moieties among 
each other.374 Most remarkably, after addition of CaCO3 the viscosity of both alginate-
methacrylate (Figure 4-2a iii) and alginate-methacrylate-dopamine (Figure 4-2a iv) 
solutions increased significantly due to ionic interaction between Ca2+ ions and alginate 
backbone, however alginate-methacrylate-dopamine solution showed a higher level of 
increase in its viscosity which was assumed to be due to catechol-ion interactions through 
formation of a bis-complex.375 Moreover, both alginate-methacrylate and alginate-
methacrylate-dopamine solutions containing CaCO3 (Figure 4-2a iii & 4-2a iv), showed 
a more pronounced shear-thinning behaviour when compared to their counterparts 
without CaCO3 (Figure 4-2a i & 4-2a ii). This is due to disruption of calcium-alginate 
egg-box model and calcium-dopamine bis-complex upon increasing the shear-rate.376 To 
further evaluate the UV crosslinking-ability of the 3D printing solutions, oscillatory 
experiments (as a function of time) upon UV irradiation were conducted and the results 
are shown in Figure 4-2b. Accordingly, both alginate-methacryate (Figure 4-2b iii) and 
alginate-methacrylate-dopamine (Figure 4-2b i) solutions experienced a significant jump 
in their storage modulus upon initiating the UV irradiation, an indication of UV cross-
linking of both solutions. Of note, alginate-methacrylate-dopamine experienced a slightly 
lower storage modulus after UV irradiation when compared to that of alginate-
methacrylate, which could be attributed to the effect of dopamine moieties in the polymer 
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absorbing part of the UV rays.377 Also, addition of CaCO3 to alginate-methacrylate 
(Figure 4-2b iv) and alginate-methacrylate-dopamine (Figure 4-2b ii) solutions caused 
a slight increase in their corresponding storage modulus associated with presence of ionic 
bonds in the formulations. Overall it was shown that all solutions had shear-thinning 
behaviours were UV-crosslinkable, making them suitable for extrusion printing.  
 
4.3.3. Morphological analysis of 3D printed patches 
 
With the aim of studying the morphology of the 3D printed patches light microscopy and 
scanning electron microscopy were implemented and the results were shown in Figure 
4-3 and Figure 4-S2 (Supporting information). First, we have evaluated the 
morphology of 3D printed structure in the absence of CaCO3 cross linker (Figure 4-3a,c). 
Accordingly, it was shown these patches possessed intricate structures with well-ordered 
dimensions, and their cross-section SEM images revealed their perfectly circular coaxial 
microstructure where the shell thickness in range of 70-84 µm. Of interest, the shell 
showed a less porous structure as compared to that of the core, probably due to absorption 
of a portion of UV light by the dopamine moiety in the core which hindered their further 
chemical cross-linking (as it was observed in rheology studies of section 4.3.2). Next, we 
have examined the morphology of 3D printed patches that contained CaCO3 cross linker 
(Figure 4-3d,f). The results showed that these patches contained opaque structures with 
rough edges due high viscosity of their precursor solutions (as discussed in section 4.3.2) 
and their cross-section SEM images further revealed their almost circular coaxial 
microstructure with occasional CaCO3 agglomerates, where the shell thickness was in 
range of 120-145 µm. Lastly, the morphology of PLA coated 3D printed patches 
containing CaCO3 cross linker were examined and the results were shown in Figure 4-
S2 (Supporting information). Correspondingly, the PLA coating was hard to detect from 
the light microscopy image, however their cross-section SEM images clearly showed the 
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PLA coating around a single strand of the structure with a thickness in range of 50-90 
µm. Of note, the coaxial structure was hard to observe in these structures as the PLA 
coating avoided full swelling of the hydrogel components. Also, the partial deformation 
of the encapsulated 3D printed structure in this SEM image was a result of cutting 
procedure to expose their cross-section for imaging purposes. Overall, the results showed 
that addition of CaCO3 cross linker to the patches caused changes to the microstructure 
of the patches due to interactions between Ca2+ and alginate backbone. Also, it was shown 
that PLA coating did not have any negative effect on the microstructure of the patches.  
 
 
Figure 4-3. (a) Light microscopy and (b & c) SEM images of 3D printed coaxial patches without 
CaCO3. (d) Light microscopy and (e & f) SEM images of 3D printed coaxial patches with CaCO3. 
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4.3.4. Mechanical properties of the 3D printed patches 
 
To further assess the effect of CaCO3 cross linker addition on the subsequent mechanical 
properties of the fabricated structures we have specifically printed single coaxial strands 
(as described in section 4.2.5 and shown in Figure 4-S1a, supporting information) and 
applied them to either static or dynamic tensile stress. Thus, measurements in static state 
were carried out for strands in both dry and wet state and the results were shown in Figure 
4-S3, supporting information. Correspondingly, in dry state no significant difference 
was observed in tensile strength values of the strands without CaCO3 (30.3 ± 3.3 MPa) 
and the ones with CaCO3 (29.3 ± 2.4 MPa). However, strands with CaCO3 had a higher 
modulus values (1.1 ± 0.1 GPa) when compared to that of strands without CaCO3 (0.7 ± 
0.05 GPa). In wet state a significant difference was observed in both tensile strength and 
modulus values of the strands with CaCO3 (0.096 ± 0.002 MPa and 0.17 ± 0.02 MPa, 
respectively) as compared to those of strands without CaCO3 (0.05 ± 0.005 MPa and 
0.025 ± 0.007 MPa, respectively). The obtained results suggested that addition of CaCO3 
cross linker has led to improvements in mechanical properties of the strands especially in 
wet state, and the corresponding values were comparable to that of other printed hydrogel 
strands in the literature.378-379 
To gain a better insight into dynamic mechanical properties of the strands an oscillating 
tension test (at a constant strain of 0.1%) in a frequency range of 0.1-10 Hz was conducted 
(Figure 4-4). The obtained results showed that for both formulations (with or without 
CaCO3) storage modulus values were significantly higher than loss modulus values over 
the entire frequency range, indicating the prominence of elastic behaviour over viscous 
behaviour in all the formulations (Figure 4-4c). Moreover, as shown in Figure 4-4a 
 
163 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
strands with CaCO3 showed a significantly higher storage modulus (8159.5 ± 182.7 MPa) 
over the entire frequency range when compared to that of strands without CaCO3 (2233.0 
± 119.3 MPa). As a result, strands with CaCO3 showed to have a significantly lower 
damping factor (0.0295 ± 0.0007) in comparison to that of strands without CaCO3 (0.051 
± 0.007) (Figure 4-4d). Overall, the measurements in dynamic conditions showed that 
strands with CaCO3 had a more elastic response to oscillating stress when compared to 
strands without CaCO3, which was further attributed to calcium-alginate and calcium-
dopamine interactions that were previously observed in rheology measurements. Lastly, 
given the superior tensile properties of structures with CaCO3, a static compression test 
was applied to 2-, 3-, and 4-layered 3D printed patches that were made from the same 
formulation and the results were shown in Figure 4-S4, supporting information. 
Consequently, a common trend was observed where the strength of the patches increased 
in accordance with their number of layers, as the 4-layers structures showed to withstand 
the most amount of compression force amongst others. 
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Figure 4-4. Dynamic mechanical analysis of 3D printed coaxial strands by using a tension clamp. 
The samples were exposed to a constant strain (0.1 %) of increasing frequencies in the range of 0.1 
to 10 Hz for 30 min. (a) Storage modulus and (b) Loss modulus of strands at different frequencies. 
(c) Storage and loss modulus at the frequency of 10 Hz. (d) Tan delta (damping factor) at the 
frequency of 10 Hz (n = 3, mean ± SD) (*P = 0.05, ****P = 0.0001). 
 
4.3.5. Gemcitabine release studies 
 
Next in vitro release of Gemcitabine from three different formulations of 3D printed 
patches (without CaCO3, with CaCO3, and PLA coated with CaCO3) were assessed as 
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Figure 4-5. In vitro Gemcitabine release studies from various 3D printed coaxial patches including 
(a-b) patches without CaCO3, (c-d) patches with CaCO3, and (e-f) PLA coated patches with CaCO3. 
(n = 3, mean ± SD) 
 
Accordingly, Patches without CaCO3 (Figure 4-5a,b) showed a burst release of the drug 
in the first 2 hr of the experiment where 78.8 ± 0.2%, 71.9 ± 0.5%, and 62.5 ± 2.6% of 
the drug was released from 2-, 3-, and 4-layers structures, respectively. However, all these 
patches reached a plateau level at the 4 hr of the release and they failed to yield a sustained 
release of the drug. Subsequently, patches with CaCO3 (Figure 4-5c,d) were tested and 
they collectively showed a slower release profiles compared to obtained results from the 
patches without CaCO3. Patches with CaCO3 still showed a burst release of the drug in 
the first 2 hr of the experiment where 50.1 ± 1.0%, 37.5 ± 2.4%, and 25.9 ± 2.0% of the 
drug was released from 2-, 3-, and 4-layers structures, respectively. Yet, these patches 
also failed to provide a sustained release of Gemcitabine as their release profiles reached 
a plateau level at the 6 hr of the release. Next, PLA coated patches containing CaCO3 
(Figure 4-5e,f) were tested and they collectively showed a slower release profiles 
compared to obtained results from the patches with only CaCO3. Correspondingly, these 
patches have released Gemcitabine in a peculiar manner over two different stages: (i) 
initially Gemcitabine was released with a faster rate in the first 10 hr of the experiment 
where 29.3 ± 0.9%, 25.7 ± 0.7%, and 24.0 ± 0.07 of the drug was released from 2-, 3-, 
and 4-layers structures, respectively. (ii) This was followed by a slower release of the 
drug which lasted 3 days (40.0%), 4 days (36.0%), and 7 days (30.0%) for 2-, 3-, and 4-
layers structures, respectively. The obtained results suggested that PLA coated patches 
containing CaCO3 had the slowest Gemcitabine release profile and specifically 4-layers 
structures were capable of releasing the drug over a period of 7 days, which was longer 
than that from other hydrogels reported in the literature.19, 274, 380-384 Furthermore, with the 
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aim of further investigating the obtained release profiles, the swelling ratio values of the 
tested patches were measured and the results were shown in Figure 4-5a. Accordingly, 
addition of CaCO3 has significantly reduced the swelling ratio of the patches from 42.9 ± 
1.0 to 17.9 ± 0.6, which was attributed to calcium-alginate and calcium-dopamine 
interactions. Moreover, addition of a PLA coating to CaCO3-contaning patches further 
reduced their swelling ration down to 1.2 ± 0.5, which was due to hydrophobic nature of 
the PLA coating which hindered fast penetration of water into the structures and 
subsequently prevented them from reaching their maximum swelling. Overall, based on 
the obtained results, PLA coated patches containing CaCO3 were chosen for further in 
vitro cell studies.  
 
4.3.6. In vitro biocompatibility of the 3D printed patches 
 
With the purpose of evaluating the biocompatibility of the PLA coated patches containing 
CaCO3, they have been tested in vitro on two human pancreatic cancer cell lines (MIA-
PaCa-2 & PANC-1) for a period of 72 hr and the results were shown in Figure 4-6. 
Accordingly, when empty patches, indicated as “– GEM”, were tested against both cell 
lines and they showed to have > 80% viability (Figure 6a & c), which was further 
confirmed with the live/dead imaging of the treated cells (Figure 6b & d). However, when 
Gemcitabine loaded patches, indicated as “+ GEM”, were tested against both cell lines 
they caused a significantly low viability in the cells (< 6%) (Figure 4-6a & c), which was 
evident from low density of viable cells in the corresponding live/dead images taken from 
treated cells (Figure 4-6b & d). Overall, these results showed that empty patches did not 
cause any significant toxicity to the cells, but long term therapeutic effect of these drug 
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Figure 4-6. In vitro biocompatibility of PLA coated 3D printed coaxial patches containing CaCO3 
either without Gemcitabine (- GEM), or loaded with Gemcitabine (+ GEM). (a) MTS cell viability 
assay of PANC-1 human pancreatic adenocarcinoma cells when treated with the patches for 72 hr. 
(b) Corresponding live/dead cell staining of treated PANC-1 human pancreatic adenocarcinoma 
cells. (c) MTS cell viability assay of MIA-PaCa-2 human pancreatic adenocarcinoma cells when 
treated with the patches for 72 hr. (d) Corresponding live/dead cell staining of treated MIA-PaCa-2 
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4.3.7. In vitro therapeutic effect of the 3D printed patches  
 
Next, the long term therapeutic effect of Gemcitabine loaded patches (PLA coated patches 
containing CaCO3) were examined in vitro by testing them against MIA-PaCa-2 
pancreatic cancer cells and the results were shown in Figure 4-7.  
 
 
Figure 4-7. Therapeutic effect of PLA coated 3D printed coaxial patches containing CaCO3, with 
Gemcitabine (+ GEM) or without Gemcitabine (control), on inhibition of MIA-PaCa-2 pancreatic 
cancer cell growth. Values are the mean (±SEM) of quadruplicate. D in the figure legend denotes 
days of treatment. ****P = 0.0001. 
 
Four different patches were tested for this purpose including Gemcitabine loaded 2-, 3-, 
and 4-layers patches, as well as empty 4 layers patches which were used as a control. 
Consequently, the results showed that empty 4 layers patches showed some level of 
toxicity to the cells for the first 24 hr of testing (cell viability dropped to almost 40%), 
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which then the cells recovered from in the following days to a point where totally viable 
cells were remained at the end of the 14th day. Most significantly, Gemcitabine loaded 2 
layers patches were only capable of inhibiting cancer cell growth for 8 days, whereas 3 
layers and 4 layers patches succeeded to prevent the cancer cell growth up to 10 days 
before the cells started to increase again. More specifically, after 14 days cells treated 
with Gemcitabine loaded 2-layers structures fully regained their viability, whereas cells 
treated with Gemcitabine loaded 3- and 4-layers patches had a viability of 72 ± 10%, and 
61 ± 9% at day 14th of the experiment. The obtained data showed that by adjusting the 
number of layers in the drug loaded patches one can control the duration of their 
therapeutic effect. Overall, the results suggested that PLA coated-3D printed patches with 
CaCO3 were suitable for long-term delivery of Gemcitabine for preventing MIA-PaCa-2 
pancreatic cancer cell growth.  
4.4. Conclusion 
 
In this study, for the first time, 3D printed coaxial hydrogel patches were fabricated for 
prolonged release of Gemcitabine. Specifically, the core-section of these patches 
contained alginate-methacrylate-dopamine loaded with Gemcitabine, while their shell 
section was solely comprised of alginate-methacrylate. Consequently, with the aim of 
enhancing the Gemcitabine release profile, the patches were first modified with CaCO3 
cross linker in both core and shell. Subsequently, characterization of these patches 
showed that addition of CaCO3 led to significant improvements in their mechanical 
properties (in both static and dynamic conditions) and swelling behaviour when compared 
to those of original hydrogel patches. However, patches containing CaCO3 failed to yield 
a prolonged release of Gemcitabine in vitro, as they released the entire drug in the first 
10 hr of the experiment. As a result, the effect of addition of a PLA coating to these 
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patches on their subsequent drug release profile was studied. Remarkably, addition of a 
PLA coating led to significant reduction in swelling of the hydrogel patches, which in 
turn translated into a prolonged release of the drug in vitro over a span of 7 days. The 
PLA coated patches showed good level of biocompatibility in vitro when tested against 
two pancreatic cancer cell lines (MIA-PaCa-2 & PANC-1). Moreover, in a 14 days in 
vitro experiment against MIA-PaCa-2 cells, the 3- and 4-layers PLA coated drug loaded 
patches succeeded to prevent the growth of cancer cells over the entire testing period. Of 
note, in vivo studies of these drug loaded patches are essential to further confirm their 
efficacy for inhibiting the tumor growth. In conclusion, these PLA coated 3D printed 
patches might be used as biocompatible implants for local delivery of Gemcitabine to 




















171 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
 
 


















172 | P a g e   
 
               
                 
          
                
                  
        
               
                 














173 | P a g e   
 
               
                 
          
                
                  
        
               
                 






Figure 4-S4. Mechanical properties of 3D printed coaxial strands following a static tensile test, (a-c) 
Stress-strain curve, tensile strength, and modulus of strands in dry state (n = 3, mean ± SD). (d-f) 
Stress-strain curve, tensile strength, and modulus of strands in wet state (n = 3, mean ± SD). (*P = 
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Figure 4-S6. (a) Swelling ratio of different 3D printed coaxial patches in simulated body fluid 
(SBF). (b) Mass of PLA coating on the 3D printed coaxial patches containing CaCO3, showing no 
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The main objective of this thesis was to develop coaxial hydrogel structures to be utilized 
as implants for controlled local delivery of therapeutics to human tumors. To this end, it 
was hypothesized that a coaxial structure comprised of (i) a core containing dopamine-
modified alginate hydrogel along with chemotherapeutic drugs would confer affinity-
controlled drug release, while (ii) a shell containg methacrylated-alginate hydrogel would 
provide a drug diffusion barrier. Consequently, in Chapter 2, a wet-spinning technique 
was employed to fabricated the coaxial hydrogel fibers (with the above mentioned 
composition), as it allows for cost-effective and high throughput production of fibers. The 
results showed that the coaxial fibers possessed superior physical properties (mechanical, 
swelling, and degradation) over single fibers that were made from pure unmodified 
alginate. Remarkably, in vitro release studies showed that the coaxial fibers were capable 
of releasing Doxorubicin over a period of 21 days, however they released Gemcitabine 
over a span of 10 hr. Zeta-potential measurements were carried out to further scrutenize 
the obtained drug release profiles, and the results showed that dopamine-modified 
alginate (the core element of the coaxial fibers) had stronger interactions with 
Doxorubicin when compared to Gemcitabine as indicated from obtained hydrodynamic 
diameter and zeta potential values. Subsequently, drug-loaded coaxial fibers were tested 
in vitro against two pancreatic cancer cell lines (MIA-PaCa-2 & PANC-1), and the results 
revealed that Doxorubicin-containing fibers had higher anti-cancer efficacy (compared to 
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empty or Gemcitabine-loaded fibers) probably due to slow release of this drug from the 
fibers. Most significantly, in vivo evaluations in mice with subcutaneous pancreatic 
cancer tumors (MIA-PaCa-2 & BxCP3-Luc cell lines) revealed that Doxorubicin-
containing coaxial fibers were able to significantly prevent the tumor growth with 
minimal toxicity when compared to intravenous injection of equivalent dosages of the 
same drugs. The obtained results in Chapter 2 showed that the proposed coaxial hydrogel 
fibers were capable of prolonged release of Doxorubicin, which in turn translated into 
optimal anti-cancer effect from Doxorubicin-containing fibers when tested both in vitro 
and in vivo. 
 
Given the obtained results in Chapter 2, the proposed coaxial hydrogel fibers were 
implemented for chemo-photothermal combinational cancer therapy. Particularly, the 
core-section of these fibers (chemo-compartment) contained dopamine-modified alginate 
along with Doxorubicin, while their shell section (phothothermal compartment) was 
composed of UV-crosslinkable methacrylate-modified algine together with Cu2−xSe 
Nanoparticles (NPs). It was hypothesized that specific biopolymeric composition of these 
fibers along with their corresponding core-shell geometry would allow controlled release 
of Doxorubicin (loaded in the core), while the Cu2−xSe nanoparticles (loaded in the shell) 
would facilitate heat generation upon near infra-red (NIR) laser irradiation. Subsequently, 
the results showed that the coaxial composite fibers allowed controlled released of 
Doxorubicin in vitro over a span of 3 weeks, and they were also capable of generating 
heat in a tunable manner (based on the length of the fiber) upon NIR irradiation, in both 
in vitro and in vivo conditions. Most remarkably, the coaxial drug-loaded composite fibers 
in the presence of NIR radiation showed superior anti-cancer effect (both in vitro and in 
vivo) when tested against breast cancer cell lines, a phenomenon attributed to their 
 
178 | P a g e   
 
               
                 
          
                
                  
        
               
                 
          
synergistic chemo-photothermal effect. Overall, the obtained results in Chapter 3 showed 
that the proposed coxial hydrogel fibers could also be used as a platform for multi-modal 
cancer therapy, as indicated from their optimal anti-cancer effect both in vitro and in vivo.  
 
Considering the obtained results in Chapter 2, the proposed composition of coaxial 
hydrogel structures came up short in releasing Gemcitabine in a prolonged manner. 
Consequently, with the purpose of developing a suitable platform for controlled release 
of Gemcitabine, Chapter 4 focused on using a 3D printing method was used to fabricate 
coaxial hydrogel patches, as this fabrication method offers considerable advantages 
including reproducibility, and ability to design geometrically complex shapes. 
Particularly, the core-section of these patches contained dopamine-modified alginate 
methacrylate loaded with Gemcitabine, while their shell section was solely comprised of 
alginate methacrylate. Subsequently, these patches were further modified with CaCO3 
cross linker and a PLA coating to facilitate prolonged release of the drug. Accordingly, 
the results showed that addition of CaCO3 to the formula enhanced the mechanical 
properties of the patches and significantly reduced their swelling ratio as compared to that 
for patches without CaCO3. Furthermore, addition of PLA coating to CaCO3-containing 
patches has further reduced their swelling ratio, which then significantly slowed down the 
release of Gemcitabine, to a point where 4 layered patches were capable of releasing 
Gemcitabine over a period of 7 days in vitro. Most significantly, when Gemcitabine 
loaded patches (PLA coated patches containing CaCO3) were tested in vitro against MIA-
PaCa-2 pancreatic cancer cells, it was shown that 3- and 4-layers patches were capable of 
inhibiting cancer cell growth for a period of 14 days. In conclusion, the 3D printed coaxial 
hydrogel patches were capable of prolonged release of Gemcitabine only after further 
modifications with CaCO3 crosslinker and an extra PLA coating around the patches to 
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inhibit Gemcitabine burst release. 
 
5.2. Recommendations for Future Work  
 
 
In this thesis a variety of coaxial hydrogel structures have been fabricated for cancer drug 
delivery, using either wet-spinning or 3D printing techniques. In Chapter 2 and Chapter 
3, wet-spun coaxial hydrogel fibers were used as platforms for local chemotherapy and 
chemo-photothermal therapy, respectively. In Chapter 4, 3D printed coaxial hydrogel 
patches were used as a platforms for local chemotherapy. Overall, in this thesis local 
delivery of Doxorubicin and Gemcitabine (chemotherapeutic drugs) was successfully 
achieved and it was further accompanied by in vitro and in vivo evidences. However, 
similar to any other body of work, there are still avenues yet to be explored in future 
works which could not be undertaken in this thesis. 
 
• Wet-spun coaxial fibers could be made from alginate of high molecular weight, which 
will substantially improve the drug release profiles. Also, instead of alginate, other 
biopolymers such as chitosan could be used to fabricate the fibers. In fact, both 
dopamine-modification and methacrylation is reported for chitosan hydrogels.  
• Application of two different biopolymeric hydrogels for core and the shell could be 
beneficial. For instance, two oppositely charged hydrogels such as alginate and 
chitosan could be used for such purpose which would subsequently lead to formation 
of more mechanically robust fibers as a consequence of their ionic interactions.  
• Other crosslinking agents should be implemented in the wet-spinning coagulation 
bath, considering that dopamine-modified polymer may establish further crosslinking 
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upon exposure to oxidizing agents such as sodium periodate or ammonium persulfate. 
These oxidizing agents can facilitate attachment of dopamine moieties on the polymer 
back bone which could act as secondary cross-linking mechanism.  
• The biopolymeric hydrogel of the core can be modified with other functional groups 
to allow further interactions with the drug, for instance thiols.  
• The intrinsic anti-cancer effect of coaxial fibers (as was observed in Chapter 3) should 
be further tested against other cancer cell lines to have more conclusive evidences.   
• The 3D-printed patches in chapter 4 must be tested for biodegradation both in vitro 
and in vivo. 
• The 3D-printed structures must be tested in vivo to prove their effect on inhibiting 
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